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SUMMARY
Arachidonic acid (AA) is metabolized by cyclooxygenase (COX), lipoxygenase 
(LOX) and cytochrome P450 (CYP) in human cells to metabolites with various 
physiological and pathological functions. There are two forms of AA - cis and tram. 
The purpose of these studies was to identify, characterize and compare patterns of 
trans-AA and AA metabolism by human platelets, hepatic microsomes and 
polymorphonuclear leukocytes (PMNs), and observe the functional aspects of trans- 
AA  on these cells. To identify and characterize the metabolites formed from trans-AA 
metabolism different pharmacological probes, HPLC and mass spectrometry were 
used. Aggregometry was used to evaluate the effects of trans-AA on platelets.
In platelets incubated with \4-trans-PJ±, the COX pathway gave rise to all-ds-15- 
HETE, \A-trans-\ 1-HETE and 14-£rarcs-5-HETE; and the LOX pathway gave rise to 
14-fnms-12-HETE and a unique thromboxane like molecule, the structure of which 
was characterized. AA-induced aggregation was inhibited by \A-trans-AA with an 
IC50 of 7.2 pM and two unique characteristics of trans-AA were observed: (1) 14- 
trans-AA was not metabolized extensively by the human platelets like AA and (2) co­
incubation with AA stimulated basal metabolism of 14-trans-AA. 14-trans-AA is 
likely to interact with platelets both via metabolism and via incorporation into the 
platelet membrane.
Profiling of 5-trans-AA metabolites generated by hepatic microsomes revealed that 
all four bonds participated in epoxidation and generated various epoxides, diols and 
hydroxyeicosatetraenoic acids (HETEs). Unlike its ds-isomer, 5,6-trans-EET was 
significantly more stable and resisted microsomal hydrolysis and glutathione 
conjugation. The microsomal metabolic profile of 5-trans-AA was different from that 
of AA and suggested that trans-AA are trans fatty acids that appear to be 
metabolically similar to xenobiotics. Experiments with PMNs suggested that 5-trans- 
AA  was metabolized to different trans-BETEs and that these modulate cell 
proliferation and viability.
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1 INTRODUCTION
1.1 General -  Arachidonic acid cascade
Arachidonic acid (AA) is a polyunsaturated fatty acid with four cis double bonds 
found in animal and human fat as well as in the liver, brain, and glandular organs, and 
is a main constituent of membrane phospholipids. It is formed by synthesis from 
dietary linoleic acid and can be metabolized by three types of oxygenase enzymes: 
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP). The 
COX pathway gives rise to prostaglandins (PCs), thromboxanes (TXs), and 
hydroxyheptadecatrienoic acid (HHT); the LOX pathway gives rise to 
hydroxyeicosatetraenoic acids (HETEs), lipoxins (LXs), and leukotrienes (LTs); and 
the CYP pathway gives rise to epoxyeicosatrienoic acids (EETs), diols and other 
metabolites. In addition, polyunsaturated fatty acids such as AA are susceptible to 
biological autooxidation by free radicals and yield to isoprostaglandins (IsoPGs), 
isoleukotrienes (IsoLTs), NO2AA and trans-AAs (Figure 1-1) (Wolfe, 1982; Oliw et 
al, 1982; Samuelsson, 1983; Hammarstrom, 1983).
Cyclooxygenase Lipoxygenase
Cytochrome P450
Arachidonic acid
Prostaglandins (PGs) 
Thromboxane (TX)
Epoxy acids (EETs), 20-HETE, 
subterminal HETEs
Isoprostaglandins, Isoleukotrienes 
trans-AAs, N 0 2AA
Leukotrienes (LTs), Lipoxins (LXs) 
Hydroxy acids (HETEs)
Figure 1-1. Arachidonic acid cascade
Arachidonic acid is converted enzymatically to PGs and TX by COX; to LTs, LXs and 
various hydroxy acids (HETEs) by LOX; and to EETs, terminal HETE (20-HETE) and 
subterminal HETEs (16-, 17-, 18- and 19-HETEs) by CYP P450. This fatty acid is also 
transformed to isoPGs, isoLTs, N02AA and trans-AAs by free radicals. The generic name 
eicosanoids was introduced by Corey et al (1980) to encompass the increasing number of 
these oxygenated products derived from 2 0 -carbon (eicosa) polyunsaturated fatty acids.
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These oxidised arachidonate derivatives are collectively termed eicosanoids (from the 
Greek eicosa = twenty; for twenty carbon fatty acid derivatives) (Corey et a l, 1980). 
Eicosanoids are formed by virtually every tissue in the body and produce a wide range 
of biological effects on inflammatory responses (predominantly those of the joints, 
skin and eyes), on the intensity and duration of pain and fever, and on reproductive 
function (including the induction of labour). Eicosanoids also play important roles in 
the inhibition of gastric acid secretion, regulation of blood pressure through 
vasodilatation or constriction, modulation of renal function, inhibition or activation of 
platelet aggregation, and they also act as critical mediators of inflammatory diseases 
such as bronchial asthma, arthritis, psoriasis, and thrombosis (Needleman et a l, 1986; 
Smith, 1989).
Platelets are involved in normal and thrombosis. Thrombotic conditions such as 
intravascular clotting in atherosclerosis, systemic inflammatory response syndrome 
(SIRS), and haemorrhagic syndromes such as disseminated intravascular coagulation 
(DIC) may be linked, at least partially, to hyper- and hypo-activity of platelets, 
respectively. The mechanism(s) by which platelets contribute to the pathogenesis of 
these conditions are not clearly understood. However, they involve the liberation of 
AA (20:4n-6) from membrane phospholipids and its subsequent oxygenation by COX 
into pro-aggregatory prostanoids (Samuelsson et al, 1976; Seeds & Bass, 1999; 
Calabrese et a l, 2000).
This study involves the investigation of the metabolism(s) of AA in platelets in the 
presence of trans-AA and the metabolism of trans-AA by platelets, microsomes and 
polymorphonuclear leukocytes (PMNs). Trans-AA contains at least one double bond 
in the trans configuration. Trans fatty acids are present in the diet. They result from 
anaerobic bacterial fermentation in ruminant animals and are thereby introduced into 
the food chain (Emken et al, 1994). Humans consume them in the form of meat and 
dairy products. The reported intake of trans fatty acid ranges from 2.6 g/day to 12.8 
g/day (Emken, 1995). Trans double bonds are also formed during the hydrogenation 
of either vegetable or fish oils. Oils are hydrogenated to increase their plasticity and 
chemical stability, hence their potential use in food products. Consumption of 
hydrogenated oils also contributes considerable amounts of trans fatty acids into 
human body. Hydrogenation results in a number of changes in the acyl chain of the
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fatty acid moiety, all of which can influence physiological parameters. These changes 
include the conversion of cis to trans double bonds, saturation of double bonds, and 
migration of double bonds along the acyl chain resulting in multiple positional 
isomers (van den Reek et al., 1986; Coulon et al, 2003; Balazy & Poff, 2004).
1.2 Arachidonic acid
Arachidonic acid is a 20-carbon essential polyunsaturated fatty acid (all c/5-5,8,11,14- 
eicosatetraenoic acid) having four cz's-double bonds at the 5th, 8 th, 11th and 14th 
carbon position from carboxyl (COOH) terminus, forming a molecule of 
5Z,8Z,llZ,14Z-eicosatetraenoic acid (Figure 1-2). Essential means that the 
mammalian cell cannot synthesize AA de novo from acetate, rather the precursor 
linoleic acid is a direct biochemical precursor. This enzymatic capability exists within 
most cells, to convert linoleic acid by chain elongation and desaturation into AA 
(Cook, 1985). Nevertheless, AA is a very common polyunsaturated fatty acid. For 
example, 10-20% of the total fatty acid content of most cells is AA (20:4 co-6 ). 
Normally, AA is not found as a free carboxylic acid within most cells, but rather 
exists esterified as a phospholipid in various lipid bilayers either at the plasma 
membrane or in separate organelle membranes such as the nucleus, endoplasmic 
reticulum, peroxisome and mitochondrion.
Arachidonic acid is typically found particularly on the 2nd carbon atom (sn-2) of 
glycerol in the glycerophospholipid. Cellular phospholipids represent a very complex 
mixture. Glycerophospholipids exist in various classes, with the four most common 
being glycerophosphocholine (GPC) lipids, glycerophosphoethanolamine (GPE) 
lipids, glycerophosphoserine (GPS) lipids and glycerophosphoinositol (GPI) lipids 
(Figure 1-2).
There are many other minor phospholipid classes including mono- and bi- 
phosphorylated forms of inositol, phosphatidic acid, phosphatidylglycerol and 
cardiolipin. The essential fatty acid, AA, occupies a central position as precursor of 
the widest variety of eicosanoids. In platelet phospholipids, AA is found mainly in 
GPC and GPE (Dobner & Engelmann, 1998).
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Arachidonic acid
14
Glycerophospholipid 
(general structure)
Name of
glycerophospholipid
Name of X Formula of X
Phosphatidic acid 
Phosphatidylcholine 
Phosphatidylethanolamine 
Phosphatidylserine
Phosphatidylinositol
Choline
Ethanolamine
Serine
Inositol
H
 CH2—CH2—N(CH3)3
 CH2— CH2— NH3
— CH2— CH — NH3 
COO"
OH
OH
OH OH
OH
Figure 1-2. Structure of AA and phospholipids
A phospholipid is composed of a glycerol backbone with a fatty acid (Ri) in sn-1 position, 
AA typically found in sn-2 position and a phosphatidyl group (phosphatidic acid / 
phosphatidylcholine / phosphatidylethanolamine / phosphatidylserine / phosphatidylinositol) 
in sn-3 position.
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1.3 Metabolism of AA
Arachidonic acid is metabolized by all cells in human body but it has a significant 
role in platelets, endothelium, smooth muscle, leukocytes, and parenchymal cells. 
Blood platelets are amongst the most active blood elements that metabolize AA by 
COX and LOX. The production of eicosanoids is a highly regulated process that is 
dependent on the acylation and transfer of AA into specific phospholipid pools by 
AA-selective acyl transferase and transacylase reactions, and the release from these 
pools by a variety of phospholipases A2 (PLA2). The role for the widely distributed 
cytosolic PLA2 in mediating stimulus-induced AA release for the production of 
eicosanoids from the COX and LOX pathways is well established (Clark et a l, 1995; 
Ichinose et a l, 2002). The levels of free AA available for eicosanoid production are 
controlled by the rate of déacylation by PLA2 and by competing processes such as 
reacylation into phospholipid and efflux from cells (Balsinde et al, 2002; Diaz & 
Arm, 2003). Metabolism of free AA is mediated by a variety of oxygenases and 
downstream synthases, which are differentially expressed in cells, and which 
determine the types of metabolites produced. The eicosanoids are released from cells 
and exert their biological effects in an autocrine or paracrine manner by binding to G- 
protein-coupled receptors (Narumiya & FitzGerald, 2001).
1.3.1 Physical properties and their relevance to AA distribution
The lipids in the cell membrane have hydrophobic/non-polar sites and aqueous/polar 
sites, therefore the fatty acids can be available in ionic forms. Like other fatty acids 
AA is amphipathic, and its hydrophobic tail can remain in a lipid bilayer while its 
polar carboxyl group (charged or uncharged) can emerge into the aqueous 
environment outside the membrane. AA has a high pKa which is crucial as it is 
responsible for the solubility and the possible distribution of the unesterified fatty acid 
in cells (Spector, 1986). Though the fatty acids exist predominantly in anionic form 
their solubility in water is poor. AA specifically binds with albumin through a 
physical process that occurs when nonpolar and electrostatic interactions are 
combined. The overall concentration of AA present in an aqueous environment can 
increase by binding to albumin and decreasing the concentration of free molecules in 
the solution (Spector, 1975).
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In human plasma the concentration of total AA is high (35 mg/ml, 0.6 mM), and 
albumin (0.1 mM) greatly reduces the effective concentration of free AA molecules, 
and permits millimolar concentrations to be stabilized in an aqueous environment. 
Physiologically, this is critical to the presentation of low concentrations of the free 
fatty acid (unbound) to cells. In the presence of albumin, the concentrations of free 
fatty acids are likely kept well below 0.1 pM (Spector, 1986; McArthur et a l, 1999).
1.3.2 Cellular concentration of AA
The concentration of free AA in resting cells is universally described as low. 
However, there are few reports of mass assay to determine the concentration of free 
AA. In resting or inactivated human platelets, the concentration of esterified 
arachidonate was measured using a mass per volume calculation and it was 
approximately 5 mM (-30 pg arachidonate/109 platelets) (Neufeld & Majerus, 1983). 
This calculated concentration represents an average for whole cells, but the level of 
free AA is very low because of the rapid action of COX and LOX. The concentration 
of AA is substantially higher in the plasma membrane as AA remains esterified in 
membrane phospholipids. The release of 1% of this reserve of esterified arachidonate 
could give up to 50 pM local concentrations prior to its release from the cell. In fact, 
around up to 1 0 % of platelet arachidonate stores could be released upon activation 
(Neufeld & Majerus, 1983). In resting leukocytes the concentration of AA is around 
0.5-1 pM (-3 pmol arachidonate/106 cells) (Chilton et al., 1996).
1.3.3 Pathways of AA release
Cell stimulation by diverse agonists leads to the activation of a variety of intracellular 
phospholipases, including phospholipases A2, C, and D. This triggers the production 
of numerous lipid mediators and represents an important step in signal transduction.
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1.3.3.1 Cytosolic AA and phospholipase A2
AA is most often esterified at the sn-2 position of the glycerophospholipid. 
Phospholipase A2 (PLA2) catalyzes the hydrolytic cleavage of glycerophospholipid at 
the sn-2 position yielding a free fatty acid and a lysophospholipid. More than 19 
different PLA2 have been identified in the mammalian system (Balsinde et a l, 2002), 
and different isoforms of PLA2 have been shown to participate in physiological events 
related to cell injury, inflammation, and apoptosis. In vitro, purified cPLA2 is active at 
concentrations of free Ca2+ (0.1-lpmol/l) similar to those reached intracellularly 
during receptor-dependent Ca2+ responses (Cummings et a l, 2000; Sun et al, 2004). 
Raising levels of Ca2+ from 100 to 300 nmol/1 causes the association of recombinant 
cPLA2 with membrane vesicles, suggesting that, in response to receptor-stimulated 
rises in Ca2+, cPLA2 may translocate from the cytosol to the cell membrane, where 
both competent G proteins and phospholipid substrate are located (Channon & Leslie, 
1990). Arachidonic acid may also be formed by metabolism of diacylglycerol by 
diacylglycerol lipase (Siess et al, 1983).
1.3.3.2 Regulation of cPLA2 activity
Cytosolic phospholipase A2 is activated in response to various stimuli such as 
cytokines, hormones, neurotransmitters, mitogens, antigens, endotoxins, and 
extracellular matrix constituents (Clark et a l, 1995; Murakami et a l, 1997). Certain 
physical and stressful stimuli including oxidation, hyperglycaemia, UV light and 
shear stress may also induce activation of the enzyme (Kramer & Sharp, 1997). The 
activation is mediated by several distinct, agonist- and cell-specific intracellular 
signals that involve guanine nucleotide-binding proteins called G proteins (Winitz et 
al, 1994; Burke et a l, 1997). The activation of stimulatory G protein increases the 
concentration of Ca2+ ion, which activates kinases such as mitogen-activated protein 
kinase (MARK) and protein kinase C (PKC), thus preferentially catalyses the 
hydrolysis of AA from the sn-2 position of membrane phospholipids (Schalkwijk et 
al, 1996; Qiu et a l, 1998; Hirabayashi et al, 1999).
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1.3.3.3 Phospholipase C/diacylglycerol lipase
Activation of PLA2 provides a direct pathway of AA release. Alternatively, release 
may be initiated by the activation of phosphoinositide-specific PLC, which cleaves 
the phospholipid at the phosphate ester bond producing l,^-diacylglycerol (DAG). 
This intermediate is in turn broken down by a DAG-lipase to yield free fatty acid and 
monoacylglycerol. DAG activates protein kinase C, thus catalyses the hydrolysis of 
AA from membrane phospholipids (Allen et ah, 1992).
1.3.4 Oxygenation of fatty acids
It is assumed that cellular oxygenases act upon AA only in their free form. The intra­
cellular concentration of unesterified AA is very low, so their liberation from 
phospholipids is the rate-limiting step. As in numerous cells, platelets contain active 
COX and LOX, PMNs contain mainly LOX and hepatic microsomes contain CYP 
P450 which can oxygenate most of the PUFAs (Samuelsson et al, 1978). When 
cellular phospholipase (phospholipase A2) is activated, AA is released from 
membrane phospholipids. Once AA is released from cell membranes, it may be 
metabolized to eicosanoids via the COX or LOX pathway (Hamberg & Samuelsson, 
1974). The COX pathway is mediated by two different enzymes, COX-1 and COX-2. 
This pathway generates prostaglandins -  PGE2, PGD2, PGF2a, PGI2 (prostacyclin), 
and thromboxane -  TXA2 (Hamberg et al, 1975) (Figure 1-3). The LOX pathway is 
regulated by 5, 12, 15-LOX and other LOXs. This pathway generates different 
HETEs, and leukotrienes -  LTB4, LTC4, LTD4, LTE4 and lipoxins -  LXA4 and LXB4 
(Lapetina & Cuatrecasas, 1979; Dutilh et a l, 1980) (Figure 1-3). The major products 
of cytochrome P450 (CYP)-catalyzed AA metabolism are regio- and stereo-specific 
epoxyeicosatrienoic acids (EETs) and their corresponding dihydroxyeicosatrienoic 
acids (DiHETEs), and 18, 19 and 20-HETE (Capdevila et al, 2000; Capdevila & 
Falck, 2000) (Figure 1-3).
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Figure 1-3. Metabolism of AA
Three major pathways are involved in AA metabolism, (a) The cyclooxygenase (COX) 
pathway results in the formation of PGG2 from AA by a COX reaction. In a subsequent 
peroxidase reaction, PGG2 undergoes a two-electron reduction to PGH2. Both of these 
reactions are catalysed by COX (prostaglandin H synthase). PGH2 serves as a substrate for 
cell-specific isomerases and synthases, producing other eicosanoids such as prostacyclin 
(PGI2) and thromboxane A2 (TXA2). (b) The lipoxygenase (LOX) pathway forms 
hydroperoxyeicosatetraenoic acids (HPETEs) and dihydroxyeicosatetraenoic acid (DiHETEs) 
by LOX and subsequently converts these to (1) hydroxyeicosatetraenoic acids (HETEs) by 
peroxidases, (2) leukotrienes (e.g. LTB4) by hydrolase and glutathione S-transferase (GST), 
and (3) lipoxins by LOXs. (c) The epoxygenase pathway forms epoxyeicosatrienoic acid 
(EETs) and dihydroxyacids by cytochrome P450 epoxygenase.
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1.3.5 Cyclooxygenase pathway
Cyclooxygenases (COXs), also known as prostaglandin H synthases or prostaglandin 
endoperoxide synthases, are fatty-acid oxygenases of the myeloperoxidase 
superfamily (Daiyasu & Toh, 2000). For many years, it was thought that the 
constitutively active COX-1 protein was the only COX in eukaryotic cells. In 1991, a 
second inducible enzyme was identified through studies of cell division; this second 
enzyme is now called COX-2 (Miller et al, 1994). COX-1 is constitutively expressed 
in many mammalian cells and tissues and is considered responsible for the formation 
of PGs and TXs involved in the regulation of physiological fimctions. COX-2 is 
considered to be an inducible enzyme that is expressed in low levels under basal 
conditions, but is strongly induced in response to inflammatory stimuli (Smith & 
Langenbach, 2001). A recent report from Chandrasekharan et al. (2000) describes a 
third cyclooxygenase (COX-3) selectively inhibited not only by paracetamol but also 
by low concentrations of some non-steroid anti-inflammatory drugs including aspirin. 
COX-3 is a variant of COX-1 which has retained intron-1 during translation and 
which is found in human tissues in a polyadenylated form. Selective inhibition of 
COX-3 may lead to discovery of potent and valuable new drugs for controlling pain 
and fever. Cyclooxygenases are important pharmacological targets for aspirin and 
other non-steroidal anti-inflammatory drugs (Smith et al, 1996).
COX-1 is expressed in many tissues including platelets where the major end product 
is TXA], a vasoconstrictor and platelet activator, and endothelial cells where the end 
product of the AA pathway is prostacyclin (PGI2), a potent vasodilator and platelet 
inhibitor. Unlike platelets which lack nuclei, endothelial cells have the capacity to 
synthesize new COX-1 , regenerating their ability to synthesize PGI2 (de Gaetano et 
al, 2003). Endothelial cells also have the inducible COX isoform COX-2, not present 
in platelets, that can synthesize PGI2 in the presence of low dose of aspirin (Marcus et 
al, 2 0 0 2 ).
Much of the work has been done on platelets because of their patho-physiological 
importance. Therefore, this study focused on the metabolic pathway mainly in the 
platelets. The first step of AA metabolism is catalyzed by COX-1 which in platelets is 
located in the dense tubular system (endoplasmic reticulum) that produces PGG2
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(Gerrard et al, 1976). The conversion of AA to PGG2 by PGH synthases can also lead 
to the formation of the side products 11R-HETE and 15-HETE (Thuresson et al, 
2 0 0 0 ). PGG2 is a very short-lived compound that is rapidly converted into PGH2 via 
PG-endoperoxidase activity of COX-1. The main oxygenated product of the COX-1 
pathway in platelets is TXA2, formed by the enzyme TX synthetase (Needleman et 
al, 1976). This enzyme’s activity is associated with the dense tubular system (Carey 
et al, 1982) and catalyzes the formation of TXA2 and 12-HHT from PGH2. However, 
some HHT may be produced from the nonenzymatic breakdown of PGH2 (Diczfalusy 
eta l, 1977).
TXA2 is formed in response to local stimuli and exerts its effects within a short 
distance of its biosynthesis. TXA2 is rapidly hydrolysed (ti/2 = 3 0  seconds) non- 
enzymatically to form TXB2 , that is the chemically stable hydration product of pro- 
aggregatory TXA2. In human, TXB2 undergoes two major pathways of metabolism, 
resulting in the formation of 2,3-dinor-TXB2 and 1 l-dehydro-TXB2, respectively 
(Ciabattoni et a l, 1989). 2 ,3 -dinor-TXB2 is an abundant metabolite that is found in 
urine (Patrono et a l, 1986). Thus, TXA2 is a transient compound, so it is difficult to 
measure accurately circulating levels in whole-animal experimental models. 
Therefore, measurement of TXB2 metabolites such as 11-dehydro TXB2 and 2 ,3 -dinor 
TXB2 in urine and plasma gives better estimates of in vivo TXA2 production 
(Ciabattoni et a l, 1989; Murphy & FitzGerald, 1994). TX synthase can be inhibited 
by imidazole (Needleman et al, 1977), substituted imidazoles such as dazoxiben 
(FitzGerald et al, 1983), and PG analogues (Gorman, 1983). Primary PGs, PGD2, E2 
and p2a, are produced in small amounts in platelets by enzyme PGD synthase (PGH-D 
isomerase), PGE synthase, and PGF synthase, respectively (Osama et al, 1983; 
Yamamoto, 1989).
PGF synthase (originally termed as PGD2 11-ketoreductase) synthesizes PGF2a and its 
isomer (1 1 -epi- PGF2a) from PGH2 and PGD2, respectively (Watanabe et a l, 1985). 
PGD synthase, long thought to be a cytosolic enzyme (Urade et al, 1985), proved to 
be a membrane bound enzyme, as determined by molecular cloning (Urade et a l, 
1989). PGE synthase (PGH-E isomerase) catalyzes the isomerization of PGH2 to 
PGE2 (Ogorochi et al, 1987).
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1.3.6 Lipoxygenase pathway
Lipoxygenases constitute a family of dioxygenases, which catalyze stereo specific 
insertion of molecular oxygen into polyunsaturated fatty acids (Brash, 1999). In 
mammals, the LOXs are divided into three major groups, 5-, 12-, and 15-LOXs, 
depending on their positional specificity of AA oxygenation. In addition, an 8 -LOX 
has been identified in mouse skin (Jisaka et a l , 1997).
In platelets, this pathway catalyzes the oxygenation of carbon 12 of AA. This 12-LOX 
leads to the formation of 12-HPETE (Hamberg & Samuelsson, 1974), which further 
reduced into 12-HETE (Grossi et al, 1989) via a glutathione-dependent peroxidase 
requiring selenium at the active site (Bryant & Bailey, 1980). It is linked to the hexose 
monophosphate shunt which provides nicotinamide adenine dinucleotide phosphate, 
reduced (NADPH) to recycle the reduced glutathione (Bryant et al, 1982). Such a 
peroxidase activity may be altered by high concentrations of aspirin-like drugs (Siegel 
et al, 1979) or by glutathione depletion leading to the formation of trihydroxy- 
eicosatrienoic acids (8,9,12- and 8,11,12-tri-OH) (Bryant & Bailey, 1979) via the 10- 
OH-11,12-epoxy intermediate (Walker et al, 1979). Lipoxygenase activity was found 
to be localized mainly in the cytosol (Nugteren, 1975; Chang et al, 1982) but around 
one-fourth of the total activity seems to be tightly bound to membranes (Lagarde eZ 
al, 1984). Unlike leukocyte 5-LOX, platelet LOX is not calcium-dependent (Chang et 
af., 1982).
The activity of 5-LOX is found in leukocytes, mainly in neutrophils and macrophages. 
Arachidonic acid is converted to 5 (S)-hydroperoxy-6 -Zra/«-8 ,11,1 A-cis- 
eicosatetraenoic acid (5-HPETE) (Shimizu et a l, 1984) and subsequently to LTA4 by 
the action of 5-LOX (Shimizu et al, 1986). LTA4 is, in turn, metabolized to LTB4 by 
LTA4 hydrolase (Radmark et al, 1984) or LTC4 by the action of LTC4 synthase 
(Izumi et al, 1988). LTC4 is converted to LTD4 and LTE4, and these three peptido- 
leukotrienes constitute a major part of the so-called slow-reacting substance of 
anaphylaxis. These LTs are synthesized primarily by mast cells, eosinophils, and 
macrophages, and are potent bronchoconstrictors and also increase microvascular 
permeability, and induce airway secretion (Dahlen et al, 1980). 12-LOX is the 
principal LOX in the brain (Shimizu et a l, 1987). 15-LOX synthesizes 15(S)-
12
hydroperoxy-5,8 ,11 -cis-13-fraH.s-eicosatetraenoic acid (15-HPETE) (Bryant et al, 
1985), a key intermediate for synthesis of lipoxins (Serhan & Samuelsson, 1988).
Three LOXs (5-, 12-, and 15-) were purified to homogeneity, and 5-LOX (Dixon et 
al, 1988), 12-LOX (Izumi et a l, 1990) and 15-LOX (Balcarek et a l, 1988) cDNAs 
were cloned. 5-LOX, 12-LOX and 15-LOX have many sequences homologous to 
each other, and, moreover, they have regions homologous to a reticulocyte LOX and 
plant LOX, such as soybean LOX (Zhao & Funk, 2004).
1.3.7 Cytochrome P450 pathway
Every cell contains GYP, but hepatic microsomes are the main storehouse of this 
enzyme. CYPs metabolize AA to HETEs and EETs. These eicosanoids are formed in 
a tissue and cell-specific manner and have numerous biological functions. CYPs can 
oxygenate AA by one or more reactions shown in Figure 1-4.
Cytochrome P450
Hydroxylation with 
double bond migration
Bisallylic
hydroxylation
Terminal hydroxylation Epoxidation
Arachidonic acid
7-HETE
10-HETE
13-HETE
5,6-EET
8,9-EET
11,12-EET
14,15-EET
16-HETE
17-HETE
18-HETE
19-HETE
20-HETE
5-HETE
8-HETE
9-HETE
11-HETE
12-HETE 
15-HETE
Figure 1-4. CYP pathway of AA metabolism
Only the primary oxygenation products are shown, HETE-hydroxyeicosatetraenoic acid; 
EET-epoxyeicosatrienoic acid.
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1.4 Biological activities of AA metabolites
Arachidonic acid is a precursor of eicosanoids, which are formed by most human cells 
and functions as autocrine and paracrine lipid mediators (i.e., they signal at or 
immediately adjacent to their site of synthesis). Eicosanoids have a broad spectrum of 
biological activities and have been implicated in the pathogenesis of inflammatory 
and atherothrombotic processes. Their synthesis is increased at sites of inflammation, 
and they can be found in inflammatory exudates. The key actions of eicosanoids are 
summarized in the Table 1-1 .
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Table 1-1. Biological activities of eicosanoids
Eicosanoid Biological activity
p g d 2 Growth inhibition, anti-aggregation, smooth muscle constriction, hypothermia, 
sleep induction, narcolepsy, acetylcholine release, inhibition of prolactin release, 
inhibition of LH-RH release, LH release (at pituitary level), increase of serotonin 
turnover
p g e 2 Smooth muscle dilatation, Na+ excretion, plasma exudation, inhibition of gastric 
secretion, hyperthermia (fever), awake state, stimulation of LH-RH release, 
regulation of catecholamine release, inhibition of natural killer cells
PGF2a Bronchoconstriction, vasoconstriction, acetylcholine release
p g i2 Vasodilatation, anti-aggregation, inhibition of gastric secretion
t x a 2 Bronchoconstriction, vasoconstriction, aggregation
l t b4 Chemotaxis, adhesion of leukocytes to endothelial cells, lysosomal release, 
superoxide generation, activation of natural killer cells, induction ofIL-2 receptor
l t c4 Bronchoconstriction, vasoconstriction, plasma exudation, LH release, LH-RH 
release, depolarization of Purkinje cells, opening of atrial K+ channel
l t d 4 Bronchoconstriction, vasoconstriction, plasma exudation
l t e4 Vasoconstriction, plasma exudation, bronchoconstriction
l x a 4 Chemokinesis, TX formation, bronchoconstriction, inhibition of natural killer 
cells, activation of protein kinase C, antagonism of LTD4 receptor in kidney
l x b 4 Inhibition of natural killer cells
5-HPETE Stimulation of steroidogenesis in adrenal gland
12-HPETE Migration of vascular smooth muscle cells, vasoconstriction
5,6-EET Secretion of somatostatin, LH, TSH, prolactin, vasodilatation, Na+, K+-ATPase 
inhibition ; inhibits platelet aggregation in vitro
8,9-EET Secretion of oxytocin, inhibition of COX
11,12-EET Secretion of vasopressin, anti-aggregation
14,15-EET Glucagon secretion, anti-aggregation, inhibition of COX
12-HETE Inhibition of Na+-K+-ATPase; proinflammatory mediator
16-HETE Inhibition of neutrophil aggregation and adhesion
18-HETE Weak vasodilator; inhibitors of ATPase
19-HETE Weak vasoconstrictor; stimulates Na+-K+-ATPase
20-HETE Regulation of membrane ion transport in the medullary thick ascending limb and 
proximal tubules; inhibition of platelet aggregation in vitro and thromboxane 
biosynthesis; stimulation of stem cell growth in the human bone marrow
11,12-DHET Na+-K-ATPase inhibition
Summary of the general biological activity of the eicosanoids adapted from(Shimizu & Wolfe, 1990; 
Spector et a l, 2004; Benatti et a l, 2004).
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1.5 Trans fatty acids
Trans unsaturated fatty acids, or trans fats, are fats produced artificially by heating 
liquid vegetable oils in the presence of metal catalysts and hydrogen (Katan et al, 
1995). The carbon/carbon double bonds in unsaturated fatty acids can exist in either 
cis or trans configuration. In the double bond of the unsaturated fatty acid, the two 
hydrogen atoms on the carbon atoms that form the double bond may be located on the 
same side of the carbon chain in which case they are termed cis, and on the opposite 
side of the carbon chain in which case they are termed as trans. Isomers of AA are 
shown in Figure 1-5.
COOH
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Figure 1-5. Structures of AA and different mono- trans-AAs
This figure represents polyunsaturated fatty acids having one trans- and three cis- double 
bonds and the double bonds are present between 5th and 6th, 8th and 9th, 11th and 12th, and 14th 
and 15th carbons.
Trans fatty acids are those unsaturated fatty acids having at least one double bond in 
the trans configuration instead of having all cis bonds. In contrast to typical cis
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isomeric configuration, the double bond angle of the trans fatty acid is smaller and the 
acyl chain is more linear, resulting in a more rigid molecule with a higher melting 
point. In cis configuration, the hydrogen atoms are on the same side of the carbon 
chain, resulting in a ‘kink’ in the acyl chain and a more flexible phospholipid 
molecule as opposed to trans which makes it more rigid (Steinhart et al, 2003; 
Stender & Dyerberg, 2004; Wahrburg, 2004).
Trans fatty acids are found in dairy fats and, mainly in products of hydrogenated fat, 
such as margarine. Hydrogenation of fatty acids is done to increase their plasticity and 
chemical stability, thus making transportation and storage easier. Food manufacturers 
also use partial hydrogenation of vegetable oil to destroy some fatty acids, such as 
linolenic and linoleic acid, which tend to oxidize, causing fat to become rancid with 
time. Commercial baked goods frequently include trans fats to protect against 
spoilage. During the hydrogenation process, variable amounts of the unsaturated fatty 
acids that are not hydrogenated are converted from the cis to the trans configuration 
(Figure 1-6). This process of isomerization from cis to trans also occurs naturally in 
the rumen of sheep and cattle; for this reason, trans fatty acids are found in the milk 
and fat of these animals (Emken et a l , 1994).
The common hydrogenation process uses a nickel catalyst and results in both the 
reduction and migration of double bonds. Because hydrogenation raises the melting 
point of the fat, the usual product is a fat that is solid at 25°C, although there is wide 
variation in physical properties depending on the starting fat and the degree of 
hydrogenation (Steinhart et al, 2003). Most of the trans fats produced commercially 
are monoenes. Trans fatty acids are also formed in human by the oxidation of fatty 
acids (Jones et a l, 1978; Ascherio & Willett, 1997; Nelson, 1998). An increased level 
of trans fatty acids can alter the biological membrane rigidity, permeability and 
asymmetry (Patel & Block, 1986; Mann, 1994).
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Figure 1-6. Formation of 14- trans-AA in vivo
Dietary ds-linoleic acid may be converted to 12-/ram-linoleic acid by N 0 2 or it may be 
supplied as 12-/nms-linoleic from diet. The elongation and desaturation process converts 12- 
frvms-linoleic acid to 14-/rûm-arachidonic acid.
1.5.1 eN02-dependent cis-trans isomerization of AA
•N02 efficiently isomerizes A A to trans-A A, and both mono trans and poly trans 
isomers have been detected (Jiang et a l, 1999). Other unsaturated fatty acids are 
also readily isomerized by "NOz. Such isomerization is significant in vivo during 
pathological conditions like inflammation and endotoxic shock where the
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formation of NO and its oxidation product NO2 are increased (Balazy & Lopez- 
Femandez, 2003).
The isomerization of AA is mediated by "NOz. Other free radicals (OH, peroxyl, 
and superoxide) do not isomerize AA. Peroxynitrite (ONOO-) also causes the 
isomerization of AA in addition to oxidation. Arachidonic acid reacts readily with 
NO2 in a dose-dependent manner, generating a mixture of products. The major 
product obtained from the NO2 AA reaction is a mixture of four isomers having 
one trans and three cis bonds (trans-AA). The reaction also produces isomers 
having more than one trans double bond (Balazy, 1994; Jiang et a i, 1999; Boulos 
etal., 2000).
Overall formation of 14 isomers of 5,8,11,14-eicosatetraenoic acid having non­
conjugated cis and trans bonds is possible (Table 1-2).
Table 1-2. Geometrical isomers of 5,8,11,14-eicosatetraenoic acid
Isomer of AA Number of isomers
All cis 1
1 trans, 3 cis 4
2 trans, 2 cis 6
3 trans, 1 cis 4
All trans 1
Of these, the four mono trans isomers appear to be the most abundant products 
generated by NO2. The isomerization is likely to involve the reversible binding of 
NO2 and the formation of a nitroarachidonyl radical followed by the elimination of 
NO2 and generation of a trans bond (Figure 1-7) (Prutz et al., 1985).
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14-fraf7s-arachidonic acid 14-nitro-15-hydroxyeicosatrienoic acid
Figure 1-7. Mechanism for NC^-mediated formation of 14-trans-KA
When N02 reacts with AA, it forms c/s-nitro-AA that spontaneously isomerizes to trans- 
nitro-AA. 7nms-nitro-AA is converted by the process of elimination to /raws-arachidonic 
acid and by the process of hydroxylation to nitro-hydroxy-AA.
NO is also responsible for cis-trans isomerization of AA. In endotoxaemic rat 
where the formation of NO is increased, the plasma levels of trans-AA are 
increased two-fold and trans-AA esterifled in the heart phospholipids increase 5- 
fold (Balazy, 2000). Because the trans-AA isomers are not readily metabolized by 
COX and LOX, but appear to be better metabolized by CYP (Berdeaux et a l, 
1998), they could function as unique markers of nitro oxidative processes related 
to inflammation (Balazy, 2000).
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1.5.2 Origin of frans-AAs -  Summary
Trans-AA may originate from two sources: the diet and endogenous cis-trans 
isomerization. \A-trans-AA and 5-trans-AA are the models of trans fatty acid to be 
studied in this thesis. 14-trans-AA can originate either from diet via 
elongation/desaturation of 12-trans-LA or by 'NOz-mediated isomerization. Dietary 
intake of trans-LA and in diet containing nitrite may also contribute to the formation 
of trans-AA (Balazy, 2000). Trans-AAs are formed in vivo via a reversible addition 
of NO2 to the olefinic cis bond of fatty acids. Thus, trans-AAs are likely to be 
formed in conditions characterized by increased exposure to "NO] such as 
inflammation, sepsis, smoking, exposure to polluted air in which the formation of 
NO and its oxidation product, "NO] is increased (Rudrum, 1995).
1.5.3 Origin of reactive nitrogen species
NO] is a potent toxic oxidant gas (Tewari & Shukla, 1989) and a major air pollutant 
that originates from the combustion of fossil fuels and other sources. The 
concentration of NO] in urban areas can reach levels up to 1500 pg/m3 (0.8 ppm), 
which varies seasonally. NO] concentrations in homes with combustion appliances 
are higher than homes without such appliances. Average indoor concentrations of 
NO] in excess of 100 pg/m3 have been measured in some homes with fuel heaters. 
Virtually all of the emitted NO] is in the form of NO, which is gradually oxidized 
into NO]. Environments containing cigarette smoke and other types of smoke may 
have higher concentrations of both NO and NO] (Jones et al., 1978; Elsayed, 1994; 
Postlethwait & Bidani, 1994). Various sources of NO] formation are shown in Figure 
1-8.
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(Nitrite)
NO+Of-> ONOO enzymes — ►Lipid peroxidation
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Air Pollution 
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Figure 1-8. Various sources of NO2 formation
NO2 forms mainly by the oxidation of nitric oxide (NO) in cells and also found to be in nature 
as a product of fuel combustion.
Platelets contain NO synthase in their cytoplasm, which upon activation generate 
NO. Nitric oxide modulates platelet reactivity by increasing cyclic GMP (Radomski 
et al., 1990). The NO% radical is a common intermediate in the NO oxidation 
pathways to nitrite. A reaction of NO with superoxide, which generates an 
intermediate ONOO", has a rate comparable to the superoxide scavenging rate of 
superoxide dismutase (SOD), and is a significant pathway by which NO% is 
generated in vivo (Koppenol, 1998). Intracellular CO2 plays an important role in the 
decomposition of ONOO" to NO2 (Goldstein et a l, 2001; Meli et al, 2002; Uppu et 
al, 1996). More recent work has identified novel sources of NO2, which involve 
enzymatic and non-enzymatic oxidation of nitrite by hydrogen peroxide (H2O2) 
(Table 1-3).
Myeloperoxidase (MPO) has been identified as an effective catalyst for the 
oxidation of nitrite to 'NO2 in addition to its role in the oxidation of chloride to 
hypochlorous acid (Kraemer et a l, 2004). The MPO/H2O2/NO2 system can induce 
the nitration of fatty acids via formation of the NO2 radical (Byun et a l, 1999; 
Eiserich et a l, 2002). A recent study demonstrated that heme catalyzes the oxidation 
of nitrite to NO2 by H2O2 without the aid of the prosthetic group of peroxidases. It is
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thus likely that in addition to protein nitration, heme and other iron complexes, in 
the presence of nitrite and H2O2, could potentially induce lipid nitration by a 
mechanism similar to the one that leads to the formation of nitro-tyrosine in albumin 
(Bian et ah, 2003).
Thus, significant amounts of N 02 can be generated in vivo by multiple pathways. 
However, the processes involving the reactions of NO2 with lipids have not been 
fully understood (Carr & Frei, 2001). N 0 2 could be an important mediator of lipid 
metabolism because it is highly lipophilic. The results obtained by Liu et al, show 
that the oxidation of NO to N 0 2 in aqueous solutions is greatly accelerated by 
phospholipids and the NO oxidation occurs predominantly in the hydrophobic 
bilayer of phospholipid vesicles (Liu et a l, 1998). This study indicates that the 
biological membrane may play an important role in the oxidation of NO. In 
addition, the hydrolysis rate of NO2 in the lipid phase is minimal (Goss et a l, 1999). 
N 02 may remain in membrane lipids long enough to react with fatty acids and 
phospholipids. The reaction of N 02 with NO produces dinitrogen trioxide (N2O3), a 
potent nitrating/nitrosating compound. In the aqueous phase, N2O3 rapidly 
hydrolyzes to form two NO2 molecules. Thus, because some nitrite may be 
converted to N 0 2 by heme or peroxidases (Schmitt et a l, 1999), there may be a 
steady concentration of N 0 2 in tissues. Additional nitrite may be supplied in the 
diet, as nitrite is a common and abundant food preservative (Cammack et a l, 1999; 
Oldreive & Rice-Evans, 2001).
Table 1-3. Biological sources of the NO2 radical
Reaction References
2NO + 0 2-> 2 -N02 (Koppenol, 1998)
NO + O2 -> ONOO" + H+ ONOOH -> NO2 + -OH (Bian et al, 2003a)
Myeloperoxidase + nitrite + H2O2 —» 'NO 2 (Byun et al, 1999)
Cu/Zn-SOD + nitrite + H2O2 -> 'NO2 (Singh e ta l, 1998)
Peroxidases + nitrite + H2O2 —> 'NO2 (Gebicka, 1999)
Cytochrome P450 + ONOO" —» 'NO2 (Mehl et a l, 1999)
Lactoperoxidase + nitrite + H2O2 —> 'NO2 (Reszka et a l, 1999)
Heme / iron + nitrite + H2O2 —> 'NO2 (Bian et al, 2003a)
Mechanism of N02 generation in cells (Balazy, 2000)
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1.5.4 Biological role of trans-fatty acids
Despite numerous epidemiological and experimental feeding studies, evidence 
regarding the health risk of tmns-FA as causative factors in the development of 
cardiovascular disease and cancer is not conclusive (Ascherio & Willett, 1997; 
Nelson, 1998; Mozaffarian et a l, 2004). However, it has been established that 
increased levels of trans-FA alter biological membrane rigidity, permeability and 
asymmetry. Additionally, none of the previous studies have considered the 
possibility that at least some trans-FA may originate from the endogenous sources 
(Patel & Block, 1986; Mann, 1994).
In endotoxaemia or inflammation, significant amounts of trans-FA isomers may be 
generated, possibly within the cell membrane phospholipids, increasing the pool of 
phospholipids containing trans-FA (Szabo et al., 1995). The trans-FA generated 
by endogenous isomerization may differ from the ones ingested with diet. The 
identification of the trans-FA that originate solely from NOz-dependent reactions 
may provide a useful index to assess the damage done to the biological membrane 
via reactive nitrogen species (RNS), and therefore, may be complementary to the 
marker importance of isoPGs, which reflect the damage to membrane mediated by 
OH radical (Balazy, 2000).
In this regard, the RNS-dependent trans-FA may function as specific lipid 
mediators of inflammation and potentially other pathologies. The trans-AA may 
remain bound within membrane phospholipids for prolonged periods and released 
following stimulation by phospholipases. Additionally, because biological 
membranes enriched with trans-FA appear to be more rigid and permeable and 
have altered phospholipid asymmetry, they may provide less protection against 
smaller molecules such as certain carcinogens. These molecules may easily cross 
membranes composed of increased amounts of the diet-independent trans-FA. 
Studies of cells exposed to trans-AA may provide supporting evidence for a novel 
mechanism involved in the association between inflammation and cancer ( Andre 
et a i, 2002; Coussens & Werb, 2002; Ip & Marshall, 1996; Slattery et al., 2001).
24
In addition to specific lipid markers, nitro-eicosanoids possess some biological 
activity. Nitrohydroxyarachidonic acid causes relaxation of vascular smooth 
muscle at micromolar concentrations via the activation of guanylate cyclase by a 
novel mechanism involving the release of NO. The mechanism of this NO release 
is unknown but, it may involve glutathione (Balazy et a l, 1998; Lufrano & 
Balazy, 2003).
Berdeaux et al. (1996) found that the addition of a \A-trans isomer of AA to rat 
platelet suspensions inhibited the aggregation induced by AA. However, the addition 
of its structural homolog 5,8,11-eicosatrienoic acid (20:3n-9) did not induce any 
modification of the platelet aggregation. By contrast, the 12-lipoxygenase pathway 
was stimulated by \A-trans-AA, by the increased production of 12-HETE. The 5,8,11- 
eicosatrienoic acid (20:3n-9), not being a substrate of the COX, did not induce any 
significant modification in the formation of TXB2 and 12-HHT. The 1 A-trans-AA 
alone did not induce any platelet aggregation. However, this fatty acid was 
metabolized to a limited extent into two products that have not been identified yet. It 
was suggested that one of them could be a product of the 1 2 -lipoxygenase pathway 
(Berdeaux et a l, 1996).
1.6 Inhibition of AA metabolism
Biosynthesis of eicosanoids is increased and sustained in inflammation and other 
pathological conditions, which have potent and detrimental effects on the functions of 
various organs. Anti-inflammatory steroids like dexamethasone inhibit the release of 
AA and its metabolites by cells, and inhibit the formation of eicosanoids by down- 
regulation of COX-2 expression (Hong & Levine, 1976; Schleimer et a l, 1986). 
Steroids inhibit cell phospholipases that are responsible for the release of AA from 
phospholipid stores, by stimulating the biosynthesis of an inhibitory protein called 
macrocortin in macrophages (Flower & Blackwell, 1979) and lipomodulin in 
neutrophils (Schoene & lacono, 1976; Hirata et al, 1980).
COXs are important targets for non-steroidal anti-inflammatory drugs (NSAIDs). 
Aspirin acetylates serine-530 of COX-1, thereby blocks TXA2 synthesis in platelets 
and reduces platelet aggregation (Vane & Botting, 2003). This mechanism of action
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accounts for the effect of aspirin on prevention of coronary artery and cerebrovascular 
thrombosis. Aspirin is less effective in inhibiting COX-2 activity, whereas celecoxib 
and rofecoxib selectively inhibit COX-2 activity as they contain a side chain to anchor 
to the side pocket of COX-2 substrate channel (Brune & Hinz, 2004). Aspirin and 
salicylate at therapeutic concentrations inhibit COX-2 protein expression through 
interference with binding of CCAAT/enhancer binding protein beta (C/EBPbeta) to its 
cognate site on COX-2 promoter/enhancer (Wu, 2003). COX-3 is selectively inhibited 
by analgesic/antipyretic drugs such as acetaminophen, phenacetin, antipyrine, and 
dipyrone, and is potently inhibited by some NSAIDs. Thus, inhibition of COX-3 
represent a primary central mechanism by which these drugs could decrease pain and 
possibly fever (Chandrasekharan et al, 2002; Brune & Hinz, 2004). Ridogrel, a 
combined TXA2 synthase inhibitor and TX-receptor antagonist, inhibits platelet 
function (McNicol & Israels, 2003).
There are five active LOXs found in humans: 5-LOX, 12S-LOX, 12R-LOX, 15-LOX- 
1 and 15-LOX-2. Several drugs have now been developed that block either 
leukotriene formation or their receptors. Baicalein and esculetin are naturally 
occurring flavonoids that inhibit 12-LOX, and thus inhibit LTB4 and LTC4 
biosynthesis at micromolar concentrations (Sekiya & Okuda, 1982; Kimura et al, 
1987). Zileuton is both potent and selective as a 5-LOX inhibitor; it inhibits the 
formation of all 5-LOX-derived lipids (Szczeklik et a l, 2001). Lukasts (i.e., 
montelukast, zafirlukast, pranlukast, pobilukast) are a group of drug that inhibit the 
function of leukotrienes by acting as leukotriene receptor antagonists (Spector, 1996; 
Suzuki et al, 2003). New specific lipoxygenase inhibitors are directed towards 
inhibition of tumour growth and potentially other effects (Poff & Balazy, 2004b).
Finally, a third pathway of AA metabolism involves oxidation by the inducible 
cytochrome P450 isozymes, and although no clinically useful drugs are yet available, 
promising research in this area (Sato et al, 2001) is directed toward yielding valuable 
drugs that block generation and symptoms of stroke (Bednar et al, 2000b).
26
1.7 Platelets and arachidonic acid
Resting platelets are small, round, disk shaped cells, which lack nuclei and are found 
in the blood. Platelets originate from the cytoplasm of megakaryocytes. They 
distinguish between normal endothelial cell lining and areas with lesions in order to 
maintain a crucial balance between anti- and pro-coagulative actions within the body. 
Platelets display several cell surface receptors. These receptors include (a) the major 
serpentine receptors for thrombin, ADP, TXA2 and epinephrine; (b) the glycoprotein 
receptor for von Willebrand factor (vWF); (c) (33 and pi integrin receptors for 
fibrinogen and collagen; and (d) the immunoglobin superfamily receptors, Fc 
receptor, FcyRIIA, and GP VI ( Andrews & Bemdt, 2004; Gibbins, 2004; Hourani & 
Cusack, 1991) (Table 1-4).
Table 1-4. Receptors of the platelet plasma membrane
Ligand Receptor
von Willebrand factor GPIbap-IX-V
Fibrinogen GPHb-IIIa or 0 ^ 3
Collagen GPIa-IIa or a2pi
GP VI (Immunoglobin superfamily)
P-selectin
Laminin a6Pi
Fibronectin asPs
Immunoglobulin G FCyRIIA (Immunoglobin superfamily)
Thrombin PAR-1, -2, -3, -4
GPIpa-V
ADP P2Yi
P2 Yi2
P2Xi
Thromboxane TP receptor
PAF PAF
Epinephrine a2
Receptors present in the membrane o f  platelets.
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Glycosylated proteins are the main receptors that are found on the cell surface. The 
most important surface glycoprotein receptor is an integrin, GP Ilb-IIIa (<xllbp3) 
which has the ability to bind both fibrinogen and vWF (Shattil & Brass, 1987). GP 
Ilb-IIIa is a heterodimeric complex composed of a platelet-unique a and p integrin 
subunit (allbpS). The alpha subunit is made up of a heavy and light chain covalently 
linked by a single disulfide bond. Both chains are formed from a pro-IIb molecule that 
is enzymatically cleaved and processed in the megakaryocyte (Shattil et a l, 1998). 
GP Ilb-IIIa however, is inactive on the surface of the resting cell. Intracellular signals 
produced by other receptor-agonist triggers its ligand binding activity. These 
intracellular signals have the ability to trigger a conformational change in the 
molecule causing it to open its ligand-binding site (Ginsberg et al, 1992). The ligand- 
binding site is specific that identifies and responds to all proteins having an Arg-Gly- 
Asp sequence present in the two major platelet ligands, fibrinogen and vWF. A 
platelet contains approximately 50,000 molecules of GP Hb-IIIa; 80% to 90% of those 
molecules are expressed on the cell surface (Shattil et a l, 1985).
The cytoplasm of platelet contains granules, organelles, the specialized membrane 
systems of the cell and the actin cytoskeleton. There are three types of storage 
granules in the platelet cytoplasm, a granules, dense granules and lysosomal granules. 
When platelets become activated, these granules can be released into the surrounding 
environment. The a granules are the most prevalent granules which contain platelet 
factor 4, g-thromboglobulin, platelet-derived growth factor and fibrinogen (Harrison 
& Cramer, 1993). These proteins serve to facilitate the adhesive process, support cell- 
to-cell communication, trigger vascular restoration, and can influence blood vessel 
function and clotting cascade. The dense granules are composed of large amounts of 
serotonin (5HT), adenosine di- and tri-phosphate (ADP and ATP), and Ca2+ (McNicol 
& Israels, 1999). If released, they can modulate vascular tone, recruit additional 
platelets to sites of injury and enhance the thrombus-forming ability of other platelets. 
The lysosomal granules can be released after stimulation by aggregating agents like 
thrombin and high concentrations of collagen (Berger et a l, 1998; Diacovo et al, 
1996; Frenette et a l, 2000; Hourani & Cusack, 1991).
Upon activation, the platelet microtubules contract and allow the platelet to change its 
shape. Activated platelets become sticky and change their shape from smooth to
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spiny, thus causing an increase in surface area. Their round shape is maintained by an 
actin-hased cytoskeleton, as they circulate throughout the vascular system. This 
cytoskeleton prevents the cell from being distorted by fluid shear forces. At the core 
of the cytoskeleton is a three-dimensional support system of actin and tubulin 
polymers. Activated and loosely connected platelets can revert to passive and free 
platelets respectively, until a certain point. When the granules are released from the 
platelets, they can no longer return to their original phase. As the activation process 
continues, granules within the platelet are pulled outwards, and they release their 
contents into the surrounding environment. This causes platelets to adhere to exposed 
surfaces (Zucker-Franklin, 1970).
The sub-endothelium contains collagen that can function as a platelet activator. If the 
endothelium is damaged, platelets attach themselves to the exposed surface and 
become activated drawing the attention and responses of other platelets to the affected 
area. Activated platelets can activate other platelets and thus the response is highly 
intensified. Platelets are able to fuse to surfaces because the platelet membrane is 
being exposed to protein binding sites on the contacting surface. Fibrinogen is the 
chief plasma protein that is drawn to and fuses with these binding sites. Binding can 
only occur if a platelet is activated (Blockmans et al, 1995; Nachmias, 1980).
In physiological conditions, platelets can contribute to hemostasis, whereby 
haemorrhage is stopped when tissue trauma occurs. However, in unhealthy arteries, 
platelet accumulation can result in thrombotic occlusion of the vessel lumen along 
with the flow of blood being impeded resulting in ensuing tissue damage. Thus, one 
of the main functions of endothelial cells is maintaining equilibrium between blood 
fluidity and swift thrombus development in response to injury. They manage vascular 
tone, synthesize inhibitors and activators of platelet function and play a role in blood 
clotting. When there is subsequent vascular damage and the extracellular matrix is 
free to mix with flowing blood because the endothelial cell barrier is destroyed, 
haemostatic thrombus formation occurs. Platelets respond to this occurrence in three 
phases involving adhesion, activation and aggregation (Gross & Aird, 2000; Ware & 
Heistad, 1993).
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1.7.1 Platelet adhesion
Initial platelet adhesion is mediated by membrane receptors that function regardless of 
cellular activation. These membrane receptors cause the first layer of activated 
platelets to be attached to the affected area within seconds. The type and seriousness 
of the damage determines which extracellular matrix components will be in contact 
with the responding platelets. The means by which platelets adhere to the endothelium 
is demonstrated in Figure 1-9.
Platelet
GPI b/llla
/C o lla g e n  in 
subendothelium
Fibrinogen
GPIb/IX
Von Willebrand 
factor
Endothelial cell
Figure 1-9. Mechanism of platelet adhesion and aggregation
This mechanism is found in the normal arteriolar circulation or in larger arteries with stenotic 
lumen. Tethering to immobilized vWF allows circulating platelets to contact a thrombogenic 
surface or adherent platelets that have been activated. Interaction o f activated platelets with 
collagen in the extracellular matrix is responsible for adhesion, and interaction with 
fibrinogen is responsible for aggregation.
These matrix components can also interact with secreted molecules such as collagen 
or bound vWF. When the endothelium is damaged the main basement membrane 
components, such as proteoglycans, collagen type IV, nidogen (entactin) laminin and 
fibulin, are allowed to mix with the circulating blood.
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Although proteoglycans are vital in coagulation modulation, they are not necessarily 
directly associated with platelet adhesion. Similarly, while collagen type IV and most 
other collagen types, can trigger platelet responses it is not as efficient as other 
collagens that are located within the vascular wall (types I, HI and VI) (Saelman et al, 
1994). During high blood flow, collagen receptors cannot function to trigger thrombus 
formation thus, glycoproteins are needed (Savage et al., 1998). There are two platelet 
membrane glycoproteins (GPs), integrin-c^Pi (GPIa-IIa) and GPVI, which interact 
directly with collagen (Savage et al, 1996). The communication between GPIb and 
vWF allows the initial layer of platelet to adhere to the surface. The interaction 
between GPIb and vWF is a requirement for typical platelet bonding (Doggett et al, 
2002).
1.7.2 Platelet activation and procoagulant activity
Platelet activation is initiated when adhesive ligands and excitatory agonists bind to 
cognate receptors located on the platelet’s membrane. It is further carried out through 
cell signalling reactions involving enzymes, substrates and co-factors engaged in 
specified protein-protein and protein-lipid interactions. Prostacyclin and nitric oxide 
are some of the inhibitory substances that aid in restricting major thrombus formation 
in disruptions within the vessel wall. Among those substances that stimulate platelet 
action are collagen, vWF, a-thrombin, ADP, serotonin (5-HT), epinephrine and TXA2 
(Heemskerk et a l, 2 0 0 2 ).
a-thrombin induces platelet activation through G protein-linked protease-activated 
receptors (PARs) which trigger intracellular signalling (Sambrano et a l, 2001). There 
have been four specific PARs identified, they are PARI, PARS, PAR4, which respond 
to thrombin and PAR2, which is activated by trypsin (Coughlin, 1999). The response 
formulated by PARs cause a series of events to occur. It causes the activation of 
phospholipase C which hydrolyzes the membrane-associated phosphatidylinositol- 
4,5-bisphosphate into inositol-tris-phosphate and diaclyglycerol. Inositol-tris- 
phosphate promotes mobilization of calcium (Ca++) from endoplasmic reticulum and 
diaclyglycerol activates protein kinase C. Increased intracellular calcium leads to 
platelet aggregation by p38 MAP (mitogen-activated protein) kinase-dependent
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activation of phospholipase A2 (Coulon et a l, 2003). The latter hydrolyzes membrane 
phospholipids and this result in AA being released from phospholipid and TX being 
formed. During platelet activation, there have been two occurrences that have been 
linked with thrombin receptors and calcium levels. The first signal was mediated by 
PARI with a subsequent calcium signal (Covic et a l, 2000). Apart from being able to 
activate platelets through PARs, a-thrombin can also trigger platelet responses by 
binding to the GPIb-DC-V complex (Mazzucato et a l, 1998).
Although ADP is vital to platelet function because it magnifies the responses of other 
agonists and it is considered to be a weak agonist itself. By itself, it only causes the 
modification in shape and reversible platelet aggregation. Further aggregation and 
secretions are the outcomes of ADP-induced synthesis of TXA2. ADP affects calcium 
and adenylyl cyclase by interacting with specific platelet receptors. It causes a rise in 
cytoplasmic calcium through interaction with the Gq-coupled P2Yi receptor, and 
inhibits adenylyl cyclase, by communicating with the Gi-coupled P2 Yi2 receptor. To 
cause normal ADP-induced platelet aggregation, both the Gq and Gi pathways need to 
be activated. Epinephrine and TXA2 can also activate platelets through specific G 
protein-coupled receptors (GPCRs) (Gachet, 2000).
Activated platelets exhibit the actin polymerization with cytoskeletal reorganization, 
secretion from storage granules and aggregation dependent on the soluble ligand 
binding to integrin-allbp3. The process of secretion involves granular contents being 
released into the cytoplasm and the extracellular space and it includes the membrane 
proteins being transferred to the cell surface (for example, P-selectin). These 
occurrences improve platelet activation and aggregation. Platelet activation causes the 
regulation of surface exposure for phosphatidylserine, which facilitates the assembly 
of enzymes into functional complexes by providing docking sites on the surface of the 
anionic phospholipids. The procoagulant activity of activated platelets leads to the 
formation of thrombin and helps to deposit fibrin within the aggregates and contribute 
to the stability of the developing thrombus (McNicol & Israels, 2003).
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1.7.3 Platelet aggregation
When platelets aggregate, this triggers the accumulation of platelets into the 
haemostatic thrombus. The aggregation step is mediated by adhesive substrates that 
are found on the membranes of activated platelets.
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Figure 1-10. Mechanism of platelet aggregation
Exposure and activation of the allbpS (GPIIb/IIIa) receptor, the final common pathway 
leading to aggregation, can be realized via different mechanisms and via different stimuli 
(Herman, 1998). The impact of the various pathways, which finally lead to the exposure of 
the GPIIb/IIIa receptor, can thus vary according to the type and/or the concentration of the 
agonists present. The mediators released during the process of platelet aggregation can 
potentiate each other and, for example, small subthreshold doses of 5-HT markedly diminish 
the amount of ADP required to induce aggregation.
33
When aiibPs or GPIIb-IIIa is activated, there is a change in the ligand-binding ability 
(Woodside et a l, 2001). Activated GPIIb-IIIa aids in stable adhesion and 
immobilization of soluble proteins such as vWF, fibrinogen and fibronectin, on the 
surface of activated platelets and more platelets are recruited on this substrate (Savage 
et al, 2002). The mechanism of platelet aggregation is shown in Figure 1-10.
1.7.4 Platelet and the development of atherosclerosis
Two of the most important characteristics of atherosclerosis are the deposition of 
lipids and the local infiltration of leukocytes (Lusis, 2000). The resulting environment 
affects endothelial cell function and increases the possibility of communication with 
other cells including platelets (Sachais, 2001). When platelets are adhered to 
atherosclerotic plaques, they become activated and then cause more aggregation 
which influences the plug progression (Ross, 1999).
A deficiency of vWF provides some protection from atherosclerosis (Methia et al, 
2001). Enhanced secretion of vWF can result in platelet stimulation and can lead to 
activation and accumulation (Theilmeier et a l, 2002). More features such as infection 
from different pathogens can trigger inflammation and lead to atherosclerosis 
(Willerson, 2002). When platelets are exposed to microorganisms, antibodies bound 
to these microorganisms can activate the platelets through the immunoglobulin G 
receptor, FCyRIIA. Therefore, recurrent infection may be the cause of the accelerated 
development of an atherosclerotic plaque because platelets are being activated and 
drawn to the affected region (Sjobring et al, 2002).
Activated platelets that have adhered to an atherosclerotic lesion can manipulate the 
development of the plaque by releasing adhesive ligands, binding molecules from 
plasma and providing a reactive surface for monocytes and lymphocytes. Among the 
molecules affected is a ligand called P-selectin, which after release becomes 
expressed on the platelet membrane (Cell et a l, 1997). Lymphocytes can attach to the 
damaged vessel regardless of the high blood flow whereas they may not have been 
able to do so if there were no interactions between activated platelets. Platelets also 
contain and release growth factors which have been known to play a role in cellular
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proliferation (Ross, 1993). Current studies place platelets in a more direct role in the 
development of the atherosclerotic lesion because platelets play a role in the cellular 
metabolism of low-density lipoproteins (Sachais et al, 2002). Similarly, when 13- 
amyloid, derived from ingested platelets, is processed, this can activate macrophages 
in an atherosclerotic plaque. These reactions further demonstrate the idea that the 
attachment of platelets to the vesicular wall contributes to chronic lesions that 
precede, typically by many years, the acute onset of arterial thrombosis (Tedgui & 
Mallat, 2002).
1.7.5 Platelets and arterial thrombosis
The normal arterial wall and an atherosclerotic plaque vary in structure. Triggering a 
platelet response can be the result of susceptible unstable atherosclerotic plaques. The 
resulting thrombosis can also be increased due to dysfunction of the endothelial cells, 
exposure of tissue and highly reactive collagens (Ruberg et al, 2002). The area 
surrounding an atherosclerotic lesion triggers shear stress due to a rise in blood flow ( 
Mailhac et a l, 1994; Strony et al, 1993). This stress also has the ability to increase 
platelet reactivity through the vWF-GPIIb pathway (Goto et a l, 1999).
1.7.6 Platelet inhibition
Platelet inhibitors are derived mostly from endogenous anti-thrombotic compounds. 
The platelet inhibitory function is mediated by NO and PGI2 generated from platelets, 
endothelial cells and leukocytes. Nitric oxide inhibits platelet adhesion, aggregation,
and stimulates disaggregation of preformed platelet aggregates. These effects of NO
( !
are mediated by guanylate cyclase stimulation and the formation of cyclic GMP and 
its subsequent transduction mechanism. Prostacyclin can prevent and reverse platelet 
aggregation similar to NO but via a different mechanism by stimulation of adenylate 
cyclase and the formation of cyclic AMP (Radomski et al, 1990). This is important 
because inhibiting the formation of prostacyclin by COX-2 can result in thrombosis 
and may in fact increase the risk of heart attacks (McNicol & Israels, 2003). COX-2 
inhibitors recently have withdrawn from market due to this effect.
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The endothelium discharges a far greater amount of NO than platelets. By stimulating 
guanylyl cyclase, NO can prevent platelets from being activated. Additionally, 
ADP/ATP can be converted to adenosine through enzymatic processes and this too 
prevents platelet aggregation. Thus, the immediate stimulus to platelet activation is 
followed after a delay by inhibition. The cycle can be quite quick experimentally, 
with the decay occurring over minutes; locally decay may be much faster. Adenosine 
is also released by all cells if they run out of oxygen. Therefore, if a platelet 
aggregation blocks a small blood vessel, downstream tissue releases adenosine which 
starts to break up the aggregation and this is pathologically important (Sogo et al, 
2000).
Some inhibitors have direct effects on blood vessels. These compounds cause the 
vessels to relax. In a manner comparable to adenosine, NO stimulation results in the 
relaxation of blood vessels. Platelets communicating with endothelial cells have some 
effects on blood vessels. Depending on the signals emitted, small aggregates can be 
broken up or more platelets can be activated and accumulate at the affected region. If 
there is no damage to the endothelium, endothelial cells release PGI2 and NO which 
inhibit aggregation and prevents the constriction of blood vessels (Hankey & 
Eikelboom, 2003).
Clopidogrel and ticlopidine, the thienopyridine derivatives, are metabolised in the 
liver to active compounds which covalently bind to the ADP receptor on platelets and 
dramatically reduce platelet activation (Savi & Herbert, 2005). Dipyridamole inhibits 
phosphodiesterase, which inactivates cyclic AMP. Increased intraplatelet 
concentrations of cyclic AMP reduce the activation of cytoplasmic second 
messengers. Dipyridamole also stimulates prostacyclin release and inhibits TXA2 
formation, also block adenosine uptake and therefore enhances effect of adenosine 
(Liu ef a/., 2004).
Glycoprotein Hb/IIIa receptor antagonists block the final common pathway for 
platelet aggregation. Abciximab is a humanised mouse antibody fragment with a high 
binding affinity for the glycoprotein Ilb/IIIa receptor. Tirofiban (a non-peptide 
derivative of tyrosine) and eptifibatide (a synthetic heptapeptide) mimic part of the 
structure of fibrinogen that interacts with the glycoprotein Ilb/IIIa receptor and thus
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compete with ligand binding of fibrinogen to the glycoprotein Ilb/IIIa receptor 
(Conde & Kleiman, 2004).
1.8 Hepatic microsomes and arachidonic acid
Beside platelets, AA is also extensively metabolised by microsomes. A hepatic 
microsome is a small vesicle that is derived from fragmented endoplasmic reticulum 
produced when hepatocytes are homogenised. Purified microsome preparations are 
routinely used to study the role of cytochrome P450s and other enzymes involved in 
drug metabolism. These preparations are a rich source of membrane-bound, 
hydrophobic enzymes originating from smooth endoplasmic reticulum and rough 
endoplasmic reticulum that catalyze phase I reactions of metabolism. The CYP 
monooxygenases constitute a major metabolic pathway for AA in the hepatic 
microsomes.
1.8.1 Cytochrome P450
Cytochrome P450 was discovered in the late 1950’s (Klingenberg, 1958). 
Cytochrome P450 refers to a super family of heme-thiolate enzymes whose Fe2+- 
carbon monoxide complex shows an absorption spectrum with a maximum at 450 nm. 
There is enormous diversity between members of the CYP family. The CYP enzymes 
can be found in virtually all organisms including bacteria, fungi, yeast, plants, insects, 
fish and mammals. All CYP genes have probably evolved from one single ancestral 
gene, which existed before the time of prokaryote/eukaryote divergence (Nelson et 
al., 1996).
Due to the large number of CYPs, a standardised nomenclature system has been 
developed. The enzymes have been organised based on identities in protein sequence. 
The enzymes are named CYP, representing cytochrome P450, followed by a number 
denoting the family, a letter designating the subfamily and a second numeral 
representing the individual enzyme. The corresponding gene name is written in 
italics. Enzymes that have more than 40% amino acid sequence identity are
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considered to belong to the same family, whereas enzymes with more than 55% 
sequence identity are in the same subfamily (Nelson et al, 1996),
The CYP enzymes have two major functions. They are involved in the biosynthesis, 
bio-activation and catabolism of endogenous compounds, such as fatty acids, steroid 
hormones, vitamins, bile acids, and eicosanoids. They are also involved in the 
metabolism of foreign chemicals and drugs. Drugs and other chemicals are often 
converted by CYP to more polar compounds that can be directly excreted or further 
conjugated by other enzymes. The conjugate makes the modified compound more 
water-soluble so it can be excreted into the urine. Some of these CYP reactions can 
lead to the bio-activation of drugs or to the formation of more toxic compounds 
(Klaassen, 1996; Guengerich & Shimada, 1998).
Within the cell, the CYPs are mainly located in the endoplasmic reticulum (ER) and 
in the inner membrane of the mitochondria. The mitochondria house several CYP 
enzymes that are involved in the biosynthesis and metabolism of steroid hormones, 
bile acids, and vitamin D (Klaassen, 1996). CYPs metabolize AA by four pathways.
1.8.1.1 Terminal and sub-terminal hydroxylation of AA
The 20th carbon of AA is called terminal carbon and 16th, 17th, 18th and 19th carbon of 
AA is called sub-terminal carbons. Arachidonic acid terminal and sub-treminal 
hydroxylations have been demonstrated in microsomes isolated from many different 
tissues (Oliw, 1994). Many studies have shown that CYPs belonging to the CYP4A 
subfamily are the predominant fatty acid terminal/sub-terminal-hydroxylases in most 
mammalian tissues including the kidney and liver (McGiff & Quilley, 1999). 
However, the CYP4A enzymes usually metabolize saturated fatty acids such as lauric 
acid at much higher rates than AA (Hoch et a l, 2000). Thus, the CYP4A enzymes 
probably play an important role in cellular fatty acid homeostasis. The formation of 
20-HETE and 19-HETE is best characterized in the kidney, as they are most prevalent 
there and have several postulated functional roles in renal physiology (Capdevila et 
al, 2 0 0 0 ).
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Microsomes from the human kidney cortex convert AA mainly to 20-HETE, which 
has been proposed to be involved in renal ion transport and vascular tone. 20-HETE 
and a glucuronide conjugate of 20-HETE have been identified in human urine 
(Prakash et a l, 1992). It has been reported that 16R-, 18R-, and 19-HETE exert 
vasodilator effects and that 16S-, and 17S-HETE inhibit renal proximal tubular 
Na+/K+-ATPase activity (Carroll et a l, 1996). Recently, it was shown that human 
PMNs contain endogenous pools of 16-HETE produced via a cytochrome P450 
pathway, and some of it was stored within PMNL membrane phospholipids (Bednar 
et al, 2000a). The products of hydroxylation of the terminal and sub-terminal carbons 
of AA by CYP are shown in Figure 1-11.
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Figure 1-11. Terminal and sub-terminal hydroxylation of AA
Terminal hydroxylation generates 20-HETE and sub-terminal hydroxylation generates 16-,
17-, 18-, and 19-HETE.
1.8.1.2 Epoxidation of AA
Arachidonic acid has four double bonds and CYP can oxygenate all of these to cis- 
epoxides (EETs). These EETs can be further hydrated by epoxide hydrolases to
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dihydroxyeicosatrienoic acids (DiHETs). The EETs/DHETs have been detected in 
many tissues and body fluids, including human liver, kidney, heart, plasma and urine 
(Capdevila et a l, 2000).
Racemic EETs can be formed non-enzymatically, but strong evidence for the 
enzymatic formation of endogenous EETs has been provided by chiral analysis of 
EETs in phospholipids. It has been proposed that EETs play a role in the structure and 
hence the function of cellular membranes (Oliw, 1994). Many studies have indicated 
that EETs are involved in regulation of vascular tone and might serve as an 
endothelium derived hyperpolarization factor (Fisslthaler et ah, 1999). EETs may also 
play a role in vascular inflammation (Node et al, 1999) and be involved in 
transcriptional regulation of PGH synthase-2 and CYP (Peri et al, 1997; Peri et al,
1998). The products of epoxidation of AA by CYP are shown in Figure 1-12.
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Figure 1-12. Epoxidation of arachidonic acid
CYPs oxidise AA at the double bond regions by epoxidases and generates 5,6-EET, 8,9-EET, 
11,12-EET, and 14,15-EET.
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1.8.1.3 Bisallylic hydroxylation of AA
In addition to four double bonds AA has three bisallylic carbons in positions 7, 10 and
13. These bisallylic carbons can be hydroxylated by CYPs (Oliw et a l, 1996). The 
bisallylic hydroxyl metabolites are chemically unstable at acidic pH, which is 
commonly used for the extractive isolation of fatty acid metabolites. At acidic pH the 
bisallylic HETEs will undergo a non-enzymatic rearrangement to cis-trans conjugated 
HETEs ( Brash et al, 1995; Oliw et al, 1993). The products of bisallylic 
hydroxylation of AA by CYP are shown in Figure 1-13.
Figure 1-13. Bisallylic hydroxylation of arachidonic acid
AA has three bisallylic carbons in position 7, 10 and 13 and CYP generates 7-HETE, 10- 
HETE and 13-HETE by bisallylic hydroxylation from AA.
The formation of bisallylic HETEs and 11-hydroxyoctadecadienoic acid (HODE) (the 
corresponding bisallylic product of linoleic acid) has been studied in liver microsomes 
of rats treated with different kinds of CYP inducers (Oliw et a l, 1996). Liver 
microsomes prepared from rats treated with phénobarbital converted AA to 7-HETE, 
10-HETE and 13-HETE, and linoleic acid to 11-HODE (Brash et a l, 1995). Steric 
analysis revealed that these metabolites were almost racemic. Dexamethasone, which 
is an inducer of the CYP3A isoforms, efficiently and selectively increased the 
bisallylic hydroxylation activity in rat liver microsomes (Homsten et a l, 1996). Rats 
treated with inducers of other CYP isoforms, e.g. CYP1A, also increased the bisallylic
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hydroxylation activity. This indicates that the formation of bisallylic hydroxy 
metabolites can be catalyzed by rat CYP3A isoforms, but that other CYP isoforms 
may also possess this activity (Homsten et al, 1996).
The formation of 13-HETE and 11-HODE has been detected in human liver 
microsomes (Oliw et a l, 1996). The human CYP isoforms that are involved in the 
formation of bisallylic hydroxy fatty acids, have not been studied (Capdevila et al, 
2000). However, it has been reported that human CYP1A2, CYP2C8 and CYP2C9 
formed large amounts of cis-trans conjugated HETEs following acidic isolation 
(Rifkind et al, 1995).
1.8.1.4 Hydroxylation with double bond migration of AA
Hydroxylation with double bond migration leads to the enzymatic biosynthesis of cis- 
trans conjugated hydroxy fatty acids. Arachidonic acid can be converted by CYP to 
six cis-trans conjugated HETEs (5-, 8 -, 9-, 11-, 12-, and 15-HETE), which are 
structurally similar to the HETEs generated by LOX, but their biosynthesis does not 
involve formation of a hydroperoxide (HPETE) (Capdevila et al, 2000). Cis-trans 
conjugated HETEs can also be formed non-enzymatically by acid-catalyzed 
rearrangement of bisallylic HETEs (Brash et a l, 1995), by the LOX pathway (Brash,
1999) or by PGH synthase (Thuresson et a l, 2000). The human CYP isoforms that 
catalyze the formation of these metabolites have not been well characterized. Previous 
studies on the formation of HETEs by CYP, which have used acidic extractions, may 
have partly overlooked the stereo selectivity and the quantitative importance of the 
cis-trans conjugated HETEs. Cis-trans conjugated hydroxy fatty acids have been 
implicated as signal molecules involved in the regulation of gene expression 
(Capdevila et a l, 2002). The products of hydroxylation with double bond migration 
of AA by CYP are shown in Figure 1-14.
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Figure 1-14. Hydroxylation with double bond migration of AA
Cis-trans conjugated hydroxy fatty acids are synthesized from AA by hydroxylation with 
double bond migration. Arachidonic acid can be converted by CYP to six cis-trans 
conjugated HETEs (5-, 8-, 9-, 11-, 12-, and 15-HÈTE).
CYP enzymes of human liver microsomes form 12-HETE with stereo specificity 
(>90% 12R-HETE) (Oliw et a l, 1996). Studies have demonstrated that 12R-HETE is 
an agonist for the LTB4-receptor and might exert inhibitory effects on Na+/K+-ATPase 
activity (Masferrer et al., 1990; Tanaka et al, 1991).
1.8.2 Relation of cytochrome P450 with COX and LOX pathway
The biological significance of the AA metabolites formed by the CYP pathway are 
not fully understood (Capdevila et al, 2000). Many studies have suggested that the 
metabolites have a wide range of physiological implications. They appear to act 
primarily within the cells of origin and do not need to be extruded into the 
extracellular space to stimulate membrane receptors. Within the cells, they have been 
proposed to be involved in the regulation of ion channels and transporters, and are 
known to act as mitogens. In whole animal physiology, they have been implicated in 
the mediation of peptide hormone release, regulation of vascular tone and volume 
homeostasis. Several studies have indicated that some of the biological effects
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mediated by CYP metabolites of AA are PGH synthases dependent. Some of these 
effects might be due to modulation of the biosynthesis of prostanoids (Oliw, 1994).
CYP metabolites of AA can be substrates for PGH synthases. 20-HETE 
(Schwartzman et al., 1989) and 5,6-EET can be converted by PGH synthase to 20- 
hydroxy-PGHz (Carroll et al, 1993) and 5,6-epoxy-PGHi (Oliw, 1984), respectively. 
Both of these compounds can be further metabolized into bioactive prostanoids. 8,9-, 
11,12-, and 14,15-EET lack the necessary double bonds to be converted to 
prostanoids by PGH synthases, but they might undergo abortive PGH synthase 
reactions or can inhibit the enzyme (McGiff & Quilley, 1999). It has been shown that 
8,9-EET can be hydroxylated at C ll and C l5 by PGH synthase (Zhang et a l, 1992).
18-HETE and 19-HETE can be converted into prostanoids by PGH synthase, but they 
are considered to be poor substrates (Capdevila et a l , 2000).
The enzymes catalyzing the formation of TXA2 and PGH are two CYP enzymes. 
CYP5A (TXA2 synthase) of platelets and CYP8A (PGI2 synthase) of the vascular 
endothelium rearrange PGH2 into TXA2 and PGI2, respectively. These two CYP 
enzymes catalyze isomerization reactions and do not require NADPH (Hecker & 
Ullrich, 1989). CYP5A also converts PGH2 to 12-HHT and malondialdehyde. 
Recently, it was shown that human drug metabolizing CYP and liver microsomes 
could also catalyze the formation of 12-HHT and malondialdehyde from PGH2 
(Plastaras et al, 2000).
1.9 Polymorphonuclear leukocytes and arachidonic acid
Stimulation of human PMNs by soluble agonists and phagocytic stimuli increases the 
levels of intracellular-free calcium and causes cytosolic phospholipase A2 (cPLA2)- 
mediated release of AA. Although AA is considered an important PMN activator, the 
molecular mechanisms through which it regulates PMN functions are still poorly 
understood and contentious. The major AA metabolites synthesized by activated 
PMN are the products of the stereospecific biotransformation of AA by the 5-LO. 5- 
HpETE, the first metabolite of the 5-LO pathway, can be reduced to 5-HETE and/or 
metabolized further by the 5-LO to leukotriene A4 (LTA4) (Borgeat & Naccache,
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1990). LTA4 is then rapidly converted to LTB4 by the LTA4 hydrolase. LTB4 is a 
biologically active compound that acts through interaction with the specific cell- 
surface receptors (Yokomizo et al., 2001).
1.9.1 Role of AA on apoptosis
Apoptosis is a tightly regulated form of cell death, also called the programmed cell 
death by which cells undergo death to control cell proliferation or in response to DNA 
damage. Morphologically, it is characterized by chromatin condensation and cell 
shrinkage in the early stage and then the nucleus and cytoplasm fragment, forming 
membrane-bound apoptotic bodies that can be engulfed by phagocytes. Apoptotic 
messages may be from outside the cell (called extrinsic inducers) like NO2 or from 
inside the cell (intrinsic inducers) are a response to stress, such as nutrient deprivation 
or DNA damage (Chiarugi & Moskowitz, 2002). Both extrinsic and intrinsic 
pathways have in common the activation of central effectors of apoptosis, a group of 
cysteine proteases called caspases, which carry out the cleaving of both structural and 
functional elements of the cell (Nicholson, 2000).
Schonberg et al. observed that n-3 fatty acids may inhibit the growth of tumour cells 
both in vivo and in vitro (Schonberg et ah, 1997). AA blocked proliferation of the 
promyelocytic leukemic HL-60 cells and this blockage which is a predecessor of both 
apoptosis and necrosis was unrelated to oxygenase metabolism or lipid peroxidation 
(Finstad et al., 1994). AA stimulates neutral sphingomyelinase activity (Jayadev et 
al., 1994), which catalyzes the hydrolysis of sphingomyelin to generate ceramide. 
Ceramide acts as second messenger that activates the cellular apoptotic machinery 
(Jayadev et a l, 1997). Mechanisms of the anti-proliferative or pro-apoptotic actions 
of AA remain to be clarified and may vary among different cell types (Cao et al,
2000). AA metabolism hold the potential basis for several new therapeutic strategies 
for treating neoplasia (Zarebska et a l , 2005).
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1.10 Aims of the study
Platelets metabolize AA and causes formation of TXA2, which causes platelet 
aggregation. However, it has been found that the \A-trans isomer of AA is not an 
agonist for rat platelet aggregation. Indeed, the proaggregant effects of AA are 
inhibited by \A-trans-AA through unknown mechanism(s) and that the trans-AA was 
metabolized into products that they have not identified (Berdeaux et ai., 1996). Jiang 
et al, (1999) also demonstrated that 14-trans-AA is one of the main products of 
oxygen free radical mediated oxidation of AA in platelet membrane phospholipids. 
The aim of this study was to examine the metabolism and effects of \4-trans-AAs in 
human platelets where AA is mainly metabolized by COX. The metabolic study of 
trans-AA by hepatic microsomes and PMNs were also observed as AA is metabolized 
in these cells by CYP and LOX respectively. The study was designed to identify and 
characterize any new metabolites formed from trans-AA using chromatography, 
radioactivity detector and mass spectrometry and for functional studies aggregometry 
was used. Studies using platelets, hepatic microsomes and PMNs were used as a 
model for trans-AA metabolism in humans. These will assist in establishing if these 
pathways exist in other tissues and in vivo.
The specific aims of this study are as follows:
1. To profile the metabolism of lA-trans-AA in platelets with special emphasis is 
on the metabolism of \A-trans-AA by COX and the generation of PG/TX 
analogues.
2. To study the effect of inhibitors (indomethacin, baicalein) on \A-trans-AA 
metabolism in platelets.
3. To study the effect of lA-trans-PA on AA metabolism and to compare it with 
platelet AA metabolism.
4. To compare AA estérification with \A-trans-PA. into platelet membrane 
phospholipids.
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5. To study the effects of \A-trans-AA. on platelets and the inhibitory effects of 
\A-trans-AA. on AA-induced aggregation.
6 . To profile the metabolism of trans-AA by hepatic microsomes and compare 
with metabolism of AA.
7. To evaluate the role of trans-AA metabolism in PMNs in relation to the effect 
of the trans-AA isomers on the proliferation and viability of HL-60 cells.
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2 M ETHODS
2.1 General and analytical methods
2.1.1 Synthesis and purification of trans-AAs
Trans-AAs were synthesized by passing NO2 over AA (Jiang et al, 1999). 
Arachidonic acid (100 p,g) was dissolved in 1 ml of hexane, and 100 pg sodium 
arachidonate was dissolved in 1 ml of 0.5 mM phosphate buffer (pH 7.4). Deuterium 
labeled AA (10 pg) was mixed with [1-I4C] AA (10 pCi) and was used to prepare the 
internal standards for quantitative analyses.
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Figure 2-1. Chromatogram of the products of NO2 reaction with AA
100 pg AA in 1 ml of hexane was reacted with 43 pM NO2 and products were extracted with 
ethyl acetate, dissolved in methanol and separated using a HPLC. Chromatogram shows that 
the NO2 radical mediated cis-trans isomerization of AA along with the formation of nitro- 
AAs.
Nitrogen dioxide was prepared shortly before the reaction with AA as previously 
described (Jiang & Balazy, 1998). In short, approximately 1 ml of liquid NO2 was 
collected from a tank via narrow teflon tubing inserted into a tightly capped, helium- 
filled glass vial (5 ml) through a teflon-lined silicon rubber seal. NO2 was delivered 
into arachidonate solution via bubbling and helium was used as a carrier gas at a rate 
of 0.1 ml/min. The final concentration of NO2 was 43-430 pM. The reaction was
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carried out for 5 min, and the lipids were isolated by extraction with ethyl acetate. The 
extracts were dried under nitrogen, dissolved in a small volume of methanol and were 
analyzed and purified by reverse phase HPLC (Krishna et a l, 2001). A chromatogram 
shows the products of the NO2 reaction with AA in Figure 2-1.
2.1.2 HPLC analyses
In chromatography, the sample is dissolved in a mobile phase, and the mobile phase is 
forced through an immobile, immiscible stationary phase. The phases are chosen in a 
way that the components of the sample have different solubilities in each phase. A 
component, which is quite soluble in the stationary phase, will take longer to travel 
through it, than a component that is not very soluble in the stationary phase but very 
soluble in the mobile phase. Because of these differences in mobilities, sample 
components become separated from each other as they travel through the stationary 
phase along with mobile phase (Parvez et al, 1985). The schematic of HPLC is 
shown in Figure 2-2.
Reverse phase (RP) HPLC was used to separate various metabolites. In RP HPLC, 
compounds stick to the RP HPLC column containing C l8 octadecyl silica in high 
aqueous mobile phase and are eluted from RP HPLC column with a highly organic 
mobile phase. In RP HPLC, compounds are separated based on their hydrophobic 
character. Lipids were separated by running a linear gradient of the organic solvent.
HPLC analyses were performed on a HPLC system (HP 1050, Hewlett-Packard, Palo 
Alto, CA) equipped with a quaternary pump, a variable-wavelength UV detector and 
using a C l8 octadecyl silica (ODS) column (250 X 4.6 mm, Beckman Instruments, 
CA). Analyses were performed by eluting the sample with a linear gradient of 
acetonitrile in water (pH 4, adjusted with acetic acid). The initial concentration of 
acetonitrile was 25% and it gradually increased to 100% (v/v) within 60 minute at a 
flow rate of 1 ml/min by a gradient program. The effluent was analyzed using an in­
line UV variable wave length detector (Jiang et al, 1999).
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Figure 2-2. Block diagram showing the components of a HPLC system
A HPLC system consists of solvent delivery system (pumps), injector, packed column and 
detector. After injection, the sample is dissolved in a mobile phase, and the mobile phase is 
forced through an immobile stationary phase packed in the column. The detector detects the 
samples and the data is sent to a computer.
An on-line radio-chromatography detector (Radoimatic Flo-One\Beta Series A-100) 
was used to detect radiolabeled products (Radiomatic Instruments, Tampa, FL) using 
Sigma-fluor scintillation fluid (Sigma Chemical Co.). Fractions were collected using a 
Gilson FC 203B (Gilson Inc., WI) fraction collector and used for gas chromatographic 
analysis (Boulos et a l , 2000).
2.1.3 UV Spectroscopy
Some purified sample fractions by HPLC system (HP 1050, Hewlett-Packard, Palo 
Alto, CA) described in section 2.2 were injected into a HPLC (HP 1100, Hewlett- 
Packard, Palo Alto, CA) equipped with a C l8(2) octadecyl silica (ODS) column (150 
X 2.00 mm, Phenomenex, Torrance, CA) and the spectra were recorded using a diode 
array detector (Hewlett-Packard G1315A). The spectra were taken from 200 to 400
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nm at a scan rate of 250 nm/s. Specific absorbance at 234 nm was for 12- HETE and 
the absorbance maxima (Imax) for the unknown metabolites were measured.
2.1.4 Mass spectrometry
For mass spectrometric analysis of the samples, GC/MS and LC/MS was used. 
Samples were derivatized before injection into GC/MS in order to make more 
volatile.
2.1.4.1 Preparation of derivatives for GC/MC
For GC/MS analyses, pentafluorobenzyl (PFB) esters were prepared. In short, 
samples were dried completely under nitrogen, and dissolved in acetonitrile (1 0 0  pi). 
Ten percent PFB (30 pi) and diisopropylethylamine (DIPEA) (30 pi) were added to a 
sample and the derivatization was continued at room temperature for 30 min. The 
samples were dried completely under nitrogen, dissolved in 50 pi of isooctane, and 
analyzed by gas chromatograph (Agilent network GC system 6890N)/mass 
spectrometer (Agilent mass selective detector 5973N).
Figure 2-3. Flow diagram showing GC/MS derivative preparation
All samples were derivatized with pentafluorobenzyl, but the samples containing hydroxyl 
group were further derivatized with trimethylsilyl and injected into a GC/MS.
TMS derivatization was done for samples having a hydroxyl group. Trimethylsilyl 
(TMS) (80 pi) and pyridine (20 pi) were added to the completely dried PFB ester 
samples to convert the hydroxyl groups into the TMS derivative. After 30 min at 
room temperature the reagents were evaporated completely under nitrogen and the
GC/MS
Samples — ► PFB esters
TMS derivative — ► GC/MS
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TMS esters were dissolved in 50 |il of isooctane and subjected to analysis by GC/MS 
(Balazy, 1991a). The schematic of sample derivatization is shown in Figure 2-3.
2.1.4.2 Gas chromatography/mass spectrometry
Gas chromatography was used for the separation and identification of volatile organic 
compounds. A gas chromatograph consists of a flowing mobile phase, an injection 
port, a separation column containing the stationary phase, and a detector. The organic 
compounds were separated due to differences in their partitioning behaviours between 
the mobile gas phase and the solid stationary phase in the column. The schematic of 
GC/MS is shown in Figure 2-4.
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Figure 2-4. Diagram showing the components of a GC/MS system
A gas chromatograph consists of a flowing mobile phase, an injection port, a separation 
column containing the stationary phase, and a detector. The samples are separated by the 
column and the detector sends the data to a computer.
Inert gas helium was used as a mobile phase. The injection port consisted of a rubber 
septum through which a syringe needle was inserted to inject the sample. The 
injection port was maintained at a higher temperature than the boiling point of the 
least volatile component in the sample mixture. Since the partitioning behaviour 
depends on temperature, the separation column was contained in a thermostat- 
controlled oven. Separating components with a wide range of boiling points was
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accomplished by starting at a low oven temperature and increasing the temperature 
gradually with time to elute the high-boiling point components.
Mass spectrometry was carried out on a quadrupole gas chromatograph 6890N 
network GC system (Agilent, Wilmington, DE) directly interfaced with a mass 
spectrometer 5973 mass selective detector (Agilent, Wilmington, DE). TMS 
derivatives of metabolites and standards were analyzed by GC/MS in an electron 
ionization mode (70 eV) or in a positive ion chemical ionization (Cl) mode (120 eV), 
whereas PFB derivatives were analyzed by GC/MS using a negative ion chemical 
ionization (NCI) mode. In chemical ionization experiments, methane (40 psi) was 
used as a reagent gas at a flow rate 40 1/min resulting in a pressure of 0.9 torr in the 
ion source.
The source and transfer line temperatures were 250 °C and 280 °C, respectively. The 
samples were dissolved in iso-octane and analyzed on a DB-1 fused silica gas 
chromatographic column (50 m, 0.25-mm internal diameter, 0.25-mm film thickness), 
(J/V Scientific, Folsom, CA). The initial temperature of the column (150 °C) was 
maintained for 1 min and then increased to 280 °C at a rate of 25 °C/min. The injector 
was used in a splitless mode at a temperature of 300 °C. Helium was used as a carrier 
gas at the pressure of 29.57 psi, delivering a total flow of 30.1 ml/min and resulting in 
a column flow of 1.3 ml/min. The relative retention time for each derivatized 
metabolite or standard was expressed as a carbon number equivalent. The measured 
retention times, under the above conditions of individual standards derivatized as PFB 
esters, were correlated with the number of carbons in a fatty acyl chain. The linear 
function (r = 0 .9 9 9 ) was used to calculate the carbon number equivalent for each 
metabolite derivative (Zghibeh et al.9 2004; Tsikas, 2001).
2.1.4.3 Liquid chromatography/mass spectrometry
Electrospray (ES) was used as it is a well-established technique allowing mass 
spectrometric (MS) analysis of various compounds without derivatization and on-line
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analysis in conjunction with liquid chromatography (LC). Schematic shows different 
components of mass spectrometer in Figure 2-5.
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Figure 2-5. Diagram showing the components of a LC/MS
A liquid chromatograph / mass spectrometer consist of an online HPLC system, ion source, 
mass analyzer and ion detector. After detection, data is sent to a computer and analyzed by a 
software system.
Electrospray is one of the interface in LC/MS that imparts very little internal energy 
into the analyte for ion generation process (Homing et al, 1974). Ions in solution 
from the eluent of the LC migrate from the bulk to the surface of the liquid under the 
influence of the high electric field strength near the tip of the needle (Figure 2-6). The 
characteristic "cone jet" geometry is the result of the liquid accelerating toward the 
collection electrode. When the electrostatic forces exceed the inward forces from the 
surface tension, a cone jet is created. The highly charged surface of the liquid jet 
immediately disperses into droplets that accelerate toward the collector electrode 
(Iribame & Thomson, 1975).
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The charged droplets evaporate in the region between the needle and the collector. 
The excess charge on the droplet concentrates on the surface as the droplet 
evaporates. This increases the field around the droplet to the point where the surface 
deforms into tear-shaped emitters of smaller particles (Ito et a l, 1986). With 
continued evaporation, this tear-shaped geometry is stable until the charge is depleted, 
the analyte crystallizes into solid particles, or the droplets completely evaporate. The 
significance of this process is that it occurs at relatively low temperatures (Gamero- 
Castano & Mora, 2000). Electro spray ionization in shown in Figure 2-6.
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Figure 2-6. Schematic diagram showing electro-spray ionization (ESI)
Schematic diagram of electrospray shows the motion of the charged droplets completing the 
mass analyzer. The high voltage applied to the needle electrode (in this case) drives the 
deformation of the liquid into a conejet-geometry. All variations of electrospray including ion 
spray, and turbo spray conform to this basic circuit.
Samples were injected in the HPLC system (HP 1100, Hewlett-Packard, Palo Alto, 
CA) equipped with a binary pump, a diode array UV detector using C l8 Ultrasphere 
ODS column (150 x 2.00 mm, 5 \i, Phenomenex prodigy, Phenomenex, Torrance, 
CA). Samples were eluted at a flow rate of 0.3 ml/minute with a linear gradient of 
acetonitrile in water (25% to 100% in 25 minute) and the effluent was analyzed by an 
online MS. Electrospray ionization MS was performed in negative ion mode on an 
API 2000 triple quadrupole LC/MS/MS mass spectrometer (Applied
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Biosystems/MDS Sciex, Forest City, CA) and data was analyzed by software package 
Analyst 1.4 (Applied Biosystems, Forest City, CA) to identify the structure of the 
unknown metabolites. The curtain gas was 35 psi, ion source voltage was -4200 volts, 
temperature of the source was 325° C, and flows of gas 1 and 2 were 35 and 50 
L/minute, respectively. The collision assisted dissociation (CAD) gas flow was 6  
L/min, declaustering potential (DP), focusing potential (FP), entrance potential (EP) 
and collision energy (CE) was -20, -350, -10 and -26 (arbitrary units), respectively. 
Samples were analyzed in Q1 MS, product ion (MS/MS) and multiple reaction 
monitoring (MRM) mode.
2.1.5 Trans-AA metabolism by LOX
A 12-LOX (200 pi) solution in 20 mM in phosphate buffer was preincubated at 37°C 
for 15 min and mixed with 14-trans-AA (100 pM). Control experiments were done 
with AA (100 pM). The incubations were carried for 10, 20 and 30 min at 37 °C and 
were terminated by the addition of methanol (1 ml). The solution was thoroughly 
mixed using a vortex and then centrifuged at 4000 rpm for 10 min. The supernatant 
was decanted and evaporated under nitrogen. Fatty acids were extracted using ethyl 
acetate (0.5 ml) and acidified water (0.5 ml) at pH 4 (containing 10% acetic acid). The 
solvent of extracts were evaporated under a stream of nitrogen. The lipid residue was 
dissolved in 100 pi of acetonitrile/water (1:1) and subjected to analysis by LC/MS as 
described in section 2.1.4.3.
2.2 Methods for studies with platelets
2.2.1 Platelet preparation
Fresh platelet concentrate (within 24 hours of collection) from human donors, who 
has not ingested any drugs known to interfere with platelet function for at least 15 
days, was purchased from Hudson Valley Blood Service (Elmsford, NY). Washed 
platelets were prepared using a method described previously (Gerrard, 1982). Briefly, 
10 ml of fresh platelet concentrate was centrifuged at 1100 g for 15 minutes at room
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temperature. After discarding the supernatant, platelets were resuspended in 5 ml 
buffer A containing 140 mM NaCl, 2 mM KC1, 14 mM NaHCOg, 5.5 mM glucose, 1 
mM MgClz, 5 mM Hepes buffer, 0.2% BSA, 1.5 pg/ml apyrase, 0.2 |_iM PGE% and the 
pH was adjusted to 6.4. Platelets in buffer A were centrifuged again at 1100 g for 15 
minutes at 21°C and resuspended in buffer B (same as buffer A, but without BSA, 
PGEi and apyrase, pH, 7.4). Platelets were counted using a Coulter Counter PS 540 
(Coulter Electronics, Hialeah, FL) and the density of platelets was adjusted to 1x108 
cells/ml.
2.2.2 Methods for observation of metabolism of trans-fldk by 
platelets
Metabolites were produced by incubating platelets with different amount of fatty 
acids for 30 minutes. To 1 ml of platelet suspension in buffer B, AA (100 pM) or 14- 
trans-AA (100 pM) or both were added and incubated while shaking at 1200 rpm in a 
37° C water bath for 30 minutes. In some experiments, platelets were preincubated 
with COX or LOX inhibitor for 5 minutes. To this mixture, 5 ml of methanol was 
added, vortexed, and centrifuged for 5 minutes at 1100 g. The supernatant containing 
fatty acids was transferred and dried completely under vacuum. Ethyl acetate (1 ml) 
and water (1 ml) were added to the tube, the pH adjusted to 4.0 by adding 10% acetic 
acid, and the tube was vortexed, and centrifuged again as before. The top phase was 
transferred to another tube and evaporated to dryness under nitrogen. Methanol (100 
pi) was added, mixed and 20 pi of the sample was injected into a HPLC system as 
described in section 2 .1 .2 .
2.2.3 Methods for observation of effects of trans-AA on platelet 
function
The aggregation study was performed according to the turbidimetric method of Bom 
(Bom, 1962; Bom & Cross, 1963). Figure 2-7 shows the function of an aggregometer.
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Figure 2-7. Diagram showing the function of an aggregometer
The platelet aggregometer measures platelet function by measuring light transmission through 
a suspension of stirred platelets. As shown in the figure above, the initial suspension is 
opaque and the resting discoid platelets give baseline oscillations. After the addition of an 
aggregating agent as shown of point A in the figure, platelets form larger clumps and the 
solution clears until maximum aggregation is achieved forming the aggregation curve.
Platelets were screened before the aggregation study for the ability to produce TXA2, 
which eliminated donors on NSAID medication or having a genetic defect of AA 
oxidase enzymes (Pareti et al, 1980). In a siliconized glass tube, 400 [iL platelet 
suspension was placed and warmed to 37°C for three minutes in a dual-channel 
aggregometer (Payton, NY). A small magnetic stirring bar was placed into the tube 
after 30 seconds and the suspension was stirred at 900 rpm. After 2 minutes, platelet 
activation was started by adding different amounts of AA, 14-trans-AA, U46619, 
ADP, epinephrine or cPAF. Aggregation was also observed with AA or other 
compounds in presence 14-trans-AA. The aggregation was monitored for 6  minutes 
with a strip chart recorder. The measurement of platelet aggregation was the output 
from turbidimetric aggregometer on a strip chart recorder and expressed in percentage 
terms as described earlier (Bom & Hume, 1967). This was achieved by calibrating the 
aggregometer in such a way that the optical density of the unstimulated platelet
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suspension represented 0% aggregation, while the optical density of the buffer B 
without any platelets represented 1 0 0 % aggregation.
2.2.3.1 Thromboxane B2 assay
The levels of TXB2, the stable metabolite of TXA2, in the supernatants were measured 
using LC/MS (as described in section 2.1.4.3) against a standard curve (Figure 2-8) 
made by injecting different known amount of commercial TXB2 standard. This 
approach provided quantitative measurement of TXB2 in platelets.
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Figure 2-8. TXB2 Standard curve
The relative abundance of TXB2 in calibration standards was determined by tandem mass 
spectrometry (MRM mode). The bottom panel shows the relative abundance of fragment ion 
m/z 169 that originated from the deprotonated TXB2 at m/z 369. Each peak results from a 
discrete injection of 5 pi by the autosampler. The interval between each injection was 1.5 min. 
The average integrated peak area of duplicate 5 pi injections of the calibration standards was 
plotted versus concentration to generate the linear calibration curve. The correlation 
coefficient is 0.992 (top).
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2.2.3.2 Membrane incorporation study
Washed human platelet suspension (1 ml) was preincubated at 37°C for 5 min and 
0.25 pCi of [1-14C]-AA (specific activity of 50 mCi/mmol, radiochemical purity > 
99%) or [l-14C]-14-rra7zs-AA (specific activity of 50 mCi/mmol, radiochemical purity 
> 99%), was added. The incubations were carried for 3 minutes at 37 °C with constant 
stirring at 1200 rpm. Then the vials were centrifuged at 2000 g for 5 min. The 
supernatant was decanted, and in the precipitate 1 ml buffer B was added and an 
aliquot (10 pi) was counted by a liquid scintillation counter. For 0-minute 
measurement, 1 0  pi of platelet suspension was counted by a liquid scintillation 
counter just after addition of radiolabeled AA or \A-trans-AA.
2.3 Methods for studies with hepatic microsomes
2.3.1 Generation, isolation, purification and analysis of 
microsomal 14-frans-AA metabolites
Rat liver microsomes (cellzDirect, Tuscon, AZ) were suspended in phosphate buffer 
(1 mg/mL), added to trans-AA isomers (final concentration 15 pM), and incubated 
for 30-180 min at 37 °C. The metabolism was stimulated by the addition of NADPH 
(1 mM) and NADPH regenerating system (CellzDirect, Tuscon, AZ). In experiments 
involving 14-tmns-AA, its radiolabeled analog, [l-u C]-l4-trans-AA (specific activity 
of 50 mCi/mmol, radiochemical purity > 99%), was used (0.25 pCi of [1-14C]14- 
irans-AA per incubation). Some experiments involved co-incubation of [1-14C]-14- 
trans-AA with equimolar amounts of [1-14C] AA. Standards of trans-EET, and 
deuterium-labeled EET were prepared by reacting w-chloroperoxybenzoic acid 
(MCPBA) with trans-AA and d8 - AA, respectively as previously described (Balazy & 
Nies, 1989). Standards of threo- and e^/zro-diHETEs were prepared by a mild acidic 
hydrolysis of cis- and fraws-EETs, respectively or by incubation with microsomes 
respectively as previously described (Balazy & Nies, 1989). The epoxides obtained 
from the reaction of \4-trans-AA with MCPBA were fractionated and incubated with 
microsomes in phosphate buffer (1 mg/mL) for 30 min at 37 °C. This procedure 
yielded 14,15-eotf/zro-DiHETE. The microsomal incubations were terminated by the
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addition of 5 volumes of cold methanol, vortexed, and centrifuged for 5 min at 1100 g 
to precipitate microsomal debris and proteins. The supernatant, which contained 
>90% of radioactivity was transferred to a glass tube and the solvent was evaporated 
under vacuum. The residue was dissolved in 1 mL of ethyl acetate and mixed with 1 
mL of acidified water (pH was adjusted to 4.0 with 10% acetic acid). The organic 
phase was separated by centrifugation, transferred to a glass tube and evaporated to 
dryness. The residue was dissolved in methanol and an aliquot (20 pi) was analyzed 
by HPLC as described in section 2.1.2. An on-line radio-chromatography detector 
(Radiomatic Flo-One/Beta Series A-100) detected radioactivity with a Sigma-Fluor 
scintillation fluid. Gas chromatography was performed on a HP-5MS capillary 
column (30 m, 0.25 mm i.d., 0.25 pm film thickness) using an Agilent 5973 GC-MS 
instrument as described in section 2.1.4.
2.3.2 Isomerization of HETEs
19-HETE (1 pg) was dissolved in hexane (100 pi) and mixed with 100 pi of a 1% 
solution of NO2 in hexane. The reaction was carried out for 1-10 minutes. The solvent 
was evaporated under nitrogen, and the lipids were dissolved in acetonitrile and 
subjected to HPLC purification on a Phenomenex Luna CIS column (150 x 2 mm, 
particle size 5 pm). The fraction at 6 -8  min was collected and analyzed by LC/MS and 
GC/MS. The isomerization produced four isomers of 19-HETE after treatment with 
NO2 for 5 min. Other HETE molecules (20-HETE, 18-HETE, 16-HETE) were also 
isomerized by NO2 and the trans isomers were isolated by HPLC and characterized 
by GC/MS as described in section 2.1.4.
2.3.3 Microsomal metabolism of S-frans-AA
A suspension of rat liver microsomes in phosphate buffer (200 pi, 1 mg/ml) was 
preincubated at 37°C for 15 min and mixed with 5-trans-AA (final concentration 73- 
736 pM). Control experiments were done with AA (73-736 pM). A NADPH- 
regeneration system solution was mixed with the tetra-sodium salt of reduced P-NAD 
phosphate (0.3 mg) and added to the microsomal mixture containing fatty acid 
substrate to stimulate the CYP-dependent metabolism. The final concentrations for
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the components of the NADPH-regeneration system were as follows: 1.3 mM 
NADP+, 3.3 mM glucose-6 -phosphate, 0.4 U/ml glucose-6 -phosphate dehydrogenase, 
and 3.3 mM MgCla. The incubations were carried out for 10 and 20 min at 37 °C and 
were terminated by adding ethyl acetate (0.5 ml) and water (0.5 ml). The solution was 
thoroughly mixed using a vortex and then centrifuged at 4000 rpm for 10 min. The 
supernatant was decanted and the remaining solution was re-extracted with ethyl 
acetate two more times, and the extracts were combined. The solvent was evaporated 
under a stream of nitrogen. The lipid residue was dissolved in 100 pi of 
acetonitrile/water (1:1) and subjected to analysis by LC/MS (section 2.1.4.3). Acid 
was not used in the extraction to minimize hydrolysis of the epoxides to diols. Control 
experiments were done without microsomes and/or NDPH-generating system and did 
not show any metabolite formation. In some experiments, the microsomes were 
preincubated with anti-CYP450 2E1 IgG protein (5 and 10 pg) for 20 min at 37 °C. 
The effect of microsomal epoxide hydrolase was tested by pretreatment of 
microsomes with a solution of dicyclohexyl urea (1 pi in DMSO, final concentration 
10 mM) (Goldfarb et al., 1993).
2.3.4 Hydrolysis of c/s- and frans-5,6-EET by microsomal epoxide 
hydrolase
5,6-trans-EEY, 5,6-cw-EET and their mixture (100 ng each) were incubated with rat 
microsomes (100 pg in 100 pi) for 10, 20, 60, 180 and 360 min. The incubations were 
terminated by addition of 100 pi of methanol. The mixture was vortexed, centrifuged 
and aliquots (20 pi) were analyzed by LC/MS as described in section 2.1.4.3.
2.3.5 Conjugation of c/s- and trans 5,6- EET with microsomal 
glutathione-S-transferase
Glutathione-S-transferase (GST) from rat liver (Sigma, 5 mg, 18 U/mg protein) was 
suspended in 500 pi of distilled water. The GST solution contained 18 U/100 pi along 
with 1 pmol of reduced glutathione (pH 6.5). A mixture of 5,6 EET isomers (100 ng 
each, final concentration 3.12 pM) were incubated with 100 pi of GST solution for 1,
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6  and 12 hrs at 37 °C with shaking. The incubations were terminated by centrifugation 
and aliquots (20 gl) were analyzed by LC/MS (section 2.1.4.3).
2.4 Methods for studies with polymorphonuclear leukocytes
2.4.1 Preparation of neutrophils from human blood
Human PMNs were isolated as previously described (Gronert et al, 1999). Briefly, 
blood from a healthy human donor (60 ml) was collected in Vacutainer tubes 
containing acid-citrate-dextrose (ACD). Blood was centrifuged at 800 rpm (134 g) 
and the pellet was gently resuspended in a Dulbecco's phosphate-buffered saline 
(DPBS) solution (1 ml) containing 6 % dextrin. After sedimentation for 30 min, the 
supernatant was transferred to test tubes containing 0.3 ml of Histopack-1077. 
Samples were spun at 1500 rpm (514 g). The sedimented erythrocytes were lysed with 
water and the PMNs were resuspended in DPBS to a final concentration of 2.5 x 106 
cells.
2.4.2 Metabolism of 5-trans-AA by PMN or HL60 cells
5-trans-AA (10 nM -10 pM) was incubated with freshly isolated PMNs or HL-60 
cells (5 x 105 cells) stimulated with calcium ionophore (A23187 1 pM) for 2 hours at 
37° C. The incubations were terminated by adding methanol and centrifuging. Lipids 
were then extracted from the sample by the addition of 5 volumes of cold methanol, 
and the internal standard, dg-12-HETE (10 ng), was added before the supernatant was 
transferred. The methanol extracts were evaporated, resuspended in acetonitrile and 
the aliquots (10 pi) were analyzed quantitatively by LC/MS (section 2 .1.4.3.) via 
monitoring of ions at m/z 319 and 335 to detect HETE isomers and LTB4, 
respectively. The MS/MS spectra were acquired by using the collision energy o f-30 
volts with nitrogen in the second quadrupole, which resulted in the decrease of the 
precursor ion intensity by about 50%. The detection limit was 100 pg of HETE 
injected on column.
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2.5 Materials
Arachidonic acid (purity >99%), thrombin, indomethacin, NaCl, KC1, NaHCOs, 
MgCb, glucose, hepes buffer, bovine serum albumin (BSA), apyrase, meta- 
chloroperoxybenzoic acid, calcium, ionophor, dicyclohexyl urea, dimethyl sulfoxide 
(DMSO), pentafluorobenzyl bromide (PFB), diisopropylethylamine (DIPEA), 
pyridine and O-bis (trimethylsilyl) trifluoroacetamide were purchased from Sigma- 
Aldrich Chemical Co. (St. Louis, MO). TXB2, PCs, HETEs, 12-HHT, EETs, 
DiHETrEs, 12-LOX and U46619 were purchased from Cayman Chemical Co. Inc. 
(Ann Arbor, MI). Baicalein and cPAF were from Biomol Research Laboratories 
(Plymouth Meeting , PA). [1-14C] Arachidonic acid (54.2 mCi/mmol) was purchased 
from Moravek Biochemical, fric (Brea, Ca). Acetonitrile, methanol, ethyl acetate, 
acetic acid and water (Fisher Scientific, Inc. Suwance, GA) were all glass distilled and 
used as received. ADP and epinephrine were from Chronolog, Inc., (Havertown, PA). 
Nitrogen, helium, nitric oxide and nitrogen dioxide were obtained from TechAir 
(White plains, NY). Rat liver microsomes CYP2E1 and NADPH-regeneration 
solution were purchased from CellzDirect (Tuscon, AZ). The NADPH-regeneration 
solution was composed of NADP+ and glucose-6 -phosphate (solution A, 100 |il) and 
glucose-6 -phosphate dehydrogenase (solution B, 20 (il) diluted 20- and 100-fold, 
respectively. Carbon 14-labeled lA-trans-AA was a kind gift from Dr. Oliver Loreau 
from CEA Saclay, Service des Molécules Marquées, Gif-sur-Yvette, France.
2.6 Statistics
Experimental results are expressed as the means ± standard error of mean (SEM) and 
are accompanied by the number of observations. Student’s t-tests were done to 
determine the descriptive statistics of this study. One way or two way analysis of 
variance (ANOVA) was done to determine the group and concentration differences. A 
value of p<0.05 was considered statistically significant. The data analyses were 
performed using the software package StatView (Version 5).
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3 RESU LTS
3.1 Interaction of trans-AA with platelets
3.1.1 Metabolism of trans-AA by platelets
Consistent with previous reports (O'Keefe et al., 1990), arachidonic acid (15 pM) was 
metabolized to TXB2, 12-HHT and 12-HETE by human platelets, which was 
confirmed by injecting standards (Figure 3-1). The next series of experiments describe 
the characterization of 14-trans-AA metabolism by human platelets. Initial 
experiments were done with radiolabeled 14-trans-AA. The following sections 
describe an in depth analysis of metabolism by LC/MS. Platelets were incubated with 
[1-14C] radiolabeled AA/14-trans-AA for 30 minutes and the metabolites were 
extracted and injected into the HPLC equipped with an on-line radio-chromatography 
detector. However, 14-trans-AA did not produce metabolites like AA, but gave rise to 
four unique metabolites. These novel metabolites were named metabolite A, B, C, and 
D. It was observed that 84 ±7% AA was metabolized by human platelets compared to 
the 42 ±5% of 14-trans-AA which was metabolized as shown in chart C of Figure 3- 
1 .
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Figure 3-1. Metabolic products of radio-labeled AA and 14-trans-AA
Washed platelet suspension (1 ml) was incubated with A. 0.5 pCi (15 pM) [1-14C] AA; and B. 
0.5 pCi (15 pM) [1-14C] 14-trans-AA for 30 minutes at 37° C with constant stirring at 1200 
rpm. The reaction was stopped by adding methanol, and fatty acids were extracted using 
ethylacetate and injected into HPLC equipped with an on-line radio-chromatography detector 
to identify the metabolic products. Figure C showed that 14-frcms-AA was not extensively 
metabolized like AA. Total metabolites equal to the sum of peak areas for TXB2,12-HHT and 
12-HETE from AA and metabolites A, B, C, D from \4-trans-AA. {n = 5, *P< 0.05, relative 
to data of AA metabolism)
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3.1.1.1 Co-incubation of platelets with c/s- and 14-trans-AA
To observe the metabolic pattern of trans-AA in the presence of cis-A A, platelets 
were incubated with an equal amount of radiolabeled cis-AA and 14-trans-AA. 
Radio-chromatograms presented in Figure 3-2 show increased formation of 
metabolites A, B, C, and D in the presence of cis-AA. Further experiments were done 
for quantification of increased production of unidentified metabolites due to co­
oxidation.
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Figure 3-2. Metabolism of radio-labeled 14-trans-AA and in the presence of AA
Washed platelet (1 ml) was incubated with A. 0.5 pCi (15 pM) [1-14C] 14-trans-AA; and B. 
0.5 pCi (15 pM) [1-14C] AA and 0.5 pCi (15 pM) [1-14C] 14-£r<m5,-AA AA for 30 minutes at 
37° C with constant stirring at 1200 rpm. Fatty acids were extracted and injected into the 
HPLC equipped with an on-line radio-chromatography detector to compare the metabolic 
products that formed from 14-trans-AA alone and those that form in the presence of cis-AA.
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From the previous experiments shown in Figure 3-2, it was unclear if the increased 
production of metabolites A, B, C and D was due to utilisation of cis or trans-AA. 
Thus, non-radiolabeled AA was mixed with an equal amount of radiolabeled 14-trans- 
AA  and incubated with platelets. The result was compared with the metabolites from 
radiolabeled 14-trans-AA alone by platelets (Figure 3-3). The formation of 
metabolites A, B, C, and D was increased in the presence of non-radiolabeled AA, 
suggests that \4-trans-AA metabolism increases in the presence of AA.
Metabolite DMetabolite CMetabolite BMetabolite A
Figure 3-3. Potentiation of biosynthesis of metabolites A, B, C, and D by AA
Platelet suspension (1 ml) was incubated with 0.5 pCi (15 pM) [1 -14C] -14-trans-AA in the 
presence or absence of non-radiolabeled AA (15 fiM) in a water bath with shaker at 1200 rpm 
for 30 minutes at 37°C. Fatty acids were extracted and injected into RP-HPLC equipped with 
an on-line radio-chromatography detector to compare the metabolic products formed by 
trans-AA alone and in the presence of AA (n = 5, *P< 0.05, relative to data of only \A-trans- 
AA metabolism).
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3.1.1.2 Effect of inhibitors on 14-trans-AA metabolism
To determine the enzymatic origin of metabolites A, B, C and D, platelets were 
preincubated with inhibitors of the oxidative metabolism of AA, indomethacin, a 
potent COX inhibitor (Salari et al, 1984)y or baicalein, a potent LOX inhibitor 
(Sekiya & Okuda, 1982), prior to incubation with AA and \A-trans-P±A. Metabolites 
of AA and trans-AA. derived from COX and LOX were identified by reversed-phase 
high performance liquid chromatography (RP-HPLC) equipped with an on-line radio­
chromatography detector. Radio-chromatograms presented in Figure 3-4 show that 
indomethacin, inhibited formation of TXB2, 12-HHT and metabolites B and C. In the 
presence of baicalein, there was decreased formation of 12-HETE along with 
metabolites A and D. These data confirm that TXB2 and 12-HHT are COX products 
and that 12-HETE is a LOX product, and suggest that metabolite B and C are formed 
by COX and metabolites A and D are formed by LOX (Figure 3-4).
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Figure 3-4. Effects of inhibitors on AA metabolism
Washed platelet suspensions (1 ml) were preincubated (A) alone or with (B) 10 pM 
indomethacin (COX inhibitor), or (C) 10 pM baicalein (LOX inhibitor) prior to stimulation 
with 0.5 pCi (15 pM) radiolabeled AA and 14-trcms-AA. Then the platelet suspensions were 
incubated in a water bath with shaker at 1200 rpm for 30 min at 37 °C. Fatty acids were 
extracted and injected into RP-HPLC equipped with an on-line radio-chromatography 
detector to observe the metabolites formed from cis- and 14-trans-AA in the presence of 
inhibitors.
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This experiment was designed to distinguish trans-AA metabolites according to the 
enzyme responsible for their production without the potentially confounding presence 
of AA. Radio chromatograms presented in Figure 3-5 show the metabolism of 
radiolabeled trans-AA in the presence of non-radiolabeled AA and a COX or LOX 
inhibitor. Indomethacin inhibited the formation of metabolites B and C, while the 
baicalein inhibited formation of metabolites A and D. These results confirm that 
metabolite B and C are the COX products and metabolites A and D are the LOX 
products.
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Figure 3-5. Metabolism of radio-labeled 14-trans-AA with non-radiolabeled AA 
and COX and LOX inhibitor
Washed platelet suspensions (1 ml) were preincubated with (B) 10 pM indomethacin (COX 
inhibitor), (C) 10 pM baicalein (LOX inhibitor) for 3 minutes and (A) 0.5 pCi (15 pM) 
radiolabeled 14-trans-AA and 14 pM non-radiolabeled AA was added for 30 minutes at 37° 
C in a water bath with shaker. Fatty acids were extracted and injected into HPLC to observe 
the metabolic products. This figure is a representative of three experiments.
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3.1.1.3 UV analyses of cis and *\4-trans-AA metabolites
In order to obtain preliminary structural data about metabolites A, B, C, and D, the 
UV absorption properties of these metabolites were determined. Platelets were 
incubated with 100 pg of cis and 14-trans-AA for 30 minutes, and fatty acids were 
extracted and injected into HPLC. Figure 3-6 shows the UV chromatogram at 234 nm 
of 12-HHT, 12-HETE as well as two unknown metabolites C and D. As AA and TX 
have absorption maxima Àmax = 205, those were not detected in this chromatogram. It 
was observed that metabolites C and D elute around the same time and have similar 
UV absorption as 12-HETE. These results suggest that metabolites C and D may have 
structural similarity to HETE metabolites. Thus, the application of advanced 
spectroscopic UV analysis (diode array) and LC/MS were used to determine structure 
of these metabolites.
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Figure 3-6. UV chromatogram at 234 nm of AA and 14-trans-AA metabolites
Platelet suspension (1 ml) was incubated with 100 pg AA and 100 pg 14-/nms-AA for 30 
minutes in a water bath with shaker at 1200 rpm for 30 minutes at 37° C. Fatty acids were 
extracted and injected into HPLC and UV analysis was done at 234 nm to observe the 
metabolic products. This figure is a representative of four experiments.
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3.1.1.4 Spectral analyses of unknown metabolites
A complete UV spectrum from 205 to 300 nm of metabolites C and D were measured 
on a Diode Array Detector. The maximum absorbances (X max) for metabolites C and 
D were 236 nm, and for 12-HETE was 234 nm (Figure 3-7). This again suggests 
structural similarities among these metabolites and with the unsaturated hydroxy fatty 
acids (HETEs).
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Figure 3-7. UV spectrum of metabolite C and metabolite D
Washed platelets (1 ml) were incubated with 100 pg 14-rnms-AA for 30 minutes in a water 
bath with shaker at 1200 rpm at 37° C. Fatty acids were extracted and injected to HPLC and 
metabolites C and D were isolated. Isolated (A) metabolites C (B) metabolite D and (C) 12- 
HETE standards were injected into a HPLC with diode array detector and spectral analyses 
were done from 205 to 300 nm.
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3.1.1.5 LC/MS analyses of the 14-trans-AA metabolites
Figures 3-8 to 3-12 show LC/MS analyses of metabolites from lA-trans-AA, 
comparison with standards, and effect of inhibitors. Use of LC/MS provided a better 
resolution than initial experiments with radiolabeled \A-trans-AA. Metabolites 
formed by platelets from AA and \A-trans-AA, were injected into HPLC equipped 
with an on-line MS. Selected ion monitoring was done for ion 369 (TXB2), 279 (12- 
HHT) and 319 (HETEs).
Metabolites formed by platelets from lA-trans-AA were injected into a HPLC system 
equipped with an online mass spectrometer by using an auto injector. These 
metabolites generated from lA-trans-AA. by platelets, showed seven peaks (Figure 3- 
8) as compared to radio chromatogram where there were four peaks (Figure 3-1 B). 
As LC/MS has better resolution and identification capacity, it detected all the 
metabolites and these were named metabolite A, Bi, B2, C%, C2, Di and D2. Further 
LC/MS analyses of the samples of experiments with COX and LOX inhibitor were 
done to identify the enzymatic origin of the metabolites.
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Figure 3-8. LC/MS analyses of metabolites of AA and 14-/ra«s-AA by human 
platelets
Metabolites generated by human platelets incubated with (A) AA or (B) 14-trans-AA, were 
separated by gradient elution RP-HPLC system. Metabolites eluted from the RP-HPLC 
column were detected by an on-line mass spectrometer. Under negative electrospray 
ionization (ESI) mode, selected ion chromatography of m/z 369 (for TXB2), 279 (for 12- 
HHT) and 319 (for HETEs) were done to identify the metabolites. The chromatogram shows 
the total ion chromatogram (TIC).
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For the identification of the peaks obtained by LC/MS, the elution times of the 
metabolites formed by \A-trans-AA (Figure 3-8) was compared with the elution times 
of LC/MS of the commercial standards (Figure 3-9). Table 3-1 shows molecular 
weight and RP-HPLC elution time of standards.
Table 3-1. LC elution time of different standards detected by mass spectrometer
Eicosanoid standard Molecular weight
RP-HPLC elution time 
[min]
t x b 2 370 7.7
12-HHT 280 14.0
15-HETE 320 16.5
12-HETE . 320 17.0
11-HETE 320 17.3
5-HETE 320 17.8
Different HPLC elusion times for commercial standards.
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Figure 3-9. Comparison of the negative-ion MS/MS spectra of various eicosanoid 
standards with metabolites of 14-trans-AA
Metabolites produced by human platelets incubated with 14-trans-AA and different 
commercial standards were injected into RP-HPLC equipped with an on-line mass 
spectrometer. In linear gradient RP-HPLC, commercial standards eluted at different times and 
their elution time were compared with the 14-trans-AA derived metabolites.
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The metabolic pattern of different metabolites generated from AA or \4-trans-PJ± in 
presence of a COX inhibitor (indomethacin) was characterized. In control 
experiments with AA and indomethacin, the formation of TXB2 and 12-HHT were 
inhibited. Formation of metabolites Bi, B2, Ci and C2 were decreased in the 
experiment with \4-trans-AA and indomethacin in comparison with 14-trans-AA 
only experiment, suggesting that these are COX products. While the formation of 
TXB2 was inhibited in the control experiment, the formation of metabolite A was not 
inhibited. This suggested that metabolite A is not formed by the COX pathway. It was 
also observed that the formation of metabolite D% was increased in the experiment 
with \4-trans-AA and indomethacin in comparison with 14-trans-AA only 
experiment. The metabolites formed by platelets from 14-trans-AA in presence of 
indomethacin are shown in Figure 3-10.
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Figure 3-10. Comparison of the negative-ion LC/MS spectra of metabolites 
produced with indomethacin
Indomethacin (10 (iM)-preincubated human platelet (1 ml) were incubated with (A) AA (100 
pg) and (B) \4-trans-AA (100 pg) for 30 minutes in a water bath with shaker at 37°C. Figure 
C is the control incubation of platelet with 100 pg 14-trans-AA. Metabolites were extracted 
and injected into linear gradient elution RP-HPLC equipped with an on-line triple-quadrupole 
mass spectrometer. Under negative electrospray ionization (ESI) mode, selected ion 
chromatography of m/z 369, 279 and 319 were done.
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Incubation of platelets with AA in presence of a LOX inhibitor (baicalein) partially 
inhibited the formation of 12-HETE. When platelets were incubated with \A-trans- 
AA  in presence of baicalein, it inhibited the formation of metabolite A and D% but the 
formation of metabolite Ci and C2 was increased (Figure 3-11). This experiment 
suggested metabolite A and D% were the LOX products.
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Figure 3-11. Comparison of the negative ion LC/MS spectra of metabolites 
produced with baicalein
Baicalein (10 pM)-preincubated washed human platelet (1 ml) was incubated with A. AA 
(100 pg) and B. 14-trans-AA (100 pg) C. 14-trans-AA. (100 pg) only for 30 minutes in a 
water bath with a shaker at 37°C. Metabolites were extracted and injected into liner gradient 
elution RP-HPLC equipped with an on-line triple-quadrupole mass spectrometer. Under 
negative electrospray ionization (ESI) mode, selected ion chromatography of m/z 369, 279 
and 319 were done.
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To eliminate any endogenous AA metabolites that might interfere with the 
understanding of the metabolic origin of unknown metabolites, platelets were 
incubated with d%-\A-trans-AA alone and with indomethacin or baicalein. It was 
observe that the formation of metabolite A and Di was inhibited by the LOX inhibitor 
(Figure 3-12C), which confirms their LOX-mediated origin. Metabolites Bi, Bi, Ci, 
C2 and D2 formation was completely inhibited by the COX inhibitor (Figure 3-12B), 
confirming their COX-mediated origin.
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Figure 3-12. Metabolism of à%-trans-AA by platelets
Washed platelets (1 ml) were incubated with A. d8-14-/nms,-AA (lOOpg) and B. 
indomethacin (10 pM) and C. baicalein (10 pM) for 30 minutes in a water bath with a shaker 
at 37°C. Metabolites were extracted and injected into linear gradient elution RP-HPLC 
equipped with an on-line triple-quadrupole mass spectrometer. Under negative electrospray 
ionization (ESI) mode, selected ion chromatography of m/z 377 and 327 were done.
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3.1.1.6 Gas chromatogram of metabolite A and TXB2
Washed platelets were incubated with \A-trans-AA, and metabolite A was extracted 
and isolated from other metabolites by HPLC. BSTFA derivatization of the metabolite 
was done and injected into a GC/MS system. The result shows that metabolite A has 
same MW (585) as of TXB2 but the elution time is 10.8 minute in comparison with 
TXB2 which is 10.4 minutes (Figure 3-13). The experiment confirms that metabolite 
A is a different compound and more polar than TXB2.
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Figure 3-13. GC/MS chromatograms of ion at m/z 585
Metabolite A, synthesized by platelets from \4-trans-AA, was separated and purified by RP- 
HPLC and derivatized to TMS ester. Sample (1 jil) in iso-octane was injected into GC/MS 
(negative ions) and (A) there was separation of metabolite A from TXB2 as metabolite A 
eluted at 11.4 min in comparison TXB2 which eluted at 10.9 min. (B) elution time for TXB2 
was confirmed by injecting commercial TXB2 standard.
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3.1.1.7 Identification of metabolites from 14-frans-AA by LC/MS/MS
Fragment ions of individual eicosanoids were determined from the LC/MS/MS 
analysis of commercial standards. Product ion MS/MS spectra of the eicosanoid 
standards were acquired by passing the (M-H)" of individual eicosanoids, which had 
been mass-selected with the first quadrupole, into the second quadrupole where they 
were dissociated by collision with ultra pure helium gas. Fragment ions generated by 
these collisions then were mass analyzed by the third quadrupole, and detected. The 
third quadrupole was scanned in 0.1-a.m.u. (atomic mass unit) increments from 15 
a.m.u. up to and including the mass of the parent ion in less than 10 seconds, and at 
least 10 scans were averaged for each MS/MS spectrum. Collision energies were 
adjusted to 15-25 eV with respect to the laboratory reference for this study. 
Representative data are shown in Figure. 3-15 to 3-21. Complete fragmentation data 
of each of the eicosanoids characterized in this study are summarized in Table 3-2. 
The product ion that was indicative of each eicosanoid is in bold type.
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Table 3-2. The molecular weights (relative abundances) of fragment ions 
observed in the negative-ion MS/MS spectra
Eicosanoid
Parent ion 
[M-H"]
Fragment ions 
(MS/MS)
Arachidonic acid 303 (100) 285 (3), 259 (3), 231 (3), 205 (3), 191 (2), 177 (3), 163 (2), 
83 (2), 59 (13)
t x b 2 369(2) 289 (9), 195 (50), 191 (3), 177 (6), 169 (100), 151 (4), 125 
(3)
p g d 2 351 (3) 333 (2), 315 (11), 297 (3), 271 (100), 233 (11), 217 (4), 
203 (7), 189 (69)
p g e2 351 (7) _ 333 (14), 315 (16), 271 (100), 235 (10), 217 (7), 206 (4), 
189 (36), 175 (10), 163 (3), 159 (2), 113 (3), 109 (2)
PGF2a 353 (92) 335 (8), 317 (11), 309 (100), 299 (11), 291 (42), 281 (6), 
273 (16), 263 (8), 255 (9), 247 (26),235 (8), 217 (8), 209 
(12), 193 (45), 171 (13), 165 (12), 111 (4)
6-Keto PGFia 369 (100) 351 (21), 333 (23), 315 (20), 307 (13), 289 (23), 271 (12), 
263 (11), 245 (39), 233 (12), 207 (36), 163 (40), 89 (15)
12-HHT 279 (40) 261 (20), 217 (15), 189 (22), 179 (100), 163 (5), 153 (6), 
135 (60), 113 (18), 107 (5), 99 (4), 81 (8), 59 (20)
5-HETE 319(45) 301 (20), 283 (4), 257 (25), 203 (22), 115 (100)
8-HETE 319(35) 301 (20), 283 (4), 257 (25), 163 (45), 155 (100), 127 (10)
11-HETE 319 (40) 301 (4), 291 (5), 167 (100)
12-HETE 319(32) 301 (49), 291 (4), 283 (7), 275 (8), 257 (89), 229 (19), 215 
(5), 208 (17), 203 (48), 189 (8),179 (100), 177 (15), 163 
(43), 153 (22), 139 (18), 135 (33), 107 (12), 59 (22)
15-HETE 319(35) 301 (80), 283 (8), 275 (11), 257 (100), 229 (7), 219 (36), 
203 (52), 175 (62), 163 (13), 149(11), 147 (14), 139 (13), 
133 (8), 121 (40), 113 (50), 99 (8), 59 (22)
Note: Ion abundances are normalized to the most abundant ion in each MS/MS 
spectrum.
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3.1.1.8 Identification of metabolite A
Metabolites generated from \A-trans-PiA by platelets were injected into a HPLC 
system equipped with an online mass spectrometer by using an auto injector. 
Negative-ion MS/MS of the different ion were done. The MS/MS spectra of novel 
metabolites were compared with spectra of commercial standards and their structures 
were confirmed.
Negative ion MS/MS were done on metabolite A, that gave rise to ion m/z 169, m/z 
195 and m/z 127 (Figure 3-14 A). When MS/MS were done on metabolite A 
generated from à%-\A-trans-AA by platelets, it showed a prominent ion m/z 129 as 
well as ion m/z 158 and m/z 200 (Figure 3-14 B). Incubation of lA-trans-AA. with 12- 
LOX also gave rise to metabolite A that gave ion m/z 127 (Figure 3-14 C). For the 
confirmation of TXB2 structure, MS/MS analysis of commercial TXB2 standard were 
done and ions m/z 169 and m/z 195 was observed (Figure 3-14 D).
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Figure 3-14. Comparison of the MS/MS spectra of metabolite A
Metabolite A, was generated by 1 ml platelets incubating with A. \A-trans-AA (100 jig); B. 
d8-14-/nms-AA (100 pg); and C. 12-LOX (100 units) with \4-trans-AA (100 jig), extracted 
with ethyl acetate and water, injected into RP-HPLC for separation and purification. Samples 
were injected into a mass spectrometer by auto injector using flow injection analysis (FIA) 
mode. Negative-ion MS/MS of ion A. 369 m/z, B. 377 m/z and C. 369 m/z were done for 
metabolite A generated by platelets from \A-trans-AA, d8-14-/r<ms-AA and by 12-LOX from 
\A-trans-kk respectively, D. Negative-ion MS/MS of ion 369 m/z were done for TXB2 
standard.
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In the last experiment (Figure 3-14), it was confirmed that ion m/z 127 is specific for 
metabolite A. Multiple reaction monitoring (MRM) analysis of transition m/z 
369—>127 was done for compound A (Figure 3-16 C. and D.) and its spontaneous 
transformation was observed. This experiment shows that ion 195 disappears from 
experiment A to C and transformed from A[l] to A[2] from experiment B to D, which 
suggested metabolite A is an unstable compound which transformed at room 
temperature.
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Figure 3-15. Spontaneous transformation of metabolite A
Isolated metabolite A was kept at room temperature (24°C) for 72 hours and injected to a 
LC/MS system. Chromatogram A and C show transition 369—>195 and 369—>127 of freshly 
prepared metabolite whereas chromatograms B and D show transition 369—>195 and 
369—>127 of metabolite 72 hours after preparation. Metabolite A was detected by transition 
369—>127 (only from metabolite A). For fresh metabolite A the transition 369—>195 shows a 
peak A[l].
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3.1.1.9 Identification of metabolites Bi and B2
The results from the previous experiment (Figure 3-12) confirmed that metabolites Bi 
and B2 are COX products. Negative ion MS/MS analysis of ion m/z 279 of metabolite 
B generated from \A-trans-AA by human platelets was done to confirm their 
structure. This spectrum was compared with the negative ion MS/MS analysis of ion 
m/z 279 of commercial 12-HHT standard (Figure 3-16).
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Figure 3-16. Comparison of the MS/MS spectra of metabolites Brand B2
Metabolite B was generated by washed platelets (1 ml) incubating with A. 14-/nm?-AA (100 
jig), extracted with ethyl acetate and water, injected into RP-HPLC for separation and 
purification. Samples were injected into a mass spectrometer by auto injector using flow 
injection analysis (FIA) mode. Negative-ion MS/MS of ion A. 279 m/z was done for 
metabolite B generated from \A-trans-AA and B. 279 m/z was done for commercial 12-HHT 
standard.
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3.1.1.10 Identification of metabolite C1
Metabolite Ci was a COX product as confirmed in a previous experiment (Figure 3- 
12). Negative ion MS/MS analysis of ion m/z 319 of metabolite Ci generated from 
\A-trans-AA by human platelets was done to confirm the structure and compared with 
the negative ion MS/MS analysis of ion m/z 319 from commercial 15-HETE standard 
(Figure 3-17).
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Figure 3-17. Comparison of the MS/MS spectra of metabolite Q
Metabolite Cl, was generated by washed platelets (1 ml) incubated with A. \A-trans-AA (100 
pg) and B. d8-14-/r<ms-AA (100 pg), extracted with ethyl acetate and water, injected into RP- 
HPLC for separation and purification. Samples were injected into a mass spectrometer by 
auto injector using flow injection analysis (FIA) mode. Negative-ion MS/MS of ion A. m/z 
319 and B. m/z 327 were done for metabolite Ci generated from 14-fnms-AA and dg-14- 
trans-AA respectively and C. m/z 319 was done for 15-HETE standard.
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3.1.1.11 Identification of metabolite C2
Metabolite C2 was a COX product as confirmed in a previous experiment (Figure 3- 
12). Negative ion MS/MS analysis of ion m/z 319 of metabolite C2 generated from 
\4-trans-Ah by human platelets was done to confirm the structure and compared with 
the negative ion MS/MS analysis of ion m/z 319 from commercial 11-HETE standard 
(Figure 3-18).
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Figure 3-18. Comparison of the MS/MS spectra of metabolite C2
Metabolite C2, was generated by platelets (1 ml) incubated with A. \A-trans-AA (100 pg) and 
B. d^-lA-trans-AA (100 pg), extracted with ethyl acetate and water, injected into RP-HPLC 
for separation and purification. Samples were injected into a mass spectrometer by auto 
injector using flow injection analysis (FIA) mode. Negative-ion MS/MS of ion A. m/z 319 
and B. m/z 327 were done for metabolite C2 generated from \A-trans-AA and d8-14-/ra«5- 
AA, respectively and C. m/z 319 was done for 11-HETE standard.
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3.1.1.12 Identification of metabolite D,
Metabolite Di was a LOX product as confirmed in a previous experiment (Figure 3- 
12). Negative ion MS/MS analysis of ion m/z 319 of metabolite D% generated from 
XA-trans-AK by human platelets was done to confirm the structure and compared with 
the negative ion MS/MS analysis of ion m/z 319 from commercial 12-HETE standard 
(Figure 3-19).
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Figure 3-19. Comparison of the MS/MS spectra of metabolite Di
Metabolite Di, was generated by platelets (1 ml) incubated with A. \A-trans-AA (100 pg) and
B. d8-14-/nms-AA (100 pg), extracted with ethyl acetate and water, injected into RP-HPLC 
for separation and purification. Samples were injected into a mass spectrometer by auto 
injector using flow injection analysis (FIA) mode. Negative-ion MS/MS of ion A. m/z 319 
and B. m/z 327 were done for metabolite Di generated from \A-trans-AA and &%-\4-trans- 
AA, respectively and C. m/z 319 was done for 12-HETE standard.
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3.1.1.13 Identification of metabolite D2
Metabolite D2 was a COX product as confirmed in a previous experiment (Figure 3- 
12). Negative ion MS/MS analysis of ion m/z 319 of metabolite D2 generated from 
\A-trans-AA by human platelets was done to confirm the structure and compared with 
the negative ion MS/MS analysis of ion m/z 319 from commercial 5-HETE standard 
(Figure 3-20).
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Figure 3-20. Comparison of the MS/MS spectra of metabolite D2
Metabolite D2, was generated by platelets (1ml) incubated with A. \A-trans-AA (100 pg) and
B. ds-M-Znms-AA (100 pg), extracted with ethyl acetate and water, injected into RP-HPLC 
for separation and purification. Samples were injected into a mass spectrometer by auto 
injector using flow injection analysis (FLA) mode. Negative-ion MS/MS of ion A. m/z 319 
and B. m/z 327 were done for metabolite D2 generated from lA-trans-AA and dg-M-Zra/w-AA 
Respectively and C. m/z 319 was done for 5-HETE standard.
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3.1.2 Effects of 14-frans-AA on platelet function
In order to demonstrate the effect of \4-trans-AA on platelets, washed platelets were 
treated as described in section 2.2.2.1 with either AA or \A-trans-Pd± and aggregation 
was analysed using an aggregometer.
3.1.2.1 Effect of 14-frans-AA on human platelet aggregation
Consistent with previous reports, AA (15 pM) induced aggregation of human platelets 
(Figure 3-21). In order to see the effect of \A-trans-AA on platelet aggregation, 
platelets were initially incubated with various amounts (15, 50 and 100 pM) of 14- 
trans-AA. Data presented in Figure 3-21 show that \A-trans-AA did not cause 
aggregation of platelet at concentrations of up to 100 pM. No aggregation or shape 
change was observed after increasing concentration and time of incubation with 14- 
trans-AA. It was concluded that 14-trans-AA does not cause platelet aggregation; 
therefore, it does not activate platelets.
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Figure 3-21. Effect of 14-trans-AA on platelet aggregation
This figure is a representative of five experiments. The indicated concentrations of 14-trans- 
AA (15, 50, 100 pM) were added to 0.5 ml of washed platelet and incubated for 4 min at 37° 
C with constant stirring at 1200 rpm. Aggregation was measured with an aggregometer and 
the results were compared to control (platelet aggregation with 15 pM AA).
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The results from experiments shown in Figure 3-21 stimulated further experiments 
designed to study whether \A-trans-AA has platelet inhibitory activity.
Data presented in Figure 3-22 show that AA (15 pM) caused aggregation of platelets. 
Preincubation of platelets with lA-trans-kK (5, 10 and 15 pM) for 4 minutes 
inhibited AA-induced aggregation. Analyses of the data indicated a 73±6% decrease 
of aggregation with 5 pM \A-trans-AA, 83.5±3% decrease with 10 pM \A-trans-AA, 
and 92±4% decrease with 15 pM \A-trans-AA as compared to the control platelets. 
This data suggest that \A-trans-AA inhibits the aggregation of platelets stimulated by 
AA in a concentration-dependent manner. The data in Figure 3-22 suggest that 14- 
trans-AA did not inhibit platelet shape change induced by AA.
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Figure 3-22. Effect of 14-trans-AA on AA-mediated platelet aggregation
Platelet suspension (500 pL) was preincubated with the indicated amounts of 14-trans-AA 
for 4 min at 37° C with constant stirring at 1200 rpm and then 15 pM AA was added. 
Aggregation was measured with an aggregometer and the results were compared to control 
(platelet aggregation with 15 pM AA alone) (n = 5, *P < 0.05 relative to data of only AA- 
induced aggregation).
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3.1.2.2 Effect of 14-frans-AA pre-incubation time on platelet 
aggregation
Platelet suspensions were incubated with M-Znms-AA (5 pM) for various periods of 
time (0-5 min). \A-trans-AA exhibited a time-dependent inhibition of platelet 
aggregation by AA (5 pM). Within the first minute the inhibitory effect of \A-trans- 
AA  increased to 75%. The maximal inhibition (88±6%) was observed after a 3-min 
preincubation as compared to the control (without 14-trans-AA) (Figure 3-23). For 
this reason, this period of incubation was used for the subsequent experiments, which 
aimed to study the effects of 14-trans-AA on AA- and other agonist-induced 
aggregation.
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Figure 3-23. Effect of 14-trans-AA incubation time on platelet aggregation
Washed platelets (0.5 ml) were pre-incubated with 14-trans-AA (5 pM) for 7 different times: 
15 s, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min at 37 °C with constant stirring at 1200 rpm 
and then AA (5 pM) was added. Aggregation was measured with an aggregometer and the 
results were compared to control (platelet aggregation with 5 pM AA) (n = 3, *P < 0.05 
relative to aggregation in 3 min).
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3.1.2.3 Concentration-dependent inhibition of aggregation by 14- 
trans-AA
In order to define the concentration-response properties of \4-trans-AA more 
carefully (Figure 3-24), platelets were pre-incubated with different amounts of 14- 
trans-AA (0, 3, 5, 7, 9 and 11 pM) and AA (3 pM). The observed results showed that 
the inhibitory effect of 14-trans-AA is concentration-dependent and the IC50 
(concentration causing 50% inhibition) of 14-trans-AA was found to be at 7.2 pM as 
calculated from the chart.
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Figure 3-24. Concentration-dependent inhibition of AA-induced aggregation by 
14-trans-AA
Platelet suspension (0.5 ml) was preincubated with different amounts (0, 3, 5, 7, 9, and 11 
pM) of 14-trans-AA for 3 min at 37 °C with constant stirring at 120 rpm and then 3 pM AA 
was added. Aggregation was measured with an aggregometer and the results were compared 
to control (platelet aggregation with 3 pM AA alone). The results suggest that the \4-trcms- 
AA-mediated inhibition of AA induced platelet aggregation is concentration dependent and 
the ID5o of 14-trans-AA was 7.2 pM (n = 3, *P < 0.05).
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3.1.2.4 Thromboxane B2 formation by platelets
The measurement of TXB2, a stable metabolite of TXA2, in supernatants of platelet 
suspension was used as index of TXA2 generation. TXA2 and PGH2 are pro- 
aggregatory metabolites of AA in platelets. Resting platelets produced below 200 
ng/ml TXB2 but in the presence of AA (3 pM), there was a significant elevation of 
TXB2 formation. Furthermore, various concentrations of \A-trans-PJv (3 to 11 pM) 
inhibited TXB2 formation in comparison with the platelets that were stimulated only 
with AA (Figure 3-25). 14-£r<ms-AA did not inhibit TXB2 formation completely even 
at llpM  although at this concentration it inhibited AA-induced platelet aggregation 
completely. Figure 3-25 shows that \4-trans-kK (3 pM) inhibited TXB2 synthesis by 
about 35% relative to the control (3 pM of AA). Increasing the amount of lA-trans- 
AA  to 7 pM had little effect on TXB2 inhibition, but a further increase in the 
concentration resulted in additional TXB2 inhibition, which at 11 pM was about 85%. 
Comparison of data in figures 3-4 and 3-5 suggests that the effect of 14-trans-AA on 
platelet aggregation can only partially be explained by the inhibition of COX by 14- 
trans-AA. In these two sets of experiments, the same concentration of AA (3 pM) 
was used and while aggregation was inhibited by \A-trans-AA at concentrations 
ranging between 3 to 7 pM, the TXB2 formation was partially inhibited. This 
suggested that \A-trans-AA is a partial inhibitor of TXB2 biosynthesis while it is a 
good inhibitor of platelet aggregation. This observation prompted the exploration of 
other mechanisms that may be affected by \A-trans-AA.
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Figure 3-25. Concentration-dependent inhibition of AA-induced TXB% formation 
by 14-trans-AA
Platelet suspension (0.5 ml) was pre-incubated with different amounts (0, 3, 5, 7, 9, and 11 
pM) of 14-trans-AA for 3 min at 37 °C with constant stirring at 1200 rpm and then 3 pM AA 
was added and incubated for 3 min. The suspension was centrifuged as 1000 g for 5 minutes 
and 20 pi supernatant was injected into LC/MS. TXB2 was measured by LC/MS as the area of 
the peak generated from ion 369 and compared with the standard curve (n = 3, *P < 0.05 
relative to aggregation with AA only).
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3.1.2.5 Effect of 14-frans-AA on U-46619
In the next experiment, U-46619 (a stable TXA2 analogue) was used as the platelet 
agonist that stimulates the TP receptor. Platelets were pre-incubated with different 
amounts of \A-trans-AA and U-46619 was added to observe the effect of lA-trans- 
AA  on U-46619-mediated aggregation. Inhibition of U-46619-mediated aggregation 
by 14-trans-AA was concentration dependent and the IC5o was found to be 2.2 pM as 
calculated from the chart (Figure 3-26). The effects of 14-trans-AA on other 
pathways of platelet activation were also explored.
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Figure 3-26. Effect of 14-fra«s-AA on platelet aggregation by TP receptor agonist
Platelet suspension (0.5 ml) was preincubated with the indicated amounts of 14-/r<ms-AA for 
3 min at 37 °C with constant stirring at 1200 rpm and then 0.2 pM U-46619 was added. 
Aggregation was measured with an aggregometer and the results were compared to control 
(platelet aggregation with 0.2 pM U46619 alone) {n = 3, *P < 0.05 relative to aggregation 
with AA only).
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3.1.2.6 Effect of other agonists
To observe the effects of \A-trans-AA on other agonists, platelets were incubated 
with ADP, epinephrine, thrombin and a stable analogue of platelet activating factor 
(PAF) called cPAF. \A-trans-AA (5 pM) inhibited ADP (50 pM)-mediated 
aggregation by 87±8% (Figure 3-27).
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Figure 3-27. Effect of ADP on platelet aggregation
Platelet suspension (0.5 ml) was preincubated with the indicated amounts of 14-trans-AA for 
3 min at 37 °C with constant stirring at 1200 rpm and then 50 pM ADP was added. 
Aggregation was measured with an aggregometer and the results were compared to the 
control (platelet aggregation with 50 pM ADP alone) (n=3, *P < 0.05 relative to aggregation 
with AA only).
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14-fnms-AA (5 fiM) inhibited epinephrine (50 pM)-induced aggregation by 85 ± 12%
(Figure 3-28).
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Figure 3-28. Effect of epinephrine on platelet aggregation
Platelet (0.5 ml) suspension was preincubated with the indicated amounts of 14-/nms-AA for 
3 min at 37 °C with constant stirring at 1200 rpm and then 50 pM epinephrine was added. 
Aggregation was measured with an aggregometer and the results were compared to the 
control (platelet aggregation with 50 pM epinephrine alone) (n=3, *P < 0.05 relative to 
aggregation with AA only).
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\4-trans-AA (5 piM) inhibited thrombin (0.5 unit/ml)-mediated aggregation by 75 ±
10% (Figure 3-29).
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Thrombin
Time [Min] o 3 6 0 3 6
14-trans-AA 0 jjM 5 pM
Thrombin 0.5 unit/ml 0.5 unit/ml
Figure 3-29. Effect of thrombin on platelet aggregation
Platelet suspension (0.5 ml) was preincubated with the indicated amounts of \A-trans-AA for 
3 minutes at 37° C with constant stirring at 1200 rpm and then 0.5 units/ml thrombin was 
added. Aggregation was measured with an aggregometer and the results were compared to the 
control (platelet aggregation with 0.5 units/ml thrombin alone) (n=3, *P < 0.05 relative to 
aggregation with AA only).
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Carbamyl platelet activating factor (cPAF) is a non-hydrolyzable PAF agonist, that 
possesses full agonist activity approaching PAF in potency and completely resists 
inactivation by acetylhydrolase (Tessner et a l, 1989). \4-trans-P±A (5 pM) inhibited 
cPAF (50 nM)-mediated platelet aggregation by 80 ± 8% (Figure 3-30).
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cPAF
i--------------1-------------1 i-------------1------------ 1
Time [Min] o 3 6 0 3 6
14-trans-AA 0 pM 5 pM
cPAF 50 nM 50 nM
Figure 3-30. Effect of cPAF on platelet aggregation
Platelet suspension (0.5 ml) was preincubated with the indicated amounts of 14-trans-AA for 
3 min at 37 °C with constant stirring at 1200 rpm and then 50 nM cPAF was added. 
Aggregation was measured with an aggregometer and the results were compared to the 
control (platelet aggregation with 50 nM cPAF alone) (n=3, *P < 0.05 relative to aggregation 
with AA only).
Data shown in figures 3-27 to 3-30 suggest that at the concentration of 5 pM 14- 
trans-AA was an effective inhibitor of aggregation induced by ADP, epinephrine, 
thrombin and PAF, which resulted in 75-87% inhibition. Thus, a trans fatty acid, 14- 
trans-AA was able to inhibit many other pathways of platelet activation in addition to 
that induced by AA.
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3.1.2.7 Membrane incorporation of 14-trans-AA
To assess changes in the AA metabolism, the incorporation of l*C-\4-trans-AA (10 
pM) into platelet and compared with 14C-AA (10 pM). The platelets were incubated 
with cis- or \A-trans-AA for 3 minutes and the radioactivity in the platelet precipitate 
was measured by liquid scintillation counter and expressed as counts per minute 
(cpm). Figure 3-31 shows that \A-trans-AA was incorporated by platelets about 3 
times more than AA. At least part of \A-trans-AA was likely to be esterified in 
platelet phospholipids membrane. This experiment demonstrates that avid binding of 
\A-trans-AA by platelets could result in changes in phospholipids of the membrane 
near various receptors that could decrease the affinity of receptors for their ligands.
■  14CA A  
0  14C 14-trans-AA
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Figure 3-31. Incorporation of radio-labeled-AA/14-/ra«.s-AA into platelet 
membrane phospholipids
Washed platelet suspension (1ml) was incubated with (A) 14C-AA (10 (iM) (B) ™C-\A-trans- 
AA (10 pM) for 3 min at 37 °C with constant stirring at 1200 rpm then centrifuged at 2000 g 
for 5 min and the precipitate containing platelets was counted by a liquid scintillation counter 
(n=3). To standardise the counts of AA and \A-trans-AA both counts were expressed as 100% 
in the control from 3 different experiments and relative percentage to control after 0 and 3 
minutes of incubation (0 min = aliquot removed immediately after adding), (n = 3, *P < 0.05 
relative to control at 0 min).
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3.2 Metabolism of trans-AA by hepatic microsomes
3.2.1 Metabolism of 14-frans-AA by microsomes
It was observed that 14-trans-AA was not readily metabolized by human platelets 
(Figure 3-1). Dietary and endogenous 14-trans-AA enter hepatic circulation, therefore 
a study of its metabolism by CYP450 in hepatic microsomes was designed. Rat liver 
microsomes fortified with a NADPH-regenerating system were incubated with 14- 
trans-AA and metabolites were analyzed by radio-activity detector showing the 
formation of metabolite tl, t2 and t3 (Figure-3-32). Comparison with synthetic 
standards allowed structural identification of cl-c4 and tl-t3 (Table 3-3).
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Figure 3-32. Metabolism of radiolabeled 14-trans-AA by rat liver microsomes
Comparison of radio-chromatograms obtained by HPLC analysis of products extracted from 
incubation of rat hepatic microsomes (180 min, 37 °C) with 14C-radiolabled forms of: AA 
(A), 14-/ra7w-AA (B) and AA plus \A-trans-AA (C). Metabolites cl-c4 was generated from 
the metabolism of AA in comparison to \4-trans-AA gave rise to metabolites tl-t3.
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GC-MS analysis oîtl-tS  revealed ions at m/z 483 (Figure 3-33), which corresponded 
to a diTMS 14C-labeled DiHETE carboxyl anion. Fraction tl contained two closely 
eluting peaks tla  and tlb  whereas t2 was a single peak and t3 was a relatively minor 
product to do mass spectrometric analysis.
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Figure 3-33. Identification of peak t l  and t2
Chromatograms of ion at m/z 483 obtained from analysis by GC-MS (negative ions) of 
products tl and t2 isolated as described in Figure 3-32B. Ion m/z 483 corresponds to a diTMS 
derivative of a 14C-labeled DiHETE carboxylic anion.
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AA and \A-trans-AA was metabolized by CYP450 epoxygenase with reduced NADP 
and metabolites were extracted with ethyl acetate, derivatized and injected into a 
GC/MS. Values are retention times in minute obtained by GC-MS analysis on a HP- 
5MS column. Ions at m/z 481 and 483 were recorded for standards and metabolites, 
respectively and the retention times were compared in Table 3-3.
Table 3-3. Comparison of retention times of standards and metabolites from 
experiments illustrated by Figures. 3-32 and 3-33
Standards AAmetabolites
14,15-*ra«s-AA
metabolites
14,15-DiHETE 9.84 cl 9.83 tlb 9.80
11,12-DiHETE 9.74 c2 9.73 t2 9.76
8,9-DiHETE 9.72 c3 9.70 tla 9.72
5,6-DiHETE 9.73 c4 9.69 t3 9.68
3.2.2 Metabolism of 5-trans-AA by microsomes
It has been shown by Balazy et al (2005) that the rate of 5-trans-AA metabolism by 
microsomes appeared to be higher than that described for 14-trans-AA. This 
observation stimulated the present study designed to observe the metabolic pattern of 
5-trans-AA by CYP of hepatic microsomes. CYP metabolized 5-trans-AA into a 
complex mixture of oxidized lipid products (Figure 3-34). The metabolism required 
oxygen and NADPH. Mass spectrometric analysis based on an LC/MS with negative 
ion detection was done to establish the complete microsomal metabolic profile of 5- 
trans-AA.
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Figure 3-34. Metabolism of 5-trans-AA by rat liver microsomes
LC/MS analysis of a lipid extract obtained from incubation of 5-trans-AA with hepatic 
microsomes fortified with a NADPH-regenerating system (A). Structural assignment of 
metabolites hl-h8 and el-e4 is summarized in Table 3-4. For comparison shown are the 
standards derived from microsomal metabolism of AA (B and C) analyzed under the same 
conditions. Chromatograms were generated from selected monitoring of ion at m/z 319, with 
the exception of DiHETEs (B), which were detected by monitoring of ion at m/z 327. Lipids 
were analyzed on a Cl8 column using a solution composed of water/acetonitrile/acetic acid 
(37.5:62.5:0.01 v/v/v) at a rate of 300 pl/min.
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Table 3-4. Identification of microsomal 5 -tra n s-A A  metabolites
RetentionTime [min] 5,6-?ra«5-Product
5.8 hi 19-HETE
6.7 h i 13-HETE
7.3 h3 10-and 7-HETE
8.1 h4 15-HETE
8.8 h5 11-HETE
9.3 h6 12-HETE
10.2 h7 8-HETE
11.0 h8 5-HETE
13.2 X
14.5 el 14,15-EET
16.9 e2 11,12-EET
17.8 e3 8,9-EET
19.9 e4 5,6-EET
The retention time and assignment of metabolites corresponds to the labelling on 
Figure 3-34; x -  indicates a compound showing a parent ion at m/z 319 that did not 
produce identifiable fragments following collisional activation and thus remained 
unidentified.
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The mass spectral analysis revealed that four epoxides were formed (products el-e4 
on Figure 3-34A, Figure 3-35a-d, Table 3-4). Each of these products eluted from the 
microbore HPLC column shortly after the corresponding synthetic standard (Figure 3- 
34b), which was consistent with the presence of a single trans bond in the microsomal 
epoxides. The mass spectra of metabolites el-e4 contained prominent ions at m/z 319, 
which upon collisional activation generated characteristic fragments that allowed 
structural identification of four epoxides (Figure 3-35a - 3-35d). These spectra were 
qualitatively similar to those that detected the cis-EETs, yet subtle differences were 
noted.
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Figure 3-35. Mass spectra of four epoxides generated by microsomal metabolism 
of 5-trans-AA
The mass spectra correspond to the following structures of the fmMj-isomers of epoxides 
(metabolites el-e4): 5,6-EET (a), 8,9-EET (b), 11,12-EET (c) and 14,15-EET (d) obtained by 
collisional activation of carboxylate anion at m/z 319.
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Additional mass spectrometric analysis involved a reaction monitoring technique to 
reveal only the compounds that contained a precursor ion at m/z 319 and a fragment 
ion at m/z 191 (transition m/z 319 -> 191) during analysis of the microsomal lipid 
extract (Figure 3-36). This analysis showed a peak at 20.7 min (Figure 3-36 b) that 
had the retention time identical to the peak generated from the 5,6-trans-EET standard 
(Figure 3-36 a). Thus, this experiment confirmed that liver microsomes oxidized 5,6- 
trans-AA to an epoxide having the oxirane ring of trans configuration.
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Figure 3-36. Identification of S-trans-EJLT
Multiple reaction monitoring (LC/MS/MS) was used to detect specific products based on 
mass transition and retention time. The chromatograms show the relative intensity of the 
peaks for the equimolar mixture of cis and trans isomers of 5,6-EET (m/z 319 —> 191)(panel 
a), and the microsomal extract (panel b). A metabolite at 20.7 min has the same transition and 
retention time as 5,6-/ra?M-EET standard. The LC/MS conditions were as in Figure 3-34, 
except the mobile phase flow rate was 250 pl/min.
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Another group of microsomal 5,6-trans-AA metabolites were dihydroxyeicosatrienoic 
acids (DiHETrEs), which likely originated from hydrolysis of the corresponding 
epoxides (dl-d4, Figure 3-37). The mass spectra revealed that four such compounds 
were detected at retention times slightly longer than those for respective all ds-EET 
standards (Figure 3-34 b). The structures were assigned based on tandem mass spectra 
obtained by collisional activation of carboxylate anion at m/z 337. This result 
suggested that because one bond of the precursor substrate fatty acid was of trans 
configuration and one of the precursor epoxide had trans configuration, the resulting 
5,6-DiHETrE eluting at 6.1 min (Figure 3-37, product d4) had the erythro 
configuration.
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Figure 3-37. Identification of diols
Mass spectrometric identification of metabolites dl-d4 as diols (DiHETrEs) resulting from 
hydrolysis of the corresponding epoxides by hepatic microsomes. Full scan spectra were 
acquired and extracted ion profile is shown for m/z 337.
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The tandem mass spectra also revealed that 5,6-fraw-AA was metabolized to a group 
of products (hl-h8 on Figure 3-34 a, Table 3-4) identified as isomers of HETEs. 
These compounds originated from CYP-dependent oxygenation by three mechanisms 
allylic, foj-allylic, and subterminal hydroxylations. Among these lipids, metabolite h8 
(Figure 3-34a) showed a mass spectrum having fragment ions at m/z 203 and 115 that 
was very similar to the spectrum of 5-HETE standard obtained from AA metabolism 
by 5-LOX (Figure 3-38). However, although metabolite h8 showed a UV spectrum 
typical for a conjugated diene with an a hydroxyl, its maximum absorbance was at 
236 nm, i.e. 2 nm more than in the UV spectrum of the 5-HETE standard (Figure 3- 
38). This suggested that compound h8 had a different double bond configuration than 
the 5-HETE standard.
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Figure 3-38. Identification of 5-HETE isomer
Comparison of UV spectra of metabolite h8 and 5-HETE standard (top). Tandem mass 
spectrum of metabolite h8 shows characteristic fragments for 5-HETE (bottom).
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A HETE metabolite eluting at 6.7 min (hi, Figure 3-34 a) showed a mass spectrum 
(Figure 3-39a) that was nearly identical to the spectrum of 19-HETE, a known 
product of AA metabolism by microsomal co-l hydroxylase. The ions at m/z 59 and 
231 were characteristic for metabolite hi and 19-HETE and corresponded to 
fragments indicated on Figure 3-39.
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Figure 3-39. Identification of metabolite hi
Tandem mass spectra of metabolites hi identified as trans isomers of 19-HETE, 
having characteristic ion m/z 59 and 231.
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Metabolite hi was further analyzed by GC/MS as a pentafluorobenzyl, trimethylsilyl 
derivative and revealed two components (Figure 3-40b). The retention time of these 
two metabolites were compared with the retention time of the all cis HETE standards 
(Figure 40a) and the products obtained by isomerization of 19-HETE, 18-HETE and 
20-HETE induced by the reaction with the N 02 radical (Figure 3-40c). This 
experiment demonstrated that a component eluting at 8.12 min (Figure 3-40b) 
matched precisely one of the four isomers of 19-HETE generated from the N 02- 
mediated isomerization (Figure 3-40c).
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Figure 3-40. GC/MS analysis of metabolite h i
Chromatograms were obtained by monitoring of ion at m/z 391 generated from the 
pentafluorobenzyl, trimethylsilyl derivatives and represent analysis of (a) a mixture of five 
all-ds HETE standards; (b) metabolite hi, and (c) products of 19-HETE treatment with N02 
showing coelution (dotted line) of one of the isomers with a microsomal metabolite.
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A minor component eluting at 7.92 min (Figure 3-40b) was tentatively characterized 
as 5,6-trans-l 8-HETE because it coeluted with a product of 18-HETE isomerization 
(data not shown). Because this metabolic pattern of HETEs resembled the one that 
was observed previously with CYP2E1-mediated metabolism of AA (Laethem et ah, 
1993), it was tested whether this isoform of CYP was involved in the microsomal 
metabolism of 5,6-trans-PJ±. Pre-incubation of microsomes with a CYP2E1 antibody 
reduced formation of metabolite hi (5,6-trahs forms of 19- and 18-HETE) by 57% 
(Figure 3-41). Biosynthesis of allylic HETEs was reduced by 28-36% and Ms-allylic 
HETEs (see below) by 40-48%. The CYP2E1 antibody had minimal effect on 
biosynthesis of epoxides. The data provided evidence that hepatic CYP2E1 isozyme 
participated in oxidation of 5,6-trans-AA. at carbons C l9 and Cl 8.
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Figure 3-41. The effect of the CYP2E1 antibody on the microsomal metabolism 
of 5-trans-AA
The number in parenthesis indicates the percent inhibition by antibody treatment for a 
metabolite represented by a chromatographic peak. The largest inhibitory effect is seen for the 
formation of trans isomers of 19-HETE and 18-HETE.
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Mass spectra of metabolites h2 and h3 (Figure 3-34) showed close similarity to the 
spectra obtained by Bylund et al. for the three Zus-allylic HETEs formed by liver 
microsomes (Bylund et ah, 1998). Metabolite h2 showed a prominent ion at m/z 193 
and m/z 149 {m/z 193-C02) and a fragmentation pattern similar to that in the spectrum 
of 13-HETE (Figure 3-42). Metabolite h3 showed characteristic ions at m/z 137, 153, 
181, 193 and 203 suggesting that this metabolite could be a mixture of 5,6-trans 
isomers of 10-HETE, 7-HETE and perhaps some 13-HETE . Consistent with previous 
observations, the Zw-allylic HETEs eluted before allylic HETEs on the reverse-phase 
HPLC and did not show UV absorbance above 205 nm.
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Figure 3-42. Identification of metabolite h2 and h3
Tandem mass spectra of metabolites h2 (top) and h3 (bottom) identified as trans isomers of 
13-HETE and a mixture of 10- and 7-HETE.
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3.2.2.1 Hepatic microsomes induced decay of 5,6-EET isomers
Incubation of equal amounts (100 ng) of 5,6-trans-EET and 5,6-cw-EET with hepatic 
microsomes revealed that the trans epoxide was significantly more resistant to 
microsomal metabolism (Figure 3-43). The initial rate of microsomal metabolism, a 
significant portion of which was hydrolysis, was about 2 -fold faster for the cis isomer. 
Following incubation for 60 min there was 3.6-fold more of the trans isomer 
remaining in solution than of the cis isomer.
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Figure 3-43. Comparison of hydrolysis rate for cis and trans isomers of 5,6-EET 
by hepatic microsomes
A quantitative LC/MS assay was used to determine the amount of each isomer (a) and the 
changes of their ratio (b) during incubation. After 60 min 32% of trans(t) and only 6.5 % of 
cisfcj epoxide remained in solution in an intact form (c) starting from initial equal amount 
(100  ng) of each isomer (d).
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3.2.2.2 Glutathione-dependent conjugation of 5,6-EET isomers
Incubation of equal amounts of 5,6-trans-'EEY and 5,6-czj-EET with glutathione-S- 
transferase (GST) (Figure 3-44) also revealed that the epoxide was significantly 
more resistant to glutathione conjugation than its cis isomer. After 360 min incubation 
with hepatic GST, the cis isomer was undetectable whereas 39.2% of the 5,6-trans- 
EET was detected in the intact form (Figure 3-44).
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Figure 3-44. Glutathione dependent conjugation of 5,6-EET isomers
Concentration of intact 5,6-EET cis and trans isomers (100 ng) remaining in solution after 
incubation with hepatic glutathione-S-transferase ( 1 8  units) and glutathione ( 1  jllM ) .
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3.2.2.3 Mass spectrometric identification of 5,6-trans -EET
A method developed by Corey (Corey et a l, 1979) was used with modifications 
(Balazy, 1991) to prepare 5,6-trans-EET, 5,6-cz>EET and d^-5,6-cis-EET from 5,6- 
trans-AA, AA and dg-AA, respectively. The LC/MS and GC/MS properties were 
compared with its cis isomer that was synthesized by the same protocol. Synthetic 
5,6-trans-EET wsa used as a standard for metabolic studies with its precursor, 5,6- 
trans-AA (Figure 3-45).
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Figure 3-45. Mass spectra of 5-cis and trans-EET
Comparison of tandem mass spectra obtained by collisional activation at -30 V of the 
carboxylic anion at m/z 319 generated from 5,6-/ra?zs-EET (top), 5,6-c/s-EET (middle) and of 
ion m/z 327 from octadeuterium-labeled 5,6-c/s-EET (bottom), which were prepared by 
iodolactionization of 5,6-trans-AA, AA and dg-AA, respectively. The spectra were averaged 
and background noise was subtracted.
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Multiple reaction monitoring (MRM) analysis of m/z 319 and 143 were done. Both 
cis and Zrcms-5,6-EET were detected by m/z 319 ion monitoring but only 5 ,6 -m-EET 
gave rise to m/z 143 (Figure 3-46).
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Figure 3-46. LC/MS analysis of cis and trans isomers of 5,6-EET
Acquisition of selected ions at m/z 319 and 143 was done. The latter appears only in the cis 
isomer. Lipids were analyzed on a Phenomenex Luna C18 column and eluted with a solution 
composed of water/acetonitrile/acetic acid (37.5:62.5:0.01 v/v/v) at a rate of 300 pl/min. 
Lipids were ionized and detected by the API 2000 mass spectrometer operating in a turbo-ion 
spray negative mode.
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3.3 Metabolism of trans-AA  by polymorphonuclear 
leukocytes and HL 60 cells
Metabolism of 5-trans-AA in freshly isolated PMNs and in HL-60 cells, and the 
metabolism of 5-trans-AA by 5-LOX in these cells were studied. 5-trans-AA (10"8 to 
10'5 M) was incubated with PMNs and with HL-60 cells (DMSO-differentiated and 
non-differentiated) stimulated with calcium ionophore (A23187 1 pM) for 2 hours. 
PMNs metabolized 5-trans-AA by a concentration-dependent mechanism (Figure 3- 
47 B). At submicromolar concentration, 5,6-frYms-8-HETE was the dominant 
metabolic product of 8 -LOX, whereas at micromolar concentrations, more of 5,6- 
fraws-15-HETE was observed suggesting involvement of 15-LOX. The identity of 
these products was confirmed by tandem mass spectra following collisional activation 
of ion at m/z 319. Trace amounts of 5,6-trans-5-HETE were also detected (Figure 3- 
47 A). However cells, whether differentiated or not, the HL-60 did not produce 
detectable LOX products from endogenous and exogenous AA and 5-trans-AA (data 
not shown).
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Figure 3-47. Determination of 5-trans-AA metabolic pattern in human PMNs
Incubation of 5-trans-AA (10"8-10‘5 M) resulted in a series of trans HETE isomers (A), of 
which IS-fram-HETE was the most prominent component at higher concentrations; (B). 
Identification of isomers was accomplished via analysis of tandem mass spectra.
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Arachidonic acid is the precursor for a number of biologically active metabolites 
formed by oxygenation through the COX, LOX and CYP pathways (Peters-Golden, 
1998; Brash, 1999; Smith & Langenbach, 2001). The eicosanoids (PCs and LTs) play 
important roles in regulating many physiological processes such as platelet 
aggregation and acute inflammatory responses (Funk, 2001). Berdeaux et al. (1996) 
observed that the addition of a trans isomer of AA (\A-trans) to rat platelet 
suspensions inhibited the aggregation induced by AA. However, the addition of its 
structural homolog 5,8,11-eicosatrienoic acid (20:3n-9) or the natural isomer (20:4n- 
6) did not induce any modification of the platelet aggregation. Addition of \A-trans- 
AA to the platelet significantly decreased TXBz and 12-HHT production but 12- 
HETE production was increased 55%. They observed that \A-trans-PJ± alone did not 
induce any platelet aggregation, rather this fatty acid was metabolized to a limited 
extent into two unidentified products; one of those was a LOX product.
4.1 Interaction of trans-AA with platelets
4.1.1 Metabolism of trans-AA by platelets
When platelets are incubated with AA, the enzyme COX causes endoperoxidation of 
AA leading to the formation of PGH2, by the reduction of PGG2 (Hamberg & 
Samuelsson, 1974). Isomerization of PGH2 leads to the generation of TXA2, as well 
as 12-HHT (Hamberg et al, 1975). In addition to the COX pathway, platelets also 
metabolize AA via 12-LOX to form 12-HpETE, followed by the reduction of the 
hydroperoxide to form the stable end product 12-HETE (Hamberg et al, 1975; 
Nugteren, 1975; Hamberg & Hamberg, 1980). To observe the metabolites of AA 
production, platelets were incubated with different concentrations of radio labeled [1- 
14C] AAs for various length of time. After incubation, the fatty acids were extracted 
and HPLC analysis was performed. Results were obtained using either radioactivity 
detector or variable wavelength UV detector.
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AA metabolism by platelets produced TXB2, 12-HHT and 12-HETE (Figure 3-1). 
The identity of these metabolites was confirmed by chromatography and UV spectral 
analysis, comparing with the standards. \A-trans-AA did not produce such 
metabolites and showed less metabolism by platelets in comparison to AA (Figure 3-1 
C). However, this metabolism was shown to give rise to four different metabolites, as 
their elution time was different from the conventional metabolites. These novel 
metabolites were labeled as metabolite A, B, C, and D (Figure 3-1). Further LC/MS 
analyses were done to characterize these novel metabolites.
When indomethacin, a potent COX inhibitor, was used in the test system, there was 
no formation of TXB2, 12-HHT or metabolite B or C. This suggested that the 
metabolites B and C are the product of the COX pathway (Figure 3-4 B). Baicalein, a 
potent LOX inhibitor, was found to cause a decrease in the production of 12-HETE, 
metabolite A and D. This suggested that these metabolites were the product of the 
LOX pathway (Figure 3-4 C).
Non-radiolabeled AA was used along with radiolabeled \4-trans-AA to observe the 
influence of AA on metabolism of trans-AA. It was found that metabolism of 14- 
trans-AA was increased in the presence of AA as all the novel metabolite production 
was increased (Figure 3-5). It suggests that AA has an influence on metabolism of 14- 
trans-AA by human platelets. The \4-trans-AA metabolism was increased in the 
presence of AA because of co-oxidation of trans-AA in the presence of AA that 
caused formation of increased amounts of unidentified metabolites. Co-oxidation of 
xenobiotics by AA, COX, and LOX has been described (Nadin & Murray, 2000). 
Then the COX inhibitor was used and it was found that there was no formation of 
metabolites B and C (Figure 3-5 B). The LOX inhibitor inhibited the formation of 
metabolites A and D (Figure 3-5 D). These experiments further confirmed that 
unknown metabolites B and C are COX products, and metabolites A and D are LOX 
products.
In order to characterize metabolites C and D, they were subjected to spectral analysis 
using an HPLC system equipped with a multiple wavelength detector. It was observed 
that both metabolite C and D showed absorption maxima at 236 nm (Figure 3-7) 
however, both were distinct from the absorption maxima of 12-HETE at 234 nm.
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Metabolites formed by platelets from lA-trans-kA showed seven peaks while using 
LC/MS (Figure 3-8 B) as compared to using radio-chromatogram where there were 
four peaks (A, B, C and D) (Figure 3-1 B). As LC/MS has better resolution and 
identification capacity, it detected all the metabolites and those were named 
metabolite A, B%, B2, Ch C2, D% and D2. These metabolites were injected into a HPLC 
system equipped with online mass spectrometer by using an auto injector and 
negative-ion MS/MS were done for identification of their structures. The MS/MS 
spectra of novel metabolites were compared with spectra of commercial standards.
A. Identification of metabolite A
a. Molecular mass of metabolite A
Metabolite A was detected during the LC/MS analysis of lipids from the incubation of 
\4-trans-KK with platelets. Metabolite A showed a prominent negative ion at m/z 
369. It eluted between two isomers of TXB2 (Figure 3-8 B). The retention times were 
as follows (on a standard HPLC and LC/MS system): TXB2 (peak 1), 7.7 min, 
metabolite A 8.1 min, and TXB2 (peak 2) 8.7 min (Figure. 3-9). Metabolite A was a 
chromatographically distinguishable metabolite having a molecular mass of 370. 
Analysis of fractions 8 and 9 (Figure 3-8) containing TXB2 isomers and metabolite A 
by GC/MS (negative ion chemical ionization) as a pentafluorobenzyl (PFB) ester, 
trimethylsilyl (TMS) ether (Figure 4-1) revealed two peaks (Figure 3-13 A) by 
monitoring of an ion m/z 585. This ion corresponded to a carboxylic anion of the 
trimethylsilyl derivative of TXB2 (Figure 3-13 B) shown below for the TXB2 
derivative:
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Figure 4-1. Trimethylsilyl ether derivative of thromboxane B2
Figure shows the structure of TMS derivative of PFB ester of TXB2 (above) and the structure 
of TMS (below).
Metabolite A showed the same ion suggesting a structure isomeric with TXB2. 
Additional analysis involved the preparation of all TMS derivatives of fractions 7-9 
(Figure 3-13) and analysis by GC/MS via electron ionization. Two spectra were 
obtained. One was interpreted as corresponding to the tetra TMS derivative of TXB2 
and the other to the unknown metabolite A. Both spectra showed a molecular ion 
(M+) at m/z 585. The GC/MS analyses also revealed that metabolite A had 3 
hydroxyl groups and one non-hydroxyl oxygen similar to TXB2. In both GC/MS 
analyses, TXB2 derivatives of the two isomers observed by HPLC and LC/MS 
analyses eluted as a single peak, distinguishable from the peak generated by 
metabolite A. Thus mass spectrometric analysis provided evidence that metabolite A 
had molecular mass of 370 and was likely to be an isomer of TXB2 or a prostaglandin.
b. Biosynthesis of metabolite A
Two inhibitors were used to probe the biosynthetic pathways of \A-trans-KK 
metabolites in platelets; indomethacin, which inhibits platelet COX at IC50 0.1 pM 
and baicalein, a plant flavonoid that inhibits platelet 12-LOX at IC50 0.12 pM. 
Experiments with inhibitors confirmed preliminary observations with 14C-labeled 14- 
trans-AA that metabolite A is a metabolite of 12-LOX. Preincubation of platelets with
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indomethacin (10 i^M) removed all COX metabolites as tested with AA metabolism 
(Figure 3-10), which revealed only 12-HETE. However, the formation of metabolite 
A was not affected by indomethacin (Figure 3-10 B) as compared to control 
experiments without an inhibitor (Figure 3-10 C). The control experiment also 
showed peaks corresponding to TXB2 resulting from adventitious activation of 
platelets during platelet preparation and incubation. This TXB2 was likely to be 
formed from the endogenous AA.
Treatment of cells with baicalein (10 pM) caused partial inhibition of 12-LOX and the 
formation of its metabolite 12-HETE. TXB2 levels were increased relative to the 
control (Figure 3-11 A vs. Figure 3-8 A). Baicalein inhibited the formation of the 12- 
HETE isomer from \4-trans-hA metabolism and also inhibited the biosynthesis of 
metabolite A (Figure 3-11 B vs. Figure 3-11 C). The results with the inhibitors 
suggest that metabolite A is likely to be a product of 12-LOX. The results were 
confirmed by the analysis of octadeuterium-labeled \A-trans-AA {à%-\A-trans-AA) 
metabolism in platelets. Compared to control experiments (Figure 3-12 A), 
indomethacin caused the increase of metabolite A and the 12-HETE analogue (Figure 
3-12 B) whereas baicalein completely inhibited the formation of the deuterium 
analogue of metabolite A (Figure 3-12 C). Analysis of &%-\4-trans-AA metabolism 
and specific ions corresponding to deuterated metabolites was useful because it was 
not confused with AA metabolites that lacked the deuterium label. Experiments with 
both labeled and non-labeled \A-trans-AA revealed a novel unique lipid product 
generated by 12-LOX having similar chromatographic polarity (by GC, LC) as TXB2 
and possibly being its isomer. Such a prostaglandin-like metabolite generated by 12- 
LOX has not been observed previously.
c. Structure of metabolite A
Data obtained so far suggested that metabolite A is a 12-LOX metabolite having the 
molecular mass of 370 identical to TXB2 and containing 3 hydroxyls, one non­
hydroxyl oxygen and a carboxylic group. Metabolite A was formed in amounts 
comparable to TXB2 from endogenous AA (Figure 3-11 C). However, mass spectra of 
metabolite A showed a lack of similarity with mass spectra of TXB2 obtained by 
LC/MS/MS and GC/MS.
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The LC/MS/MS spectrum of metabolite A obtained by collisional activation of its 
carboxylic anion at m/z 369 (Figure 3-14 A) showed a prominent ion at m/z 127 
which was shifted by 2 a.m.u. in the spectrum of deuterium-labeled metabolite A 
(Figure 3-14 B) indicating that it had one of the original double bond configuration. 
Additionally, ions of m/z 155 and 158 were observed in the spectra of unlabeled and 
dg-labeled metabolite A respectively, suggesting that it had three carbons that were 
bound to the deuterium in the precursor substrate \A-trans-AA. In trying to identify 
the structure of metabolite A (Figure 4-2), it was noticed that prominent ions at m/z 
127 and 155 are also found in the spectrum of isoprostaglandin Fia-IV (Morrow et al, 
1990), therefore it is likely that a similar structural fragment is in metabolite A.
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Figure 4-2. Suggested structure of metabolite A and dg-metabolite A
In LC/MS/MS study metabolite A shows ions at m/z 127, 155 and 225 (above) and structure 
of d8-metabolite A below.
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The structures of ions at m/z 127 and 155 (Figure 4-3) for metabolite A, are proposed 
as follows:
.COO"
m/z 127
COO"
m/z 155
Figure 4-3. Suggested structures of ions at m/z 127 and 155
Figure shows the proposed structures of ion at m/z 127 and ion at m/z 155 originated from the 
a cleavage of metabolite A.
Both ions are generated from a bond cleavage at the hydroxyl group at carbon C8 . 
The ion at m/z 127 originated from a cleavage of bond C7-C8 followed by the 
transfer of a hydrogen to C7. Ion at m/z 155 originated from the a cleavage of the C8- 
C9 bond with the abstraction of hydrogen generating an aldehyde. Additional 
fragments can be generated from the upper chain of metabolite A structure. Ions at 
m/z 181 and 183 (Figure 4-4) originated from the keto-enol tautomeric form that can 
exist for metabolite A.
— 183
OH
COOH
HO
Keto form of metabolite A
COO"
m/z 183
Figure 4-4. Suggested structure of keto form of metabolite A
LC/MS/MS of keto form of metabolite A gives rise to ion at m/z 183 (above) and the 
structure of ion m/z 183 is shown (below).
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Additional evidence to support the proposed structure of metabolite A comes from the 
detection of ions at m/z 225 and 195 (Figure 4-5). Ion 225 is likely to originate from 
the cleavage of the pyrene ring.
COO"
m/z 225
HCO
COO"
m/z 195
Figure 4-5. Formation of ion at m/z 195 from ion m/z 225
Figure shows the formation of ion m/z 195 from ion m/z 225 that is likely to originate from 
the cleavage of the pyrene ring.
While the presence of the ion at m/z 195 could be confused with the same ion that 
originates from the analysis of TXB2 (Figure 4-6) and because metabolite A and 
TXB2 eluted closely, there was same uncertainty about this ion.
OH
OH 
Thromboxane B2
LC/MS/MS
0
▼ !  ^ v
m/z 169 m/z 195
Figure 4-6. Structures of LC/MS/MS cleavage products of TXB2
Figure shows the structures of LC/MS/MS cleavage products of thromboxane B2 (ions at m/z 
169 and m/z 195)
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This concern was removed by the analysis of metabolite A biosynthesized by platelets 
from octadeuterium-labeled \A-trans-AA. Deuterium-labeled metabolite A produced 
a carboxylic anion at m/z 377 suggesting that it originated from the deuterium-labeled 
precursor \A-trans-AA. The spectrum of dg-metabolite A showed a prominent ion at 
m/z 129 (Figure 4-7), which suggested that it contained two deuterium atoms as 
compared to ion 1 at m/z 127 from non-labeled metabolite (Figure 3-14).
Figure 4-7. Ions of d8-metabolite A from dg-labeled \4-trans-AA
Figure shows LC/MS/MS fragments of dg-metabolite A, showed a prominent ion at m/z 129 
and ions at m/z 158 and m/z 2 0 0 .
Similar reasoning leads to structure of ions at m/z 158 and 200, which contained three 
and five deuterium atoms, respectively.
d. Proposed mechanism of metabolite A biosynthesis
The data suggested that metabolite A is a unique metabolite that was a product of 12- 
LOX likely having a structure similar to that of thromboxane. A key experiment was 
performed with purified 12-LOX enzyme, which was incubated with \A-trans-hh. 
This experiment yielded a metabolite that had a spectrum showing ions at m/z 127, 
155 and 183 from the activation of the ion at 369 (Figure 3-14 C). Metabolite A was 
likely to be formed by the following mechanism (Figure 4-8).
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Figure 4-8. Proposed mechanism of formation of metabolite A
14-trans-AA is metabolized by platelet 12-LOX to 14-trans-12-HpETE radical, which by 
isomerization and reduction forms iso-thromboxane.
In summary, metabolite A is a product of 12-LOX in platelets and obtained from a 
purified enzyme. The biosynthesis of metabolite A in platelets was inhibited by 
baicalein. Ions characteristic for metabolite A (m/z 127, 155, 183) were also found in 
an iso-prostaglandin F2a type IV (Morrow et al, 1990), which strongly supported the 
configuration of the upper chain containing the carboxyl group of metabolite A. 
Metabolite A has a structure similar to TX. Many other possibilities was considered
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for structure of this metabolite that included prostacyclin, PGs, iso-PGs and LT 
structures. None of these structures fit the proposed structure of metabolite A. It is 
interesting to note that a structure similar to metabolite A was reported by Morrow et 
al., (1996) who reported iso-thromboxane B2 type III (Morrow et a l, 1996) from 
spontaneous oxidation of AA in vitro. In contrast to the report by Marrow et al., 
metabolite A described here is an enzymatic product of platelet 12-LOX. 
Thromboxane synthase may be involved in the formation of metabolite A in platelets.
B. Identification of metabolite B
Metabolite B contained two isomers (B% and B2, on Figure 3-8) that show LC/MS/MS 
spectra almost identical to the spectrum of standard 1 2 -hydroperoxyeicosatrienoic 
acid (12-HHT). Metabolite Bi (Figure 4-9) was the authentic 12-HHT resulting from 
spontaneous decomposition of TXA2 and loss of malonyldialdehyde (Figure. 3-9). 
Metabolite B2 was likely to have the structure shown on the Figure 3-16 with the bond 
C1 0 -C1 1 having trans configuration.
Figure 4-9. Formation of ion m/z 179 from Metabolite
Figure shows the suggested structure of metabolite Bi (12-HHT) and LC/MS/MS product of 
metabolite Bi which formed ion m/z 179.
It is unlikely that metabolite B2 (Figure 4-10) originated from spontaneous 
decomposition of metabolite A, which was a LOX product.
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Figure 4-10. Formation of ion m/z 179 from Metabolite B2
Figure shows the suggested structure of metabolite B2 (%-trans-12-HHT) and LC/MS/MS 
product of metabolite B2 which formed ion m/z 179.
Metabolite B2 was probably a by-product of endogenous AA metabolism by 
COX/TXS (thromboxane synthase).
C. Identification of metabolite C
a. Metabolite Ci
Metabolite Ci (Figure 3-8, 3-10) was a major product of \A-trans-AA metabolism. 
Biosynthesis of this metabolite was inhibited more than 80% by indomethacin but not 
by baicalein suggesting that metabolite Ci was a product of COX. This metabolite 
showed maximal U V  absorbance at Xmax 236 (Figure 3-7) and retention time close to 
15-HETE (Figure 3-9). In the co-incubation experiments with equimolar amounts of 
AA, the formation of metabolite 0% was accelerated by about 5-fold (Figure 3-3). 
LC/MS analysis showed abundant carboxylate anion at m/z 319, which when 
collisionally fragmented showed a pattern of ions characteristic for a HETE. The 
LC/MS/MS spectrum of metabolite Ci (Figure 3-17 A) showed fragments 
corresponding to loss of H2O (m/z 301), CO2 (m/z 275) and H2O plus CO2 (m/z 257)
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which one typically found in the spectra of HETE molecules. An abundant fragment 
at m/z 219 (Figure 4-11) was likely to correspond to a fragment anion (C13H19COO") 
resulting from the cleavage at the hydroxyl group (Figure 3-17 A). Loss of 44 a.m.u. 
(CO2) yielded anion at m/z 175. Both ions are also found in the LC/MS/MS spectrum 
of a standard sample of 15-HETE. Ion at m/z 113 is also typical for 15-HETE and 
results from the cleavage of the C6-C7 bond with a hydrogen shift yielding anion 
C5H9COO". The key question about the structure of metabolite Ci is the configuration 
of the double bond next to the hydroxyl group. In 15-HETE the configuration of this 
bond (but carbons C13-C14) is trans. In metabolite C% this bond is likely to be c/s. 
This conclusion is supported by detection of ion at m/z 121 in the spectrum of 
metabolite Ci. This ion is absent in the spectrum of 15-HETE. Ion at m/z 121 is likely 
to originate from cyclization induced alcoxyl anion and attack C8 yielding an eight 
carbon anion.
COO
OH
all-c/s-15-HETE 
(Suggested structure of metabolite C.,)
LC/MS/MS
Figure 4-11. LC/MS/MS cleavage of metabolite Ci
LC/MS/MS metabolite C% (all-c/s-15-HETE) formed ions m/z 219 and m/z 175.
Ion 121 can be formed only if the C13-C14 bond is cis, if this bond is trans as in 15- 
HETE, ion 121 is not formed. Thus the data are consistent with the metabolite Ci 
being an isomer of 15-HETE, the all-c/j-15-HETE. Incubation of platelets with
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deuterium-labeled \A-trans-AA (dg-14-rmMJ-AA) as shown in Figure 3-12 resulted in 
octadeuterium-labeled metabolite C% having molecular mass of 328 (Figure 3-17 B). 
Ion at m/z 226 in this spectrum was at 7 a.m.u. higher than ion 219 in unlabeled 
metabolite Ci, thus confirming the structure of 15-HETE. There was an ion analogous 
to ion 121  at m/z 125, and it was very small probably because of isotopic effects 
involved in its formation. Thus \4-trans-AA was metabolized mainly to 15-HETE by 
COX, and the LOX inhibitor stimulated its formation. The UV absorbance maxima of 
metabolite Ci shifted to the chronically by 2  nm in comparison to the maxima of the 
UV absorbance for 15-HETE standard. 15-HETE which has a trans-cis configuration 
of the conjugated bonds in the a position to the hydroxyl ion and its absorbance 
maximum is at 234 nm. The absorbance at Xmax= 236 nm would be consistent with a 
cis-cis configuration. Thus the structure of metabolite Ci, is likely to be 
5Z,8Z, 11Z, 13Z-15-hydroxyeicosatetraenoic acid (all-cz's-15 -HETE). The
stereochemistry of the hydroxyl was not determined because of the limited 
availability of the material.
b. Metabolite C2
Metabolite C2 was also a product of COX and was a HETE molecule. Its LC/MS/MS 
spectrum showed a characteristic ion at m/z 167 (Figure 3-18 A) that was also found 
in the spectrum of 11-HETE standard. This ion was shifted by 4 a.m.u. to m/z 171 in 
the spectrum of octadeuterium-labeled metabolite C2 (Figure 3-18 B). This fragment 
ion likely originated from the cleavage of the C10-C11 bond and contains a 
transformed proton, and has the structure of a carboxylate anion C9H15COO" or 
C9H11D4COO' in deuterium analogue. Thus the mass spectrum and work with 
inhibitors suggested that metabolites C2 was likely to be an isomer of 11-HETE. The 
spectrum of this metabolite showed a lot of similarity with the mass spectrum of 1 1 - 
HETE standard (Figure 3-18 C).
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Figure 4-12. LC/MS/MS cleavage of metabolite C2
LC/MS/MS metabolite C2 ( 14-trans-11 -HETE) formed ion m/z 167.
The double bond configuration of the C14-C15 bond was unlikely to be changed as a 
result of incubation with platelets and metabolism of 14-trans-AA by COX, and thus 
the data support the structure of 14-trans-11 -HETE (5Z,8Z,12E,14E-11- 
hydroxyeicosa-tetraenoic acid) (Figure 4-12) for metabolite C2. \4-trans-\ 1-HETE 
contains a hydroxyl ion that is in a position to the two conjugated trans double bonds. 
The maximal absorbance of such configuration is at >umax = 236 nm, identical to 
metabolite Ci.
D. Identification of metabolite D
a. Metabolite D%
Metabolite D was a product of LOX as demonstrated in preliminary results on Figure 
3-4 using radiolabeled 14C-14-/nms-AA. More detailed analysis using LC/MS 
revealed two components in metabolite D (Figure 3-8, 3-10). Biosynthesis of 
metabolite Di was almost completely inhibited by treatment of platelets with baicalein 
suggesting that this metabolite was a product of 12-LOX (Figure 3-11, 3-12). The 
LC/MS/MS spectrum of metabolite Di (Figure 3-19) showed a prominent ion at m/z 
179 resulting in a form that is typical for HETEs fragmentation at carbon bond next to 
the hydroxyl group.
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Figure 4-13. LC/MS/MS cleavage of metabolite Di
LC/MS/MS metabolite D% ( 14-trans-12-HETE) formed ion m/z 179.
Experiments with deuterium-labeled 14-trans-AA yielded an octadeuterium-labeled 
metabolite D showing an ion at m/z 184 (Figure 3-19 B) that is consistent with a 
fragment having 5 deuterium. Loss of 44 a.m.u. (CO2) from ions 179 (Figure 4-13) 
and 184 produced ions at m/z 135 and 140, respectively. The data suggest that 
metabolite D% was a 14-trans-12-HETE. The spectrum of metabolite Di was similar to 
the spectrum of 12-HETE standard. The trans bond from precursor substrate was not 
likely to change the configuration as a result of the reaction with 12-LOX and this 
trans bond had no effect on the fragmentation. However, 14-trans-12-HETE eluted 
after the peak of 12-HETE (Figure 3-9).
b. Metabolite D2
A minor component of metabolite D designated as metabolite D2 (Figure 3-8, 3-10, 3- 
11) was likely a product of COX as experiments with d^-14-trans-AA showed 
complete inhibition of formation by indomethacin (Figure 3-12). Baicalein also had 
some inhibitory effect on its formation (Figure 3-11). The mass spectrum revealed the 
structure of metabolite D2 to be a 14-/r<ms-5-HETE (Figure 4-14).
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Figure 4-14. LC/MS/MS cleavage of metabolite D2
LC/MS/MS metabolite D2 ( 1 A-trans-5-HETE) formed ion m/z 115.
In summary, \A-trans-AA was metabolized by two set of enzymes (COX and LOX) 
in the platelets. The metabolites of COX pathway were 12-HHT, all-ds-15-HETE, 
\A-trans-\ 1-HETE, and 14-/ra«5-5-HETE and the LOX pathway were iso­
thromboxane, 12-HHT and 14-trans-12-HETE. The metabolites are shown in
Figure 4-15.
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Figure 4-15. Summary of metabolism of 14-trans-AA by human platelets
14-/nms-AA was metabolized by COX and LOX in platelets. The COX products were 12- 
HHT, 13-trans-15-HETE, M-frcws-l 1-HETE, and 14-£r<ms-5-HETE and the LOX products 
were iso-thromboxane, %-trans-12-HHT and 14-trans-12-HETE.
4.1.2 Effects of 14-trans-AA on platelet function
In order to determine whether the effects of trans-AA on rat platelets showed by 
Berdeaux et al, exist in human, the current study looked at the same experiments 
using human platelets. Arachidonic acid (15 pM) induced aggregation of human 
platelets and different concentrations (15, 50 & 100 pM) of 14-trans-AA were used to 
induce platelet aggregation, but there was no evidence of platelet aggregation or shape 
change (Figure 3-21). This led to the idea that 14-trans-AA does not cause platelet 
aggregation or shape change by itself. Indeed, aggregation of platelets by AA was 
decreased by pre-incubation with 14-trans-AA (Figure 3-22), consistent with the
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previous result (Berdeaux et ah, 1996). These results suggest that the aggregation of 
platelets by AA was inhibited or antagonized by \A-trans-PsA or by novel metabolites 
o f \A-trans-AA.
In order to observe the concentration-response aggregation shape (Figure 3-24), 
platelets were pre-incubated with different amounts of \A-trans-AA (0, 3, 5, 7, 9 & 11 
pM) and AA (3 pM). The observed results showed that the inhibitory effect of 14- 
trans-AA is concentration-dependent and the IC50 (inhibitory concentration at 50%) 
of lA-trans-AA was found to be at 7.2 pM.
Since TXA2 is known to cause platelet aggregation and the level of TXB2 (non- 
enzymatic hydrolyzed product of TXA2) reflects the level of TXA2, experiments were 
performed with measurement of TXB2 level to determine the effects of TXB2 on 
platelets treated with \A-trans-AA. While measuring aggregation levels, the level of 
TXB2 was measured using LC/MS against a standard curve (Figure 2-8). Platelets 
were pre-incubated with lA-trans-AA and results showed that the levels of TXB2, as 
seen in Figure 3-25, decreased in the presence of increasing amounts of lA-trans-AA. 
At the highest concentration of lA-trans-AA (11 pM), approximately 1700 ng/ml of 
TXB2 was found. So, while the formation on TXB2 was not completely inhibited, 
platelet aggregation was completely prevented. This experiment confirmed that the 
inhibition of platelet aggregation by lA-trans-AA occurs in the presence of TXB2 
production.
Tests were also performed to determine whether lA-trans-AA inhibits TP receptor- 
mediated aggregation. A TP receptor agonist (U46619) was used to observe platelet 
aggregation. Platelets were pre-incubated with different amounts of lA-trans-AA and 
U46619 was added to observe the effect of lA-trans-AA on U46619-mediated 
aggregation. After careful observation and data interpretation, it was determined that 
the inhibition of U46619-mediated aggregation by lA-trans-AA is concentration 
dependent and the IC50 was found to be 2.2 pM (Figure 3-26). This experiment 
confirms that lA-trans-AA inhibits TP receptor aggregation with U46619. Platelet 14- 
trans-AA metabolism may result in the formation of novel products that could inhibit 
platelet aggregation. This is why the structural characterization of lA-trans-AA 
metabolites was an important part of understanding its action on platelets.
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The effects of 14-trans-AA on other pathways of platelet activation were also 
explored. To observe the effects of \A-trans-AA on other agonists, platelets were 
incubated with ADP, epinephrine, thrombin and cPAF. It was observed that lA-trans- 
AA (5 pM) inhibited ADP-mediated (50 pM) aggregation by 87%±8 (Figure 3-27), 
epinephrine-induced (50 pM) aggregation by 85%±12 (Figure 3-28), thrombin ( 0.5 
unit/ml) mediated aggregation by 75% ± 1 0  (Figure 3-29) and cPAF (50 pM) 
mediated platelet aggregation by 80% ± 10 (Figure 3-30). These experiments show 
that the inhibitory effect is not specific for the TP receptor. lA-trans-AA is a non­
specific inhibitor that inhibits ADP-, epinephrine-, thrombin- and cPAF-mediated 
platelet aggregation.
Experiments were also performed to determine the amount of trans-AA and AA that 
goes into the membrane phospholipids. Platelets were incubated with 14C-AA or 14C- 
14-trans-AA to assess the incorporation into membrane phospholipids. The data 
presented in Figure 3-31 shows that 14-trans-AA was transported into platelets about 
3 times faster than AA. At least part of 14-trans-AA was likely to be esterified in 
platelet phospholipids membrane. This experiment demonstrates that avid binding of 
14-trans-AA by platelets could result in changes in the phospholipid membrane near 
various receptors that could decrease the affinity of receptors to their ligands.
4.1.3 Relationship between metabolism and effects
It is very well known that metabolism of AA has profound effect on platelet function 
as the COX-mediated product (TXA2) causes receptor-mediated aggregation. It was 
anticipated that trans-AA. could be metabolized into oxidized lipids that may have 
modulatory effects on platelets. The study revealed that lA-trans-AA is metabolized 
into novel products and AA stimulates trans-AA metabolism, trans-AA metabolites 
were structurally profiled and a complete profile of metabolism, which is original and 
unique was established. But the amount of generated metabolites were very low, 
therefore it was not feasible to isolate and purify sufficient quantity for biological 
activity study. However, this study established the structures and enzymatic origins of 
the metabolites even though it was not possible to synthesize these metabolites in 
larger quantities for testing with platelet. Particularly the observation of the
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production of metabolite A is very interesting because it is an analogue of TX and 
therefore, it is possible that it may be relevant and may modulate platelet function via 
interaction with TP receptor. Further study is required to establish the role of 
metabolite A as a mediator of the inhibitory effect of \A-trans-KA. Figure 4-16. 
shows the formation o f \A-trans-AA and it’s effects on platelet function.
NO Nitro oxidation N 0 2"
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Unknown
mechanism  ^ inhibition of 
aggregation
COX
8-frans-12-HHT
all-c/s-15-HETE
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14-frans-5-HETE
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Figure 4-16.14-trans-AA and platelet function
Illustration shows the basic concept of interaction of 14-trans-AA and platelet. The key 
expected effect of 14-trans-AA is that it will reduce platelet aggregation induced by AA. It is 
also expected that while aggregation will be greatly reduced in the presence of AA, the 
biosynthesis of PGHa endoperoxidase is not efficiently reduced therefore some of PGH2 may 
be available for endothelial cells to be converted into PGI2. Thus, \4-trans-AA may 
favourably affect the balance between TXA2 and PGI2.
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4.2 Metabolism of frans-AA by hepatic microsomes
Previous experiments with \4-trans-AA and platelets have found that \4-trans-P±A is 
not readily metabolized by platelet COX and LOX as compared to AA (Figure 3-1 C). 
Thus, it was thought that perhaps trans-AA isomers function more like xenobiotics 
amenable to hepatic microsomal metabolism that could be of importance in their 
activation into more reactive oxidized lipids. Most of what has been known in the area 
of polyunsaturated fatty acid metabolism by hepatic microsomes involves studies of 
CYP) 45O/NADPH-dependent monooxygenation of the cis double bonds into 
epoxides of cis configuration. Such a process generates four epoxides (EETs) of AA 
(Capdevila et a l, 1981). Further metabolism of the EETs involves hydrolysis to 
vicinal diols, dihydroxyeicosatrienoic acids (DiHETEs), by cytosolic or microsomal 
epoxide hydrolase (Poff & Balazy, 2004b). In contrast, microsomal metabolism of 
fatty acids that have both cis and trans bonds has not been well characterized. Studies 
of the trans-AA metabolism could be important in providing a better understanding of 
their biological effects (Jiang et al, 1999; Balazy & Lopez-Femandez, 2003) as these 
fatty acids have been suggested to contribute to cardiovascular disorders, cancer and 
other pathologies (Hunter, 1982; Ascherio et al, 1994). Therefore, trans-AAs were 
incubated with hepatic microsomes to understand the metabolic profile of their CYP 
metabolism.
4.2.1 Metabolism of 14-frans-AA by microsomes
Hepatic microsomes were incubated with AA and \A-trans-AA. Metabolism of AA 
and trans-AA required oxygen and reduced NADP indicating that these fatty acids 
were oxidized by a CYP450 epoxygenase, a monooxygenase enzyme. At incubation 
time of 90 min or longer, vicinal diols (DiHETEs) were the major products (Figure 3- 
32). They originated from hydrolysis of the initially formed epoxides (EETs) of trans- 
AA  and AA by microsomal epoxide hydrolase.
However, the metabolic profile of 14-trans-AA was much different from that of AA 
(Figure 3-32 A and B). While AA produced four major metabolites (cl-c4), lA-trans-
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AA produced three metabolites at a comparable rate of metabolism (Figure 3-
32). The retention times of tl-t3 were longer than cl-c4 by about 1 min suggesting 
that they were likely to be Zrcms-isomers of cl-c4, because a similar difference was 
seen between trans-AA and AA. Incubations of equimolar amounts of AA and trans- 
AA  generated a complex mixture of metabolites and indicated that 14-trans-AA 
modulated the metabolism of AA (Figure 3-32 C).
GC-MS analysis confirmed that the four AA metabolites cl-c4 were DiHETE 
molecules. Each fraction produced a single chromatographic peak and a spectrum 
with an abundant ion at m/z 483, which corresponded to a diTMS 14C-labeled 
DiHETE carboxyl anion. Comparison with synthetic standards allowed structural 
identification of cl-c4 (Table 3-3). Thus, metabolites cl-c4 corresponded to four 
DiHETEs, which were the hydrolysis products of the respective EETs (el-e4). GC- 
MS analysis of tl-t3 also revealed ions at m/z 483 (Figure 3-33). Fraction tl 
contained two closely eluting peaks tla  and tlb  (Figure 3-33) whereas t3 was a 
relatively minor product. This suggested that tl-t3 were DiHETEs and thus 14-trans- 
AA, like AA, was metabolized primarily by epoxygenase and epoxide hydrolase 
system. Comparison of retention times (Table 3-3) revealed that metabolite tlb  had 
similar retention time as 14,15-DiHETE and thus was likely to be 14,\5-erythro- 
DiHETE resulting from hydrolysis of 14,15-fnms-EET. This observation is consistent 
with another study which showed that the erythro isomer tlb  eluted before the threo 
isomer cl (Abalain et a l, 1983).
Further confirmation of this observation was obtained by analysis of products of the 
reaction of lA-trans-AA. with m-chloroperoxybenzoic acid (MCPBA), which 
produced a mixture of epoxides. These epoxides were separated and hydrolyzed by 
incubation with microsomes. The most polar and thus earlier eluting epoxide by 
HPLC was isolated and following hydrolysis produced a DiHETE that had identical 
retention time as the microsomal product tlb  (Figure 3-33). This procedure provided 
fairly pure standards of 14,15-rra?zs-EET and 14,15-e^/zra-DiHETE for comparison 
with microsomal products. Other 14-frYzws-AA-derived microsomal metabolites had 
retention times similar to those of other standard DiHETEs (Table 3-3). Thus, because 
three cis bonds in lA-trans-P^A were available for epoxidation, it suggests that 14- 
trans-AA was metabolized via a CYP P450/NADPH system to four epoxides, which
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were hydrolyzed by epoxide hydrolase to one erythro diol and three threo diols each 
having a trans double bond (Figure 4-17).
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Figure 4-17. Microsomal epoxidation of 14-trans-AA
The epoxidation of 14-trans-AA by hepatic microsome produced four epoxides one of which 
was a trans epoxide and 3 other were cis epoxides. Microsomal epoxide hydrolase converted 
the epoxides into diols, one of which was an erythro diol and 3 other were threo diols with 
one trans double bond.
Hydrolysis of epoxides by microsomal and cytosolic epoxide hydrolases is highly 
stereoselective. Thus, c/s-EETs generate exclusively Z/zreo-DiHETEs by an SN2 
mechanism described by Zeldin et al, (1993) and while Znms-EETs have not been 
observed before, other trans epoxides such as a Zmw-epoxide of stearic acid are 
hydrolyzed exlusively into erythro diols (Gill & Hammock, 1979).
The metabolic profile shown in Figure 3-32 C indicated that many metabolites of 14- 
trans-AA coeluted with metabolites of AA. Even more complex mixture of 
metabolites was observed from microsomal metabolism of all four trans-AA isomers 
and AA. Such mixture might have contained up to 20 EETs, including four trans- 
EETs. It is thus possible that past measurements of endogenous CYP450-AA 
metabolites might have inadvertently detected EETs and DiHETEs derived from
trans-AA. More advanced analytical methods will be needed to isolate and analyze 
these isomers.
4.2.2 Metabolism of 5-trans-AA by microsomes
5-tmns-AA is a recently identified trans fatty acid that originates from the cis-trans 
isomerization of AA initiated by the NO2 radical. This trans fatty acid has been 
detected in blood circulation and it has been shown that it functions as a lipid 
mediator of the toxic effects of NO2 (Zghibeh et al, 2004). To understand its role of a 
lipid mediator, the metabolism of 5,6-trans-AA by liver microsomes stimulated with 
NADPH was studied. Profiling of metabolites by LC/MS revealed a complex mixture 
of oxidized products among which were four epoxides, their respective hydrolysis 
products (DiHETEs), and several HETEs resulting from allylic, bis-allylic and 
terminal/subterminal hydroxylations. It was found that the C5-C6 trans bond 
competed with the three cis bonds for oxidative metabolism mediated by CYP 
epoxygenase and hydroxylase. This was evidenced by the detection of 5,6-trans-EET,
5.6-erythro-DiHETE, and an isomer of 5-HETE (Figure 3-34). Additional lipid 
products originated from the metabolism involving the cis bonds and thus these 
metabolites had the trans C5-C6 bond. CYP2E1 metabolizes AA to 18- and 19-HETE 
(Bylund et a l, 1998). The 5,6-trans isomers of 18- and 19-HETE were likely to be 
products of the CYP2E1 because a neutralizing antibody partially inhibited their 
formation without having an effect on the formation of the epoxides (Figure 3-41). 
The experiments of microsomal hydrolysis and GST-mediated conjugation when both 
epoxides were incubated demonstrated that the major product of CYP metabolism,
5.6-trans-'EEY was significantly more stable than its cis isomer (Figure 3-43 and 3- 
44).
Thus, 5,6-trans-YEY was more resistant to metabolism by key enzymes active at the 
site of its formation in the liver. These two enzymes represent efficient pathways that 
inactivate exogenous and endogenous epoxides, many of which can cause toxicity by 
binding to DNA and proteins. While it appears that both 5,6-EET isomers can be 
formed by hepatic microsomes, the trans isomer is more likely to escape hepatic 
metabolic transformations and perhaps enter circulation in the intact form (Figure 4-
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18). These experiments have provided the first indication that such an epoxide may 
have a longer half-life than its opposite isomer. While many studies have detected the 
biological activity of the cis epoxides of linoleic and arachidonic acids (Capdevila et 
al, 1986; Capdevila et a l, 1988), comparative biological data for fatty acid trans 
epoxides are rare (Katz, 2002).
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Figure 4-18. Summary of the key steps involved in the hepatic microsomal 
metabolism of 5-trans-AA
5-trans-AA was metabolized into three classes of lipid products: EETs, DiHETEs and 
HETEs. Allylic, bis-allylic and sub-terminal (co-1 plus co-2) were the three forms of HETE 
molecules derived from 5-trans-AA. Allylic hydroxylation gave rise to 5-, 8-, 12-, 11- and 
15-HETE, bis-allylic hydroxylation gave rise to 13-, 10- and 7-HETE and sub-terminal 
hydroxylation gave rise to 19- and 18-HETE. CYP epoxygenase, a monooxygenase that was 
capable of epoxidation of the 5-trans-AA double bonds and generated 5,6-/nm?-EET and 5,6- 
trans-S,9-, 11,12-, 14,15-c/j-EETs.
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These experiments do not exclude the possibility that the differences in the rates of 
hydrolysis and GST conjugation were caused by the inhibitory effect of the trans 
isomer. The lipids characterized in this study constitute a novel class of lipids that 
could function as lipid markers of the N 02 radical, originating from steps of AA 
isomerization followed by CYP-mediated monooxygenation. The findings of 5-trans- 
AA  metabolism by CYP could be further developed to detect 5,6-frYms-EET 
stereospecifically in vivo along with other products of 5,6-trans-AA metabolism.
4.3 Metabolism of trans-fiJK by polymorphonuclear 
leukocytes
Treatment ofHL-60 cells with AA and its mono trans isomers revealed that only one 
trans-AA isomer, 5-trans-AA, have a potent apoptotic effect. Cells treated with 5- 
trans-AA had significantly less DNA than corresponding control cells. 5-trans-AA 
increased the degradation of DNA to nucleosomal subunits that appeared as a 
subGo/Gi peak beginning within 24-48 hours post-treatment. Other trans-AA isomers 
and AA did not modulate the growth and apoptosis HL-60 cells.
A number of studies have shown that AA metabolism is linked to HL-60 cell 
proliferation and survival during myeloid maturation (Steinhilber et al, 1993a; 
Dittmann et al, 1998; Hoemlein et a l, 1999; Nie et al, 2001; Arita et a l, 2001). An 
important role in triggering apoptosis in HL-60 (Brungs et a l, 1994; Ghosh & Myers, 
1999; Poff & Balazy, 2004a) and other cells (Miller et al, 1990; Ghosh & Myers, 
1998) have been found for 5-LOX, which metabolizes AA to 5-HETE and LTB4. It 
was initially thought that because 5-trans-AA is a unique AA isomer having the trans 
at the critical site for 5-LOX catalytic activity, which causes hydroxylation at the 
carbon 5 double bond, it might inhibit 5-LOX and 5-HETE formation by competing 
with AA metabolism. However, 5-LOX products in HL-60 cells were not detected. 
Other reports have shown that HL-60 cells do not express 5-LOX mRNA 
constitutively, and although HL-60 cells can exert 5-LOX activity after differentiation 
(Steinhilber et al, 1993b), they frequently fail to form 5-LOX products when cultured 
in 0.5 % DMSO for 48 hrs (Hoemlein et al, 1999b). Activation of 5-LOX in HL-60 
appears to require a complex system of cofactors and cytokines (Steinhilber et al.
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1993c; Brungs et al, 1994a). In contrast to HL-60 cells, control experiments with 
PMN showed a very active metabolism of 5-trans-AA into a group of novel lipids 
among which was a trans isomer of 15-HETE. Thus, 5-trans-AA induced apoptosis in 
HL-60 cells via a mechanism that was 5-LOX independent and may be mediated 
through esterification/deesterification within cell membrane, which is consistent with 
a relatively long time required for induction of the antiproliferative effect.
4.4 General discussion
It has been established that trans-AA isomers might originate from two sources: 
dietary fat (Sébédio & Christie, 1998) and endogenous cis-trans isomerization (Jiang 
et al, 1999). 14-trans-AA is an AA isomer that can originate from both sources and 
has been detected in human blood plasma (Zghibeh et a l, 2004). Rats fed with 
partially saturated canola oil that contained \2-trans-\mo\Qic acid (\2-trans-LA), 14- 
trans-AA appeared in blood, suggesting that elongation and desaturation of 12-trans- 
LA leads to formation of \A-trans-AA (Ratnayake et al, 1994). On the other hand, 
reaction of AA with nitrogen dioxide, nitrite (acidified), N2O3, and peroxynitrite 
causes AA isomerization and formation of trans-AAs, among which \A-trans-AA was 
identified (Jiang et a l, 1999). Conditions that result in elevated levels of NO2, such as 
sepsis and smoking have also resulted in elevated levels of trans-AA (Balazy, 2000b). 
Thus, \A-trans-AA is an interesting trans fatty acid that could be a marker of 
inflammation and excessive exposure to NO2, but can also be due to excessive dietary 
trans-linoleic acid (Balazy & Poff, 2004). The study of its effects on platelets was 
therefore justified.
This study found unique properties of 14-trans-AA. This isomer:
a) inhibited platelet aggregation stimulated by AA, ADP, epinephrine, U46619, 
thrombin and PAF at low micro-molar concentrations.
b) inhibited platelet aggregation induced by AA that was not correlated with 
inhibition of COX, TXA2 or PGH2.
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c) was metabolized to unique set of metabolites, a major component being an isomer 
of 15-HETE.
d) The metabolism of \A-trans-AA was faster in the presence of AA, an effect known 
as AA-induced co-oxidation.
It was noticed that a compound having properties of \4-trans-AA would make an 
interesting anti-platelet agent.
1) \A-trans-AA inhibited platelet aggregation, but the levels of TXB2 were only 
partially inhibited. Thus if this property holds in vivo, lA-trans-KA is not likely 
to inhibit PGH formation from platelet-derived PGH2. All COX inhibitors such 
as aspirin inhibit PGI2. Therefore, the dose of aspirin is important. Lower doses 
are aimed to inhibit platelet aggregation without inhibition of PGI2. With 14- 
trans-AA, this concern will be removed. 14-trans-AA will inhibit platelets, but 
PGI2 will be formed from platelet-derived PGH2. More studies are needed to 
establish this postulate.
2) 14-trans-AA inhibited platelet aggregation induced by U46619 with IC50 of 2.2 
uM, which suggests that \ 4-trans-AA inhibited TP receptor. Other work 
supports that 14-trans-AA also inhibits TP receptor in micro vessels (Chemtob, 
2005). Because 14-trans-AA is structurally different from TXA2 and U46619, it 
is not likely to be competing with these two ligands, but it is likely to either 
modify the TP receptor directly or change the receptor environment either by 
allosteric interaction or by modifying surrounding membrane possibly via 
incorporation into sn-2 position of phospholipids.
3) 14-trans-AA protects platelets from pro-aggregatory activity of other agonists. 
More studies will be needed to establish whether this property is maintained in 
vivo, at what concentrations and for how long.
4) Formation of 15-HETE isomer from \4-trans-AA could be an important 
positive feature. 15-HETE is a precursor for lipoxins those are anti­
inflammatory. Work by Serhan et al. was shown that aspirin-induces formation
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of aspirin triggered 15-epi-lipoxin A4 (ATL) (Chiang et a l, 2004). So all-cw-15- 
HETE, a product of \A-trans-AA, is likely to be a substrate for 5-LOX to 
generate a novel class of anti-inflammatory lipoxins. Additional studies will be 
needed to establish this property in vivo.
In summary, 14-trans-AA is likely to interact with platelets by several mechanisms - 
one is via metabolism but that will require isolation of unstable metabolites and the 
other is via incorporation into the platelet membrane. Many interesting properties of 
14-trans-AA appear to make it a candidate template for a novel anti-platelet drug; 
new analogues are being developed to address this possibility.
The lipid metabolites characterized in the study with trans-AA and hepatic 
microsomes constitute a novel class of lipids that could function as lipid markers of 
the NO2 radical, originating from steps of AA isomerization followed by CYP- 
mediated mono-oxygenation. Many studies explored various aspects of microsomal 
epoxidation and hydroxylation of AA and other PUFAs; however, considerably less is 
known about such a metabolism of trans fatty acids. Detection of oxygenated 
metabolites derived from tans-AA would require specific assays that would involve 
chromatographic separation of cis- and frafzs-isomers. 5,6-EET has been detected in 
vivo in the rats, human platelets, and rat erythrocytes (Ozawa et al, 1988; Katz, 2002; 
Goodfriend et al, 2004). Because a special analytical approach needs be applied for 
the separation and simultaneous detection of the two 5,6-EET isomers (Corey et al, 
1980), previous studies (Ozawa et al, 1988; Katz, 2002; Goodfriend et al, 2004) 
were likely to detect both of these isomers. The findings of this study could be further 
developed to detect S-trans-YET stereospecifically in vivo along with other products 
of 5-trans-AA metabolism (summarized in Figure 4-18). While many studies have 
addressed concerns regarding the adverse health effects of trans fatty acids (Slattery 
et al, 2001; Lemaitre et a l, 2002; Stender & Dyerberg, 2004), mechanisms of their 
activity are not well understood. Oxidative microsomal metabolism described in the 
present study could be an important aspect in the activation of trans-AA and possibly 
of other trans fatty acids into unique metabolites, among which the fraMs-epoxides 
could be a distinct and characteristic group although it is unclear what cellular role 
they may play in the formation of biologically active metabolites.
155
5-trans-AA appears to be a toxic trans-fatty acid that causes apoptosis ofHL-60 cells 
via Gi phase arrest and also apoptosis and death of microvascular endothelial cells 
(Kermovant et a l, 2004). Cigarette smoking, hypoxia, and sepsis induce AA 
isomerization and increase the levels of trans-AA, including 5-trans-AA, in blood 
circulation. 5-trans-AA and other trans-AA are likely to be formed via N 02-mduced 
isomerization within cell membrane as phospholipid esters from which they can be 
released by phospholipases. NO2 required for such isomerization may originate from 
exogenous sources such as urban air or cigarette smoke, but also from endogenous 
sources such as oxidation of nitrite (Bian et a l, 2003). The levels of endogenous 
trans-AA as free acids can reach 0.5 pM (Balazy, 2000), however, the levels of 
esterified trans-AA within cells are unknown, but probably unlikely to reach 
concentrations required to induce apoptosis. The effects of 5-trans-AA may be 
mediated through esterification/deesterification within cell membrane, which is 
consistent with a relatively long time required for induction of the antiproliferative 
effect.
4.5 Future work
Further work relating to this project is being actively persued. Novel water-soluble 
analogues are being synthesized and they will be tested for biological activity because 
the most important aspect of this project is the finding that \A-trans-AA can 
dissociate between aggregation and TXA2 formation. This may have profound effects 
on platelet interaction with vascular wall. Therefore, the future studies will focus on 
the effect of trans-AA on TXA2 and PGI2 biosynthesis following exposure to trans- 
AA. The studies will be performed in vitro and in vivo. Eventually I envision that 
trans-AA could serve as a template for the development of drugs to rival the NSAID 
family and spare PGI2 biosynthesis.
Another important conclusion from performed studies is the identification for the first 
time of the Zrarzs-epoxides from trans-AA. Future studies could be designed to 
identify trans-AA in vivo and they can be used as biomarkers of hepatic trans-AA 
metabolism. One study also revealed a huge difference between cis and trans epoxide
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in term of hydrolysis and GSH conjugation and it will be fascinating to compare these 
properties in vivo. This could be accomplished by the use of LC-MS.
Another important aspect of this study is the effect of 5-trans-AA on cell 
proliferation. Future work will establish in greater details the role of 5-trans-AA in 5- 
LOX mediated mechanisms of neoplastic cell proliferation and tumorigenesis.
4.6 Conclusion
This dissertation explored a new and original aspect of trans-FA biochemistry. 
Despite a great interest in the effect of trans-FA on human health, very little is known 
about their metabolism in the cardio-vascular system. Although recent studies show 
the trans-FA have profound effect in this system, almost nothing is known about the 
mechanism by which the trans-FA exerts their effects. The hypothesis is that many of 
the effects of trans-FA are related to their oxidative metabolism. This dissertation is 
the beginning of the exploration and established numerous novel oxidative 
metabolites and novel biological effects. As a pioneering study it opens doors for 
additional studies in many directions: biological; structural; and analytical. In this 
respect it could be viewed as a preliminary study of a new area of research regarding 
trans-FA. This study will be continued and definitely provide answers to many 
questions that arise from the data presented in this dissertation.
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